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The current environment for drug discovery and disease treatment relies heavily on 
genomic analysis, structural biology and chemical biology techniques. With the enormous 
advances in genomic analysis and structural biology, the use of and desire for targeted therapies 
has increased. However, as more genomic data for cancer disease state pathology becomes 
available we must ask increasingly difficult questions and even produce new technologies, such 
as activity-based probes, to answer these questions.  
In particular, targeted kinase inhibitors for the treatment of cancer has become a mainstay 
for drug development for both industry and academia, but it is evident that the genomic data is 
not always indicative of protein expression. Additionally, protein expression alone does not 
completely characterize functional activity. Therefore, in order to more accurately validate drug 
	   xii	  
targets and predict drug efficacy, we must not only identify possible targets but also determine 
their activity in vivo.  
The goal of this work was to develop a probe for Protein Kinase A that would act by 
alkylating a conserved cysteine in the substrate-binding pocket of the enzyme. We hypothesized 
that by targeting the substrate-binding pocket we could effectively utilize the natural substrate 
selectivity filters as well as take into account multiple endogenous regulatory mechanisms. We 
produced probes utilizing portions of the pseudosubstrate inhibitor PKI that demonstrate the 
ability to label the catalytic subunit of Protein Kinase A in an activity-dependent manner, thus 
making it an important first step in a new class of activity-based probes for the kinome.  
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Chapter 1: Introduction  
1.1: Proteomics 
The sequencing of the human genome has yielded a complete image of the possible 
products of gene expression in the body.1 As the technology has advanced, sequencing has been 
increasingly used to characterize disease states with fascinating results. However, the genomic 
data does not always directly correlate to the phenotype.2,3 Which is partly due to the genotype 
not always being indicative of the cellular environment, especially the post-translational 
modifications that may occur.2 This is particularly true in human malignancies, where multiple 
genetics mutations may provide phenotypes with increased survival advantages that result from 
downstream effects.4  
In general, the field of proteomics seeks to determine actual protein amounts and general 
characteristics of the phenotype.5 Proteomic data can be acquired in a multitude of ways, ranging 
from qualitative to quantitative analysis.6,7 Important tools and technologies available for 
proteomic analysis are continuously improved upon and invented. However, some mainstay 
technologies and techniques are: molecular probes, gel electrophoresis, chromatography, mass 
spectrometry, and immunochemistry. It is only through the appropriate execution of these 
experiments and expert interpretation that the data obtained gains significant value. 
Proteomics has influenced oncology for many decades, with examples dating back to the 
early twentieth century where researchers analyzed blood plasma by gel electrophoresis to link 
increased protein expression with the cancer phenotype.8 Since early publication such as this, 
proteomics has been utilized in various ways to delineate the cancer disease state.8,9 While this 
information is very useful, it does not have the level of detail required to link protein activity 
with expression. This disconnect has provided a new frontier for characterizing phenotypic 
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function in diseased states thus expanding traditional proteomics to include a new area known as 
chemical proteomics.10  
1.2: Chemical Proteomics 
In the field of proteomics, the gap of data between protein levels and functions has 
formed a specialized application. That is, activity-based proteomics, or chemical proteomics. 
Activity-based proteomics utilizes small molecules, known as activity-based probes (ABPs), to 
selectively react with a residue only in the active form of an enzyme.11-13 This selective reactivity 
enables tagging of enzymes exclusively in their active state for analysis. This direct measurement 
technique allows the quantification of aberrantly active enzymes and can help to identify novel 
drug targets, inhibitors, and relevant pathways. Clarifying the relationship of expression and 
activity is the major task of activity-based proteomics, the process of conducting such 
experiments with an ABP is known as activity-based protein profiling (ABPP).14-17 
1.2.1: Activity-Based Probes 
 To conduct ABPP, an activity-based probe must be developed, and there are many 
criteria and factors to consider. Activity based probes (ABPs) must be covalent inhibitors and 
selective for the active form of the enzyme. For different classes of enzyme, there are different 
approaches to achieve this type of selectivity.18-21 Identifying a mechanism of action that will 
allow a probe to label in an activity-dependent manner is the first step. With some enzyme 
classes, this challenge is more obvious than with others. The cysteine proteases, for example, 
have a nucleophilic cysteine in the active-site that is critical for activity. This active site not only 
serves as an important location to target, but by its nature will yield an inhibitor that behaves in 
an activity dependent manner.20 In general, kinases do not utilize a nucleophilic amino acid for 
phosphoryl transfer, this in turn provides a challenge for developing an activity-based probe. The 
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few examples of known ABPs in the kinome target a cysteine that is found in the ATP-binding 
pocket. While these cysteines do not directly participate in catalysis, their alkylation causes 
inhibition of the enzyme. It is also suggested that by binding in the nucleotide binding site they 
are acting in an activity-dependent manner. While this approach has proved valuable for 
developing ABPs and irreversible inhibitors for a number of kinases, the bulk of the kinome 
remains without such probes.17 This is in part due to the conservation of nucleotide binding 
pockets across not only the kinome but the entire proteome. Therefore, we set out to develop a 
new strategy to target kinases in an activity-dependent manner that does not rely on targeting the 
ATP-binding site (see Chapter 3). 
Figure 1: Major components of an activity-based probe (ABP). 
 
ABPs consist of three major components (Figure 1). First, there is a reactive moiety 
(electrophile) i.e., warhead, for selective covalent modification of the desired residue. These 
electrophiles can range from moieties geared towards specific side chains containing nitrogen, 
sulfur, or oxygen to actual substrates that become covalently attached when the enzyme acts 
upon it (Table 1). Selection of the electrophile is an important decision when designing a probe. 
Some of the major considerations one should factor is whether their goal is to produce a family 
selective or a target selective probe. If the goal is to develop a family selective probe, the 
warhead is selected solely on selective reactivity. The acyloxymethylketone (AOMK) moiety is a 
Tag Linker Warhead
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prime example of a reactive moiety being selected to produce a family selective ABP. It is a very 
selective electrophile, and inherently only weakly electrophilic. Only by placement in close 
proximity to the nucleophilic residue does the reaction occur (in biological systems). The 
halomethylketone moieties have seen widespread application, their reactivity can be attenuated 
significantly by the leaving group halogen. Iodomethyl ketone for example is not an ideal 
electrophile for developing a selective ABP because it is very reactive towards cysteine (and 
other nucleophilic residues). However, iodomethyl ketone has been appended onto a generic 
scaffold and used in conjunction with click chemistry to characterize the cysteinome. Similarly, 
the bromomethyl ketone is generally too reactive for the development of a selective ABP. The 
chloromethyl ketone can be utilized in a variety of different applications. For instance, 
chloromethyl ketones are a primary ingredient in protease inhibitor cocktails.  In contrast to the 
iodo- bromo- and chloromethyl ketone is the fluoromethyl ketone which has a significantly 
reduced reactivity profile.   
 
 
 
 
 
 
 
 
 
 
	   5	  
Table 1: Representative selective electrophiles 
 
 
Second, there must be a linker, or recognition sequence, to connect the warhead and tag. 
The difference between the two can be reduced to whether your probe is selective for a family of 
proteins or a single target. In general, a generic hydrocarbon linker is chosen when the purpose is 
to develop a family selective ABP (Figure 2, FP-biotin). With a linker the most important 
variables are length and desired physical properties (if required for solubility/cell permeability). 
The recognition sequence provides the greatest selectivity as it serves as the primary scaffold and 
can have the greatest variability and this is utilized when the desired outcome is a target selective 
ABP (Figure 2, fmk-pa).10 The scaffold can and should be optimized to have greater affinity and 
selectivity than a simple linker.22 Common examples of recognition sequences include small 
molecules, peptide substrate sequences (proteases), and adenosine triphosphate (ATP) analogues 
(kinases).  
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Figure 2: Activity-based probes with different linker styles, family and target selective. 
 
The final requirement is a detectable tag for quantification. Selection of a tag is generally 
limited to fluorescent, affinity, and click based tags (Figure 3, 4). There are many fluorescent 
options available and are quite often dependent on the selected system. For example, when 
examining isolated proteins or lysates by gel electrophoresis, one does not need to consider cell 
permeability or background fluorescence. In such a case, generic rhodamine or rhodamine 
derivative is acceptable. However, if the probe is destined for use in vivo, a fluorophore such a 
BODIPY should be considered due to its physical properties allowing for cell permeability. 
Additional probes with varying absorption and emission properties are commercially available, 
allowing a researcher to select Stoke shift values, wavelengths, and quantum yields. Having 
appropriately tailored fluororphores is particularly important when FRET based applications are 
to be considered.  
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FP-biotin
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F
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Figure 3. Representative fluorophores and a click handle. 
 
 
Affinity tags can also vary greatly. Deciding on an affinity tag relies heavily on the 
application.  For small molecule/probe development, biotin is the most commonly used affinity 
handle (Figure 4). This is due to its favorable size and known high affinity for streptavidin. 
Biotin is also easily appended onto a peptide or small molecule by simple chemical 
transformations and its solubility can be attenuated for different labeling applications. Other 
affinity tags may take the form as short peptides and quite often are used on the target itself and 
not the probe: histidine (His tag), Myc tag, human influenza hemagglutinin (HA tag), and etc. 
(see Figure 4). These may be appended by chemical or biological methods and offer high 
selectivity; however, size/steric bulk becomes an issue when attempting to use the peptide-based 
affinity tags.  
 
O
OH
O
NN
Rhodamine Click
N B N
F F
BODIPY
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Figure 4: Representative affinity labels and click handle. 
 
1.3: Irreversible Inhibitors of the Kinome 
The beginnings of an activity-based probe lay within the development of irreversible 
inhibitors. The development of selective irreversible inhibitors is a critical first step in the 
production of an activity-based probe, because one of the requirements for ABPP is that the ABP 
be irreversible. The kinome is one of the most numerous and varied class of enzymes found in 
nature. Kinases catalyze the transfer of a phosphate group from a nucleotide to a substrate. This 
post-translational modification has significant effects on cell signaling, phenotype, and disease 
state. This central role to the basic foundations of life have caused many kinases to be the center 
of drug discovery efforts.17 The vast majority of kinase inhibitors are competitive inhibitors of 
the ATP-binding pocket, which is highly conserved.23 Because of this conserved binding site and 
mechanism of action by the inhibitors, off-target activity is always a consideration. There is a 
concerted effort to develop selective inhibitors by capitalizing on different mechanisms of action 
for inhibition. Of particular interest is the focus on the irreversible targeting of cysteines in the 
kinome.  
Targeting cysteines for the regulation of kinase activity has long been used, if not well 
understood. Numerous examples exist dating back long before their binding mechanisms were 
HHHHHH EQKLISEEDL
Histidine Tag C-Myc Tag
S
NHHN
O
O
OH
HH
D-biotin Click
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fully developed. These range from allosteric to orthosteric cysteine alkylating compounds. The 
solution of many crystal structures has enabled a structure-based design push for selective kinase 
inhibitors. The interest in irreversible kinase inhibitors has increased, and the most prevalent 
approach in the literature utilizing a nucleophilic cysteine is a strategy that targets the ATP-
binding site (Table 2). Through the use of multiple selectivity filters, residue binding 
interactions, gatekeeper interactions, and location of the target cysteines, a significant number of 
irreversible inhibitors for the kinome, many with clinical relevance, have been produced. Indeed, 
many screening platforms have been developed to determine off-target activity/selectivity for the 
kinome. However, the development of selective kinase inhibitors has only been completed for a 
small fraction of the kinome. 
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Table 2: Examples of irreversible kinase inhibitors (green are natural products, blue have been 
further developed into ABPs, and black are generic Type I irreversible inhibitors). 
 
 
The prevailing strategy for the development of irreversible kinase inhibitors is producing 
a number of Type I inhibitors. Many reversible inhibitors that bind in the ATP-binding pocket 
with a known cysteine in close proximity have been altered with medicinal chemistry techniques 
to produce irreversible inhibitors. This successful approach has resulted in major efforts to 
develop new strategies for producing irreversible kinase inhibitors. The current set of cysteines 
being actively targeted reside in four distinct positions within the ATP-binding pocket: roof 
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region, DFG region, glycine-rich loop region, and the hinge binding region. Each of these 
regions has examples of being targeted by irreversible kinase inhibitors; however, some are more 
effective than others. This set of irreversible kinase inhibitors that bind exclusively to the ATP-
binding pocket, and are competitive with ATP, are known as Type I binding inhibitors.  
Diverse examples exist in the literature of type I cysteine modifying inhibitors of the 
kinome that target each of the four cysteines. Dual specificity mitogen-activated protein kinase 7 
(MAP2K7) is involved in mitochondrial cell death and its inhibition has been of interest. The 
inhibitor 5Z-7-Oxozeaenol (5Z7O, Table 2) has been demonstrated to inhibit MAP2K7 in a Type 
I binding mechanism by crystallography and shown to alkylate Cys218, which is located at the 
outskirts of the hinge region.24 It was also pointed out that there are 11 such similar cysteines in 
the kinome, i.e., this conserved cysteine is also targeted by EGFR, Nek2, KDR, IKKb, ITX, 
BMX, JMK1-3, and BTK inhibitors.25 A cysteine located in the β-strand (DFG region) is 
targeted by the activity-based probe “FMK” for the kinase RSK.26 Similar cysteines in the β-
strand have been targeted effectively against TAK1, ERK2, GSK3b, and MEK1.27-29 Cysteines 
located in the glycine-rich loop region have been effectively targeted against FGFR1-4 and have 
been the subject of ABPP.30,31 A cysteine identified in the roof region has been targeted in Her2 
and has shown increased efficacy over reversible inhibitors. This strategy has thus far proven 
effective at producing efficacious kinase inhibitors with the potential for turning into ABPs.17 
However, selectivity does continue to be an issue that requires additional binding interactions to 
address.25 
Much effort has since been put forth to develop Type II inhibitors. Type II inhibitors also 
bind to the ATP-binding pocket and take advantage of the DFG-out configuration. It has been 
demonstrated that, by utilizing the additional binding interactions from the DFG-out 
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configuration as a selectivity filter, increased-kinome wide selectivity can be achieved.28 This 
approach has also found applications in the production of irreversible kinase inhibitors, as Type 
II inhibitors have been altered with medicinal chemistry techniques to produce cysteine 
alkylating Type II inhibitors.28 These representative examples have produced highly selective 
and efficacious inhibitors but their application to the kinome is limited and certainly would not 
be applicable as an ABP, as the DFG-out configuration is inactive. Targeting other cysteines 
outside of the ATP-binding pocket would provide a route to produce inhibitors with access to 
more kinases. Type III inhibitors (allosteric inhibitors) have had sporadic success as reversible 
inhibitors, and few examples (if any) exist that conclusively display irreversible inhibition that is 
also saturable.32 
Substrate competitive, or type IV binding, irreversible inhibitors are becoming more 
prominent, as it is suggested that the natural selectivity filters involved with the substrate-binding 
site will provide similarly increased selectivity in complex biological mixtures.33 Many examples 
exist and a predominant case is with Protein Kinase B (PKB, or AKT). AKT has been the subject 
of numerous inhibition studies for various disease implications, most notably cancer. AKT1 has 
a number of solvent exposed cysteine residues that when alkylated modulate activity, most 
notably Cys310 in the substrate-binding site, specifically the activation loop (or T-loop). This 
particular cysteine has been demonstrated to be alkylated by peptidomimmetic compounds 
(TPCK, Boc-Phe-VK), and natural products (lactoquinomycin, wortmanin, and berberine); upon 
alkylation, inhibition of catalytic activity is resultant.34-36 
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Figure 5: Peptide-based inactivators of PKB by a Type IV binding mechanism. 
 
Protein Kinase A (PKA, or cAMP-dependent protein kinase) is the prototype kinase and 
has been the first in many regards for various studies and is the target of this thesis. The pathway 
to the development of an ABP goes through irreversible inhibitor design, and a thorough 
knowledge of the available data on irreversible inhibition of your target is required to avoid 
repetitious results therefore a brief overview of Type IV inhibitors of the prototype kinase is 
below. 
Protein Kinase A (PKA) is the prototype kinase with two cysteine residues that have been 
thoroughly investigated throughout the years, and one in particular has been shown to modulate 
catalytic activity: Cys199.37-41 Cys199 is located in the substrate-binding pocket, specifically the 
activation loop (T-loop) and alkylating or oxidizing this residue inhibits catalytic activity.42,43 
Cys199 has been shown to be nucleophilic and react with a variety of different electrophiles and 
inhibitors. Taylor and colleagues demonstrated that oxidation at Cys199 by glutathione was a 
endogenous regulatory mechanism.37 Additionally, in separate studies conducted by Taylor, 
Cys199 was alkylated by Michael acceptors, sulfhydryl moieties, and halomethyl ketones 
(Figure 6).44-46 More early (1982) work by Taylor and colleagues, produced a peptide based 
affinity probe that formed a disulfide bond with Cys199; this probe contained the sequence 
LRRACLG with the cysteine oxidized with Npys so that it will selectively oxidize Cys199 
(Figure 7).44  
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Figure 6: Small molecules used by Taylor et al to inactivate PKA at Cys199. 
 
Figure 7: First designed irreversible peptide-based inactivator of PKA 
 
A number of other groups have also taken advantage of the substrate-binding pocket and 
the nucleophilic cysteine located in the activation loop. Shaltiel and colleagues used a 
combination of known amino acid substrate sequences to hypothesize that: 1) both a basic and 
hydrophobic moiety, 2) or only the basic moiety were important recognition elements, and that 
by producing these one would develop an active site directed labeling compound.47 They 
examined the inhibitory effects of Nα-tosyl-L-lysine chloromethyl ketone (TLCK) and Nα-tosyl-
L-phenylalanine chloromethyl ketone (TPCK) to test this hypothesis (Figure 8).  It was 
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determined that both labeled Cys199 and inactivated PKACα by this mechanism, and reagents 
such as chloroacetamide and chloroacetic acid did not. This was important early work in 
characterizing not only the promiscuity of previously thought to be selective trypsin and 
chymotrypsin inhibitors, but in mapping the active site of PKA. It is important to note however, 
that their labeling was greatly affected by their simulated biological conditions. Specifically, it 
was noted that when MgATP was added to their labeling conditions, inactivation of PKACα was 
prevented.47 In another publication it was demonstrated that this could be an additional 
regulatory mechanism in which substrate specificity is altered by the immediate environment of 
the cell (a type of reversible spatial regulation). Finally, the reactivity of the sulfhydryl groups in 
response to these stimuli was determined, and it was indeed affected greatly.48  
 
Figure 8: Inhibitors used by Shaltiel et al to characterize the active site of PKA. 
 
E. T. Kaiser (1938-1988) also pioneered significant early work with PKA and produced 
multiple publications in the development of active site (Type IV) directed affinity labels for 
PKACα (Figure 9). Kaiser’s work centered on peptide based affinity labels. He coauthored with 
Taylor the 1982 paper that detailed disulfide bond mechanism based peptide affinity labels.44 
They went on to further examine the substrate-binding pocket by synthesizing a number of 
subsequent peptide based affinity labels incorporating bromoacetamides and chloroacetamides in 
addition to the oxidized cysteine residues used to form the disulfide at Cys199. However, only 
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the bromoacetamides showed any labeling activity. Their radiolabaled probes and trypsin 
digestion experiments help form early models of the substrate-binding site (prior to crystal 
structure). They hypothesized that the conserved nature of this cysteine among known kinases 
(considerably fewer at the time), would provide a general strategy to develop affinity labels that 
work by a similar mechanism to determine active site sequences.49 Kaiser and Miller also 
produced a peptide based photoaffinity label that produced similar results when used to discover 
the residues responsible for substrate recognition.50 Further they characterized a small library of 
their peptide based covalent inactivators and known ones (the disulfide forming compounds 
explored previously, Figure 9). Their results were particularly noteworthy in light of what we 
now know in that, in addition to them further demonstrating the amino acids that play a role in 
substrate recognition, their probes were prevented from covalent labeling in the presence of 
physiologically relevant concentrations of MgATP.51 
Figure 9: Peptide-based active site directed affinity labels for PKA by Kaiser et al.  
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Contemporary to the work of Kaiser et al., two other groups produced Type IV 
irreversible inhibitor studies. Glass and colleagues produced a photoaffinity labeling peptide 
based on the PKI(6-22) scaffold and show that it does label the catalytic subunit of PKA. They 
cite “soon to be published” work in complex biological mixtures, but that work was never 
published.52 A group at Louisiana State University published a study detailing the fluorescent 
affinity labeling of the catalytic subunit with a small molecule. They propose a novel mechanism 
of action in that their small molecule reacts with two residues, lysine-72 and cysteine-199, by 
forming an isoindole derivative with PKACα.53 However, in a simultaneous publication they 
note the similar mechanism and inhibitory activity against Protein Kinase G (cGMP-dependent 
protein kinase, or PKG).54 
Lawrence and colleagues attempted similar affinity labels with the aid of the now 
available kinase crystal structures, and the ability to express recombinant PKACα (previous 
groups had been using purchased or isolated mammalian proteins from various mammalian 
sources). They essentially demonstrated the structure-based design principle of our approach by 
synthesizing multiple affinity probes and performing substrate analysis. Early work was focused 
on appending an oxidized cysteine at the C-terminal end of a peptide inhibitor to selectively 
oxidize Cys199 (Figure 10). These peptides were effective at inhibiting PKACα by reacting 
specifically with Cys199. Interesting, ATP blocked labeling of their peptide probes as well, 
lending support to the hypothesis that there is a confirmation change of the cysteine in the 
presence of a nucleotide.55 They state that they were continuing structure-activity relationship 
studies on these series of peptides but nothing has been published with them since (although a 
different strategy was used in 2011 and is discussed in chapter 2). They do note, however, that in 
addition to labeling Cys199 they also labeled a similar cysteine in Protein Kinase G, PKG.56 
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Selectivity between the two similar kinases was not achieved at first but they were able to tune 
for PKG over PKA in a later paper.55,57 However, they moved into methods to detect PKACα 
activity while not inhibiting and will be discussed in chapter 2, methods to detect PKA activity.  
 
 
 
Figure 10: Peptide-based affinity labels for PKA, representative peptides from Lawrence et al. 
 
 
A contemporary example of peptide-based affinity labels that target the Cys199 of 
PKACα in the activation loop comes from Tung et al. They utilize a mechanism-based 
inactivation method that effectively is silent until it labels the free catalytic subunit of PKA 
(Figure 11).58 This example is particularly interesting in that the probe was designed to remain 
quenched until reacting with PKACα, effectively only reporting the amount of catalytic subunit 
not bound to regulatory subunits or inhibited by any other substrate competitive mechanism. 
Tung et al examine their probe in various conditions to display selectivity in biological mixtures 
and quantitate levels of the protein in various ways with the hypothesis that this could be used to 
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detect PKA levels in cancer patients. The mechanism and lead compound are shown below in 
Figure 11. The researchers did not however publish data concerning the protective effects of 
ATP (or lack thereof) against their probe.58 
 
 
Figure 11: Mechanism-based quenched fluorescent probe of PKA 
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1.3: Activity-Based Protein Profiling 
Genomic analysis relies almost exclusively on manipulating gene expression (RNA-
interference, knock-out/down, etc.) in order to determine a protein’s function and importance in a 
disease state. This approach is usually coupled with a generic proteomics approach (mass 
spectrometry, blotting techniques etc.) to correlate protein levels with genomic analysis. 
Activity-based protein profiling (ABPP) has arisen out of a necessity to determine, in addition to 
total protein amounts (proteomics), protein function in complex biological mixtures.15,59 The 
successful design and implementation of a covalent ABP is a critical step to begin the process of 
characterizing the active site, and activity (not always the same) of specific proteins and/or 
families of proteins (discussed in section 1.2).  
1.3.2: ABPP Applications 
ABPP applications include, but are not limited to, molecular target identification, drug 
discovery, off-target analysis, and active site characterization.14,15,60 Molecular target 
identification is dominated by gel electrophoresis ABPP techniques.15 Healthy and disease state 
samples are compared for aberrantly active (or inactivated) protein levels. The resulting 
differences can be attributed to the disease state and warrants further examination.15,61 Drug 
discovery efforts can be enhanced with an ABP.62 By competition with potential drug candidates, 
a subsequent decrease in probe labeling is noted and can be interpreted in a number of different 
ways. Additionally, if a family selective ABP is being utilized, off-target binding analyses can be 
conducted by this competitive labeling experiment.18,20 By serendipity an ABP may identify a 
novel protein that shares the mechanism of action of the target enzyme. This can enable the 
identification and subsequent classification of new or old proteins with previously unknown 
function(s).15,20 
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1.3.3: Historical Perspective of ABPP Development 
ABPP at its onset was primarily focused on protease and protease-like enzyme 
families.11,18,21 This is due to the catalytic mechanism of these enzymes being well defined which 
allows for a more straight-forward probe design. The serine hydrolases have seen significant 
progress in ABP development and implementation in ABPP. Serine hydrolases encompass a 
number of different proteins, which include lipases, proteases, esterases, and peptidases. Despite 
the differing substrate specificity, the diverse proteins converge on a shared active site 
mechanism of action. This catalytic mechanism utilizes a serine residue that is made nucleophilic 
in the active site for subsequent attack on the carbonyl carbon of the substrate to form a 
tetrahedral intermediate. Water then hydrolyzes the following acyl-enzyme intermediate to 
regenerate the serine and eject the product. Targeting the transition state of an enzyme is an 
effective strategy to produce inhibitors. The fluorophosphonate, and aryl phosphonate 
electrophiles have been shown to be effective reactive moieties for ABPP of the serine 
hydrolases.18,63-67 
An effective example of ABPP applied to the serine hydrolases is from the Jessani group 
using the phosphonate electrophiles as transition state mimetics that also form a covalent bond. 
Their work lead to the identification of the integral membrane protein KIA1361 as an important 
biological target in aggressive cancers.68 These probes have been conclusively demonstrated to 
selectively react with the active form of the enzyme and not physiologically relevant inactive 
forms; this makes them effective tools for ABPP. Certain other groups have developed similar 
probes and have used them extensively in ABPP applications that examine the cancer 
phenotype.15,69 
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In a similar setting, the cysteine proteases have garnered remarkable success in ABP 
development and applications in ABPP.13,19,20 However, the subtle differences in the active site, 
the differing mechanism of action, the nature of the nucleophile (serine OH as compared to the 
cysteine SH), and hard-soft acid base interactions allow for orthogonal targeting by electrophiles. 
Of particular interest is the fluorophosphonate electrophile: it does not inactivate the cysteine 
proteases. Many other cysteine selective electrophiles do covalently label the cysteine proteases 
with varying efficiency and selectivity. The acyloxymethyl ketone (AOMK) electrophile 
synthesis and application has been optimized and tailored to the cysteine protease family.20 
AOMK has also demonstrated intrinsic selectivity for the cysteine proteases while generally not 
reacting with less potent nucleophiles.70 The solid phase synthesis of AOMK containing 
peptides/small molecules has been disclosed and has since spurred a large increase in ABPP of 
the cysteine proteases.19,20 
Many more enzyme classes have been targeted with varying degrees of success; however, 
as our understanding of enzyme catalysis and active site dynamics increases, so has the pool of 
potential targets for ABP development increased.17,71,72 Not only can we target new catalytic 
mechanisms but new classes of enzymes. It is indeed important that more ABPs be developed to 
target and characterize more disease states.  The kinome has proved a bountiful source of 
therapeutic targets but has mostly evaded wide spread irreversible inhibitor development and 
thus the potential for ABP development.17,23 
1.3.4: ABPP and the Kinome 
There is a current need for ABPs for the kinome. Many kinases are implicated in various 
disease states, however their immediate function is difficult to elucidate without such probes.59,73-
75 Currently there are few examples of selective kinase activity-based probes that target RSK, 
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BTK, and FGFR (Figure 12),26,31,76,77 all of which target the conserved cysteine in the nucleotide-
binding site.17 There are also examples of non-selective ABPs, where, simply put, a known 
irreversible inhibitor has been outfitted with a tag and electrophile.78 While these approaches 
have yielded successful ABPs, there are many kinases with a cysteine in the ATP-binding pocket 
(approximately 200), and the ATP-binding site is conserved among many enzymes and enzyme 
classes.26,73 This has made it difficult to achieve the level of selectivity required for selective 
enzyme activity-based protein profiling (ABPP) since more proteins than those in the kinome 
utilize ATP; a significant portion of the proteome has a nucleotide binding site.17  
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Figure 12: Adenine base and representative activity-based probes for the kinome. 
It is generally assumed that if Type I inhibitors, ATP-competitive, can bind to a kinase 
nucleotide binding site, it is in its active confirmation and therefore with the appropriate 
placement of a tag can be an ABP.17,59,60,71 As a result, the ABPs available for the kinases rely on 
this mechanism of action to inactivate in an activity-dependent manner. There have been a 
number of examples of how one might discover irreversible inhibitors that behave in this 
manner, and while they may produce ABPs Type I in nature, they are unable to, or currently are 
not being used to, examine other mechanisms of action. 73 
There is another binding site that has similar activity dynamics in the kinome, and in 
some cases is more sensitive to active site dynamics; this site is the substrate-binding site.33 In 
addition to providing the scaffold for proper orientation of a substrate for phosphoryl transfer, 
the substrate-binding site is sensitive to many post-translational modifications that do not always 
affect the nucleotide binding site. For example, PKACα is regulated by an endogenous inhibitor 
peptide that does not prevent binding of ATP; therefore, a (theoretical) Type I ABP would not 
account for such a regulatory mechanism. To date, there currently is no other general strategy to 
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develop, or singular example of, an ABP that does not rely on an ATP competitive mechanism in 
the kinome. Therefore, the development of a general strategy to produce ABPs for the kinome 
that relies on the substrate-binding site would have significant impact on the field. 
1.4: General Hypothesis 
The above is the summary knowledge gained towards the development of Type IV 
covalent inactivators of PKACα and their applications. Using this and the vast literature on PKA 
(see chapter 2), we hypothesize that an activity-based probe can be effectively developed for the 
prototype kinase that utilizes a binding pocket other than the ATP-binding pocket. But utilizing a 
high affinity pseudosubstrate peptide with a known binding site (active-site directed) and 
mechanism of action, we can effectively target Cys199 of PKA in an irreversible and selective 
manner to produce an activity-based probe for activity-based protein profiling. We additionally 
suggest that this approach can be generalized, by nature of its application to the prototype kinase 
and existence of similar cysteines in other kinases, for activity-based protein profiling of the 
kinome. This hypothesis was tested by synthesizing a number of peptidomimetic compounds 
based on a structure-based design approach and their mechanism of action was investigated by 
both various inhibition and gel electrophoresis assays (see section 3.12).  
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Chapter 2: cAMP-Dependent Protein Kinase 
2.1: cAMP-dependent Protein Kinase 
 Phosphorylation is an important regulatory post-translational modification in eukaryotes. 
Phosphorylation is often responsible for regulating the dynamics of the cellular environment; at 
the same time it is often reversible by enzymes known as phosphatases. Phosphorylation is the 
transfer of a phosphate group to a substrate. Enzymatic proteins that catalyze the transfer of a 
phosphate group are known as kinases. Common substrates include serine, threonine, and 
tyrosine.  Eukaryotic protein kinases (EPKs) make up a superfamily of homologous proteins. 
The EPK homology region is defined by the catalytic (or kinase) domain; this domain is 
approximately 250 amino acids. The catalytic domain is responsible for the catalytic activity and 
is where the phospho transfer takes place. Kinases generally utilize ATP or GTP as their 
phosphate source and catalyze the transfer of the terminal gamma phosphate to the substrate.79 
The phosphate transfer process can be viewed as a general three-step mechanism. The first two 
of which are not necessarily in this order: 1) the nucleotide binds to the nucleotide binding 
pocket of the catalytic domain; 2) a substrate binds in the substrate-binding pocket of the 
catalytic domain; 3) there is a transfer of the gamma-phosphate to the substrate.79 The first two 
steps may not necessarily occur in that sequence and may occur in a difference sequence in 
vivo.80,81 It was previously believed that a divalent cation, such as Mg2+, was required for the 
phosphate transfer step. This has recently been shown to not be the case in terms of phosphate 
transfer alone (for PKACα), the divalent cation plays a larger role in release of ADP which is the 
rate limiting step in catalysis turnover.80 Taylor and colleagues have demonstrated phosphoryl 
transfer in the absence of divalent metal cations.80 
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The kinase superfamily is referred to as the kinome and accounts for ~2% of the human 
genome. The kinases are broken up into eight broad classes based on the homology of their 
catalytic domains: AGC; CAMK; CMGC; TK; TKL; STE; RGC; and CK1. PKA is a member of 
the AGC kinase family, the AGC kinases are serine/threonine specific kinases. Because the 
cAMP-dependent protein kinase (PKA) was the first crystallized, and its core residues (40-300) 
are highly conserved, it is the prototype kinase.82 PKA is undoubtedly the most studied and 
perhaps well understood of the protein kinases. The catalytic subunit α of PKA (PKACα) was 
the first kinase crystal structure to be solved; this protein continues to be the template to which 
we base general kinase structure and function on.42,83 This structure also contributed to the 
initiation of a new chapter in eukaryote protein kinase (EPK) drug discovery, structure-based 
drug design.84 
2.2: Structure of PKA. 
Specific regions of PKA are often referred to when discussing inhibition strategies, and 
these regions often serve as the template for the modeling of other kinases. The main portions of 
the kinase that are involved with substrate, inhibitor, or regulatory function and/or binding are 
the nucleotide binding loop (51-56), hinge region (120-126), catalytic loop (162-173), E-helix 
(140-159), 3rd beta strand (67-75), C-helix (85-97), activation loop (184-208), and the P+1 loop 
(211-214). These regions are highlighted in Figure 13 below with the crystal structure of 
PKACα, which contains the catalytic subunit with ATP, and the inhibitor peptide PKI(5-24) 
(PDBID: 1ATP). Type IV inhibitors bind to the substrate-binding pocket (occupied by substrate, 
white in Figure 13) made up by the activation loop (magenta) and the catalytic loop (teal). It is 
important to note that affects made outside of the pocket (such as post-translational 
modifications) can greatly affect the characteristics of the substrate-binding site. Cysteine-199, 
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the cysteine which we focus on for this thesis, is located on the activation loop. Cysteines in the 
activation loop are very common and their location is often conserved. For example, the human 
kinome contains 99 kinases that share a cysteine in the same spot as PKACα (to be discussed 
later). Many more cysteines exist thoughout the activation loop and their presence is an 
indication of their potential to be targeted (see Chapter 3 Figure 69 for complete human kinome 
activation loop sequence alignment with cysteine highlights). 
The activation loop (or T-loop) is characterized by a conserved DFG (aspartic acid-
phenylalanine-glycine) start sequence and ends at the APE (alanine-phenylalanine-glutamic acid) 
motif. This region is highly conserved in eukaryote protein kinases (EPKs) and is heavily 
involved in the catalytic activity of EPKs. For most EPKs the activation loop is disordered when 
the kinase is not phosphorylated at the appropriate residues (Thr 197 for PKA). This disordered 
nature of the region reduces affinity of substrates and, in result, the kinase catalytic activity is 
severely diminished or completely abolished. Therefore, the nature of the activation loop and by 
extension the substrate-binding pocket is an important regulatory factory in the kinome (see 
section 2.3 on PKA regulation below). 
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Figure 13: Major regions interacting with the active-site. Image generated on pymol. 
 
2.3: Expression and Regulation of PKA. 
PKA consists of multiple subunits and splice variants produced in most mammalian cell 
and tissue types. There are three catalytic subunits denoted alpha, beta, and gamma (PKACα, 
PKACβ, PKACγ). The alpha and beta are the two major isoforms found in humans. The gamma 
subunit is primarily expressed in the prostate. In addition to the catalytic subunits are regulatory 
subunits; these regulatory subunits also have multiple isoforms: Ia, Ib, IIa, and IIb. The 
regulatory subunits all have cAMP binding domains (CBDs), and have high affinity for the 
second messenger. However, the different regulatory isoforms have different affinities for 
cAMP.42,85,86 This allows for greater regulation of cAMP signaling, by having different amounts 
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of PKA activated at different thresholds of cAMP (discussed below). However, the main focus 
will remain on the alpha subunit, PKACα. 
Despite the localized expression of the catalytic subunit isoforms, their regulatory 
mechanisms are essentially the same. PKA is regulated by multiple endogenous regulatory 
mechanisms, many of which are conserved or very similar within the kinome.84 Upon 
transcription, PKA is autophosphorylated on Ser 338 and then rapidly phosphorylated on Thr 
197 by PDK1.87 However, these phosphorylations are considered silent when left as is, in that 
they are not dephosphorylated by known phosphatases.38 Additionally, the phosphorylation 
occurs immediately during (auto) and upon transcription (PDK1).87 However, it has been 
demonstrated that oxidation of Cys199 by glutathione, a physiologically relevant post-
translational modification, renders the pThr 197  and pSer 338 residues susceptible to 
phosphatase activity.38 Whether or not this is a physiologically relevant event remains to be 
conclusively determined. What is clear is that phosphorylation at Thr 197 causes an ordering of 
the activation loop (and by extension the substrate-binding pocket as a whole), which increases 
substrate-binding resulting in increased catalytic activity.87 Of particular note is that the inhibitor 
peptide (PKI, IP20) binds to the dephosphorylated isoform with ~9 fold less affinity than for the 
phosphorylated isoform (6.4 vs 54 nM).87 
Once translated, PKACα forms the inactive holoenzyme by binding as a heterotetramer 
with two regulatory subunits. These regulatory subunits bind with high affinity to the substrate-
binding site and occlude substrates from binding; therefore, inhibiting the catalytic activity of 
PKACα.88-92 However, the second messenger cAMP binds to the regulatory subunits 
cooperatively and with high affinity, which causes the release of the free, catalytically active, 
enzyme.92 
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The free PKACα may still remain inactive because it can bind to the endogenous 
inhibitor peptide, the heat-stable protein kinase inhibitor (PKI).93,94 PKI binds selectively and 
with very high affinity to the free catalytic subunits of PKA. In addition to substrate competitive 
regulation, cysteine 199 can be oxidized with glutathione, which inhibits activity. The specific 
residue interactions between the pseudosubstrate inhibitor PKI and the catalytic subunit are 
detailed in a 2-D representation below.  
 
 
 
Figure 14. PKI(14-24) 2-D representation of intermolecular interactions with PKACα. 
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In addition to the regulatory mechanisms described above, the functional effect of PKA is 
also spatially and temporally regulated by A-Kinase anchoring proteins (AKAPs), of which there 
are more than fifty (when splice variants are considered).95 The regulatory subunits bind to the 
AKAPs, which are clustered, and upon stimulation with cAMP, catalytically active PKACα is 
released in a localized fashion. The original AKAPs were isolated as contaminants when 
attempting to purify regulatory subunit.95 It is clear that PKA functional activity is not only 
regulated in a dynamic nature but it is tissue specific (see Table below for a list of AKAPs and 
their tissue expression). It is because of this dynamic activity that current methods to detect PKA 
activity in vivo do not necessarily reflect the function of PKA in that state and no one method 
available can decipher all the data. 
 
Table 3. Selection of known A-Kinase Anchoring Proteins (AKAPs).95,96 
AKAP Tissue Expression 
D-AKAP1 Ubiquitous 
AKAP-KL Kidney, lung, thymus, cerebellum, heart 
AKAP110 Testis 
AKAP79 Ubiquitous 
mAKAP Heart, brain, skeletal muscle 
AKAP18α Heart, brain, lung, pancreas, kidney 
AKAP18β Kidney, brain 
AKAP18γ Heart, brain, placenta, lung, pancreas 
AKAP18δ Heart, kidney inner medulla 
AKAP95 Nuclear matrix 
AKAP350 Ubiquitous 
Isoform Yotiao Brain, heart, placenta, skeletal muscle, pancreas, testis 
D-AKAP2 Ubiquitous 
AKAP220 Testis, brain, kidney 
Gravin All tissues except liver 
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AKAP-Lbc Ubiquitous 
AKAP28 Lung 
GSKIP Ubiquitous 
MyRIP Ubiquitous 
Rab32 Ubiquitous 
SKIP Heart, brain, ovary, spleen 
BIG2 Placenta, lung, heart, brain, kidney, pancreas 
Ezrin Blood cells, placenta, secretory epithelia, brain 
WAVE-1 Brain, platelets, liver 
MAP2 Brain, ovaries 
Neurobeachin Ubiquitous 
MTG8 Brain, lymphocytes 
Myosin VIIA Ubiquitous 
MTG16b Ubiquitous 
Synemin Muscle 
PAP7 Ubiquitous 
Myospryn Skeletal and heart muscle 
SFRS17A Ubiquitous 
Merlin CNS 
Moesin Blood 
AKAP85 Lymphocytes, epithelial cells 
Pericentrin Ubiquitous 
RSK1 Ubiquitous 
 
 
 
The second messenger cAMP is generated from ATP by adenylate cyclases (ACs), whose 
activity can be increased by extracellular signals. Levels of cAMP are regulated by extraceullar 
signals that can activate ACs through G-protein coupled receptors (GPCRs) and 
phosphodieserases (PDEs) that catalyze the breakdown of cAMP.97 GPCRs can be coupled to a 
variety of G protein complexes which in turn can positively or negatively effect AC activity. For 
example, the Gαs protein increases AC activity and the Gαi inhibits AC activity. In a healthy 
physiological state, PKA acts as the main intracellular target of cAMP. Once cAMP is generated, 
	   34	  
it binds to the regulatory subunits that inhibit PKA and causes the release of catalytically active 
PKACα.97 
 
 
 
 
Figure 15. Schematic representation of cAMP-dependent activation of PKA. 
 
2.4.1: PKA activity. 
PKA is ubiquitously expressed and is responsible for the regulation of multiple proteins 
and transcription factors via phosphorylation of many Ser/Thr residues that directly result in 
increased cAMP levels (often resultant from GPCR stimulation).6 The consensus sequence for 
phosphorylation by PKACα is RRXS.6 A brief sample of various protein substrates is listed 
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below in Table 4.98 Taylor and colleagues have performed a quantitative mass spectrometry 
based proteomic analysis to identify many proteins whose expression is effected by directly 
altered by PKA.6  
 
 
Table 4. Selected substrates of PKACα. 
PKA Substrates 
Muscle Glycogen Synthase 
Phosphorylase Kinase α 
Protein Phosphatase 1 
CREB 
Liver Tyrosine Hydroxylase 
Phopholamban 
USP20 
PKACα (auto) 
CDC25B 
ABL1 
NFKB1 
CLDN3 
RORA 
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Table 5. Proteins whose expression is increased (green) or decreased (red) directly by PKA 
activity. 
PKA-Dependent Protein Expression 
Isocitrate dehydrogenase (NAD) subunit γ 
glutathione reductase 
glyoxylate reductase 1 homologue 
mortality factor 4-like protein 2 
isoform 4 of E3 ubiquitin-protein ligase 
nuclear autoantigenic sperm protein isoform 1 
isoform 1 of Rab GDP dissociation inhibitor β 
GTP-binding nuclear protein Ran 
prostaglandin E synthase 3 
translin-associated protein X 
F-actin-capping protein subunit α2 
(Rpsa-ps7) similar to 40S ribosomal protein SA 
scavenger mRNA-decapping enzyme 
exosome complex exonuclease RRP41 
isoform 2 of phosphoglycerate mutase family member 5 
(gm4492) similar to gag 
isoform 2 of acidic leucine-rich nuclear phosphoprotein 32 family member E 
peptidyl-prolyl cis-trans isomerase 
Annexin A5 
sinalosome complex subunit 4 
leucine-rich repeat containing protein 59 
isoform 1 of 36biquitin carboxyl-terminal hydrolase isozyme L5 
Tnpo1 transportin-1 
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The different holoenzymes play a role in PKA’s normal function as well. Type I 
holoenzymes (defined by which regulatory subunit the catalytic subunit is bound, for Type I it is 
RI) are typically found in the cytosol and Type 2 are generally localized to the membrane. The 
dynamics of PKA signaling modulate cell cycle entry in multiple systems. PKA has also been 
identified as a regulator of deubiquitinase (DUB) activity for GPCRs, thus playing a role in 
receptor desensitization. PKA has also been demonstrated to have an important role in the 
regulation and development of Schwann cell (SC) growth and proliferation.88 
 PKA signaling is closely tied to β-adrenergic stimulation. Upon stimulation of a 
positively coupled to cAMP GPCR, cAMP is generated and causes the release of free, 
catalytically active PKACα. A brief illustration of PKA’s role in heart muscle contractility and 
energy production in the tissue is shown below in Figure 16.98 When this signaling is perturbed, 
various disease states can result.96,98 
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Figure 16. PKA’s role in heart contractility and energy consumption. 
 
 
 
2.4.2: Aberrant PKA activity. 
Aberrant PKA activity has been implicated in a number of cancers, with opposing affects 
of both increasing and decreasing cell proliferation.99,100 For example, it has been shown that an 
increase in the expression of regulatory subunit IA, which results in a decrease of PKA catalytic 
subunit activity, causes increased cell proliferation in human melanoma cells.101,102 Conversely, 
the cAMP response element modulator (CREB) is activated by PKA. Studies have shown that 
increased levels of PKA increase CREB activity and contribute to cell proliferation in various 
cancers.103 It has also been demonstrated that certain forms of cancer excrete PKACα, known as 
extracellular protein kinase (ECPKA); the activity and amount of ECPKA strongly correlates 
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with tumor size.104 This is a particularly interesting observation for PKA in that a probe that 
selectively detects ECPKA, such as the one discussed in this thesis, could be a valuable tool in 
the clinic as a detection method for a tumor biomarker.  
Aberrant PKA activity has been identified and implicated the PKA pathway as a 
therapeutic target in Cushing’s disease.105 This example is another prominent illustration of the 
normal PKA catalytic activity being influenced by alterations in its regulatory subunit binding.105 
The reduced affinity of catalytic subunit for the regulatory subunit, and therefore its ability to 
form the inactive holoenzyme, cause an increased basal level of PKACα activity.105 
PKA activity is, not surprisingly, implicated in a number of other endocrine disorders as 
well.97,105 Instead of normal stimulation of GPCRs by endogenous hormones, mutations and/or 
regulatory perturbations that increase basal levels of PKA activity lead to related disease states. 
Aberrant PKA activity has been implicated in the endocrine disorders hyperthyroidism and 
acromegaly.106-109 Because PKA plays such a central role to cAMP signaling and protein 
expression, its involvement in various disease states is vast and diverse; therefore, methods to 
detect PKA activity have often been sought. 
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2.5: Current methods to detect PKA and PKACα activity.  
There are numerous antibodies commercially available for Western blot detection of 
many aspects of PKA, including both catalytic subunits (generally nonspecific splice variant 
detection), and the regulatory subunits. Some of these antibodies are non-selective, that is they 
detect all forms of PKA. There are also phosphorylation specific antibodies which only detect 
catalytic subunits of PKA that have been phosphorylated at Thr 197. These phospho specific 
antibodies are one current technology used to quantify active amounts of PKA. However, these 
antibodies are unable to take into account the other mechanism of regulation that PKA is subject 
to. Another common practice is to measure a specific substrate, or even total phosphorylation 
events that could be attributed to PKA. For example, there are CREB phosphorylation specific 
antibodies and by quantifying the levels of phosphorylation, it is reasoned that increased (or 
decreased phosphporylation) is an indicator of PKA activity. Additionally, a common antibody 
recognizes the substrate consensus sequence of PKA (RRXS/T) in its phosphorylated form 
RRXpS/T and by quantifying global detection of phosphorylation (or in some cases 
visualization) can be interpreted to be an indicator of PKA activity. These methods tend to fall 
short of truly accurate active levels of PKA and better reflect situational specific increases in a 
particular event correlated to PKA activity.  
There are a variety of sophisticated kits and detailed methods to analyze substrate 
turnover in complex biological mixtures and isolated protein solutions for both well and lesser 
equipped laboratories. Genomic sequencing is a stand by for most biology labs, however this 
does not address the phenotype. Substrate turnover is another common method, but this generally 
cannot be used in vivo nor can it account for pathway redundancies, e.g., a secondary enzyme 
causing additional activity due to overlapping consensus sequences (see discussion of consensus 
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sequence antibody for PKA activity above). When substrate is used in vitro it is very effective. 
Multiple detection methods can be employed to detect substrate turnover with isolated enzyme 
including, but not limited to, radiometric analysis, UV detections, fluorescence polarization, 
fluorescence-resonance energy transfer (FRET), thin-layer chromatography, and blotting 
techniques. We utilized a commercially available FRET based assay to determine out PKA 
activity in vitro and will be our procedures discussed in detail in the experimental section.  
There are a number of examples of a substrate-based probes to measure phosphate 
transfer at the source, both in whole cell and isolated enzyme assays. These probes utilize 
substrates demonstrated to be selectively phosphorylated by PKACα (kemptide for example), 
and a fluorophore whose emission is shifted when bound to and phosphorylated by PKACα. 
Lawrence and colleagues developed such a probe utilizing a coumarin derivative tag and a 
quencher dye for detection. When the probe is phosphorylated by PKA it causes a sharp increase 
in the coumarin fluorophore’s emission spectra allowing for selective detection. Through 
numerous peptide syntheses and various dyes, they optimized the substrate properties for 
maximum signal with minimal background. This is also detectable and quantifiable in real time 
so it has been used to characterize the location of PKA that is in the process of, or has very 
recently, phosphorylated the substrate based probe. This allows quantification of the relative 
amounts of PKA in mitochondrial microenvironments.110 
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Figure 17. Substrate-based probe of PKACα catalytic activity. 
 
 
 
Lawrence et al have also described a unique probe for detecting intracellular levels of 
PKA. They utilize a portion of PKI as an active site directed scaffold. However, instead of 
targeting Cys199 in the substrate-binding pocket, they target a non active-site cysteine (Cys 343) 
that does not inhibit the enzyme. Once their probe has bound, they expose it to UV light and a 
photoreactive moiety causes the release of PKI and only the labeled portion of the probe 
covalenty bound to the auxillary cysteine remains. Here they report that their probe identifies 
free and catalytically active enzyme yet does not inhibit it and thus they can tag it and follow its 
activity as a result of various stimuli.111 
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Figure 18. Active-site directed probe with electrophile directed towards Cys343. 
 
 
Another group has developed an affinity assay based on the PKI scaffold.93 In essence, 
this is the purpose of our probe but as applied in a reversible situation. PKI’s mechanism of 
action is well documented and therefore this report concludes that it can be used to selectively 
detect and measure amounts of free and catalytically active amounts of PKACα. They utilize 
residues 5-24 of PKI and express it linked to glutathione S-transferase (GST, with a Gly5 linker): 
GST-PKI(5-24). Upon generation of GST-PKI(5-24), they immobilized it onto solid glutathione 
beads for use in affinity purification. They were able to pull down catalytically active PKA and 
perform a number of activity-based experiments. An interesting outcome was the confirmation of 
H89 (a high affinity ATP competitive inhibitor of PKA) reducing affinity of PKI for the catalytic 
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subunit. However, they go on to note that the assay simply evaluates relative degrees of PKI 
affinity and does not quantify PKACα activity itself.93 
Imperiali and Shults have developed a generalizable strategy to apply to numerous 
protein kinases and display the utility of their approach on PKACα. They append a Sox residue 
to the C-terminal a PKA substrate (Ac-Leu-Arg-Arg-Ala-Ser-Leu-Pro-Sox-NH2). When the 
substrate is unphosphorylated, the affinity for Mg2+ of the substrate (has an engineered β turn for 
Mg2+ binding and is the lynch pin for the technique) is minimal, but upon phosphorylation the 
affinity increase dramatically. This increased binding of Mg2+ causes a detectable fluorescence 
signal to be generated by the Sox residue.112 
 
 
Figure 19. Sox residue used for selective detection of Mg2+ binding which was correlated to 
phosphorylation of substrate. 
 
 
Uri and coworkers have developed an easily accessible assay that utilizes thin-layer 
chromatography to detect PKA substrate turnover activity.113 They appended 5-TAMRA (a 
common fluorophore) to kemptide (a commonly used and commercially available PKA 
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substrate) and developed TLC conditions sufficient to separate the phosphorylated and non 
phosphorylated substrates, thereby allowing for selective detection and quantification.113 While 
this assay is generally only applicable in situations with isolated enzyme, its simplicity and 
accessibility make it noteworthy. 
The mechanism based fluorescence reporter mentioned in the irreversible Type IV 
inhibitors section of Chapter 1 (Figure 11) can also be included here in the review of methods to 
detect PKACα activity.58 Tung and colleagues’ mechanism based fluorescence reporter 
selectively reacts with Cys199 in the activation loop. Until this selective interaction occurs, the 
probe they developed remains quenched. In experiments they conducted in fetal bovine serum 
spiked with PKACα, they noted significant increase in fluorescence intensity in a dose 
dependent manner with increasing PKACα concentration.58   
PKA activity is an important indicator of cellular homeostasis and, as such, probes that 
accurately detect the activity of PKACα in vivo would have diverse applications in a variety of 
diseased and non-diseased systems. Here we report the efforts and resulting data towards the 
production of an ABP for the cAMP-Dependent Protein Kinase A (PKA). PKA is the prototype 
kinase, therefore the strategy described in the following text may serve as a general strategy to 
target other kinases with a similar cysteine in the activation loop.  
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Chapter 3: Development of ABPs for PKACα 
 Chapter 2 details the dynamic regulatory mechanism associated with PKACα catalytic 
activity. These mechanisms reinforce the high degree of sensitivity associated with the substrate-
binding pocket. Therefore, a probe that is selective for the active conformation of the substrate-
binding pocket would have significant advantages in terms of monitoring more accurately the 
levels of active protein available in the cell. Below is detailed the rationale for selection of the 
peptide scaffold as the recognition sequence and the subsequent structure-based design used to 
implement it an effort to produce an ABP.  
3.1: Background on the heat-stable protein kinase inhibitor (PKI) 
 The heat-stable protein kinase inhibitor (PKI) is endogenously expressed as a 76 amino 
acid protein (7,989 Da). It was identified by Edwin G. Krebs et al. in 1971.114 They detailed 
many characteristics of PKI; most notably, it was shown to be an efficacious inhibitor of 
PKACα.114 Many groups have performed subsequent structure-activity relationship studies on 
the peptide scaffold to determine the amino acids critical for binding, selectivity, and effective 
inhibition. Below is a brief summary of the data obtained in the context of PKI as a selective, 
active-site directed, peptide inhibitor. 
 The expression of PKI has been shown to vary greatly between tissue types. A study done 
on various rabbit tissues revealed that brain tissue had the highest levels of endogenous PKI. 
Cardiac muscle and skeletal muscle had roughly equivalent amounts of PKI, at about 1/3 that of 
the brain. The liver, kidney, and thymus only had a fraction of PKI as compared to brain and 
muscle tissues.115 These amounts were reported as units/g and generally only serve as relative 
amounts for these purposes.  
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 Multiple truncations of the full length PKI have been found to retain significant inhibition 
activity against PKACα. Many of the initial structure-activity relationship studies relied on 
isolating endogenous sources of PKI and truncating it with different proteolytic enzymes. Also, a 
few synthetic peptides are included (discussed in next paragraph).114-118 Some notable fragments 
that were identified are listed in Table 6 below. While these studies effectively demonstrated that 
it is possible for fragments of the full-length heat-stable protein kinase inhibitor to inhibit the 
catalytic activity, the peptides were limited to truncations made by their proteolytic enzymes and 
therefore the studies were not exhaustive.  
 
 
 
 
Table 6. Fragments of PKI and the corresponding Ki values for PKACα. 
Sequence Ki 
TTYADFIASGRTGRRNAIHD 0.3 nM 
TTYADFIASGRTGRRNAIHD - NH2 2.3 nM 
TTYADFIASGRTGRRNAI - NH2 3.1 nM 
TYADFIASGRTGRRNAI - NH2 1.7 nM 
FIASGRTGRRNAIHD - NH2 73 nM 
IASGRTGRRNAIHD - NH2 115 nM 
GRTGRRNAIHD - NH2 57 nM 
GKTGRRNAIHD - NH2 370 nM 
ADFIASGRTGRRNAI - NH2 90 nM 
DFIASGRTGRRNAI - NH2 97 nM 
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The next round of structure-activity relationship studies performed on PKI brought in a 
number of synthetic peptides. Among these is the primary example of the minimum sequence 
required for maximum inhibition, PKI(14-22)-Amide, with a Ki of 36 nM along with valuable 
structure-activity relationship data. PKI(14-22)-Amide, surprisingly, has an even lower Ki than 
PKI(14-24)-Amide (57 nM).94,117,119  This is one of the major reasons PKI(14-22) was selected as 
the “full length” ABP recognition sequence. 
 
 
 
Table 7. Structure-activity relationship analysis by amino acid substitution. 
PKI(14-22)  Ki 
GRTGRRNAI - NH2 36 nM 
GRTGRRAAI - NH2 550 nM 
GRTGRRGAI - NH2 110 nM 
GRTLRRNAI - NH2 390 nM 
GRAGRRNAI - NH2 140 nM 
GRTGRRNAL - NH2 180 nM 
GRTGRRNAG - NH2 1400 nM 
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3.2: PKI Selectivity. 
Full length PKI is regarded as being very selective for PKACα in complex biological 
mixtures.116,120 The selectivity of PKI(14-22)-Amide has been examined on a number of isolated 
enzymes; however, a full panel of kinase inhibition has not been published.116,119,121 Proteome 
selectivity of a derivative of PKI(14-22) is briefly addressed by an affinity pull-down experiment 
performed with murine tissue lysates.  One enzyme that in particular continues to be part of the 
equation when considering PKI’s in vivo activity is the cGMP-dependent protein kinase, PKG.  
The activation loop sequences of these two kinases have high similarity, and as a result the 
shorter PKI sequences have activity against PKA and PKG.118,119 
 
 
 
 
Table 8. Sequence alignment of DFG---APE regions of PKA and PKG. 
 
Activation Loop Sequence alignment 
PKA DFGFAKRVKG-- RTWTLCGTPEYLAPE 
PKG DFGFAKKIGFGKKTWTFCGTPEYVAPE 
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Table 9. Representative PKI fragments and their corresponding affinity for PKG.119,121 
PKI Fragments PKA Ki PKG Ki PKG/PKA 
TYADFIASGRTGRRNAI - NH2 1.7 nM 37820 nM 22247 
GRTGRRNAI - NH2 36 nM 8000 nM 222 
 
 
Additionally, various derivatives of the PKI inhibitor peptide have been produced to 
attenuate its activity profile. One research team has attached the DPTsh1 shuttling peptide to 
PKI(5-24)-Amide to produce a selective, cell permeable, peptide-based, inhibitor of PKACα.122 
Various lengths of the inhibitor peptide PKI are commercially available from many vendors. 
Additionally, these peptides are available with various N-terminal modifications; one of which is 
the addition of a myristyl group, which has been demonstrated to make the peptide cell 
permeable while maintaining affinity (our lab determined the IC50 of commercial Myr-PKI(14-
22)-Amide to be 47.9 nM) .120 
3.3.1: Inhibitor rationale: Structure-based design of PKI-based compounds. 
The multiple crystal structures of PKACα have played vital roles in deciphering the 
complex regulatory mechanisms that attenuate its catalytic activity. The first crystal structure of 
PKACα was the first of any protein kinase and thus provided valuable data concerning the 
makeup of the active site.83 Prior to this crystal structure, the use of active-site directed probes 
and subsequent analysis was the main method to determine the residues that make up the binding 
site (classical). Additionally, the first crystal structure was published as a His6 tagged 
recombinant protein bound to both ATP and a portion of the heat stable protein kinase inhibitor 
PKI(5-24). This particular crystal structure clearly illustrates the proximity of Cys199 to the P+1 
and P+2 positions of the inhibitor peptide.  
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PKI-Ile22 occupies the hydrophobic site at the P+1 position, this position has been 
demonstrated to have significant effect on the binding affinity of the peptide inhibitor (see Table 
4, above). From the crystal structure the distance was measured from the alpha carbon on the C-
terminal end of the peptide to estimate where the electrophilic carbon of an electrophile, such as 
a chloromethyl ketone, would reside. It was determined to be 7.3 Å for an Ile22 based 
electrophile. At the P+2 position is a histidine residue that has numerous interactions with 
surrounding residues (the specifics of which are detailed in Figure 14). From the crystal structure 
(1ATP) the distance was from the alpha carbon on the C-terminus side of His23 to estimate 
where an electrophile, like glycine halomethyl ketone, would reside; it was determined to be 8.3 
Å (Figure 20 below). 
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Figure 20. Distance analysis of relevant alpha carbons to the side chain of Cys199. 
 
 
3.3.2 Activity-Based Probe Rational: Selecting PKI as the active-site recognition sequence. 
Numerous inhibitors that target the ATP-binding site have been developed. Most of these, 
however, show little selectivity for PKACα. This is mostly due to the conserved nature of the 
nucleotide-binding site among many proteins in mammalian cells. Additionally, inhibitors of this 
nature must have high affinity to compete with millimolar concentrations of intracellular ATP if 
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they are to make the transfer from the lab to the clinic. While there have been some covalent 
inhibitors produced for other kinases that target the ATP-binding site, PKA does not have an 
appropriately placed cysteine necessary to be a target of this strategy. 
PKI has been demonstrated to be highly selective for PKA in vivo. In addition to its high 
selectivity, PKI (and many of its fragments) have high affinity for PKACα based on the available 
information and, perhaps most importantly, the mechanism of action of pseudosubstrate 
inhibitors. More specifically, by binding with the substrate-binding pocket of PKACα, PKI binds 
competitively with a number of endogenous regulatory mechanisms (reviewed in Chapter 2.3). 
Therefore, PKI presented itself as an ideal candidate as the recognition scaffold for the 
generation of an activity-based probe of PKACα.  
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Figure 21. View of critical amino acids in PKI for affinity for PKACα. 
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3.4: Single Amino Acid Analogues 
3.4.1: Rational and design of single amino acid analogues. 
 The distance between the carbonyl carbon of the P + 1 Ile22 and Cys199 in the cocrystal 
structure 1ATP is 6.8 Å, the C-terminal α-carbon distance is 7.3 Å and the C-terminal α-carbon 
at the P+2 position is 8.3 Å. The objective was to selectively react with this cysteine in the 
activation loop by utilizing endogenous binding mechanisms and a known binding mechanism of 
action. The project began by preparing a library of single amino acid analogues to capitalize on 
the hydrophobic binding pocket at the P+1 binding site of PKI, and its close proximity to the 
cysteine. It was hypothesized that the single amino acid, isoleucine, would maintain affinity for 
the hydrophobic binding pocket such that it would position itself appropriately for an appropriate 
cysteine selective electrophile. Also, this binding mechanism should be predictive of the full 
length peptide, thus providing valuable data pertaining to its activity-based mechanism of action 
and ability to inhibit the enzyme by alkylating Cys199.  
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Figure 22. Close up on Ile22 and proximity to Cys199. 
 
 
The first round of single amino acid analogues were centered around isoleucine, 
phenylalanine, and glycine. It was hypothesized that the isoleucine would bind in a similar 
manner to the isoleucine in PKI (Figure 23), the phenylalanine may be either able to increase 
hydrophobic interactions or be too large and thus provide important selectivity data, and the 
glycine would serve as a control for the backbone and/or amide in conjunction with the vinyl 
ketone to demonstrate the added binding interactions of the side chains.  
3.4.2: Preparation of the single amino acid analogues. 
The initial electrophile selected was the vinyl ketone electrophile, this is a particularly 
electrophilic moiety. Also, a vinyl ketone ensures labeling at the desired nucleophilic cysteine if 
the binding hypothesis holds true. Analogues were prepared in a short two-step synthesis. 
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Starting with the commercially available t-butyl carbamate (Boc) protected amino acids, a 
standard coupling was performed with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI) 
hydrochloride, 1-hydroxybenzotriazole (HOBt) hydrate, 4-methylmorpholine as the base, N,O-
dimethylhydroxylamine hydrochloride, and dichloromethane as the solvent at ambient 
temperature for 16 hr to generate the Weinreb amide leaving group. The Weinreb amide is a 
suitable leaving group for the subsequent Grignard reaction with vinylmagensium bromide in 
ether at 0 °C to produce the Boc protected amino acids with a vinyl ketone electrophile at the C-
terminal position. A control ethyl compound was synthesized by taking compound 2 and 
reducing the vinyl group with Pd/C and hydrogen gas at 1 atm for 16 hr. 
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Figure 23. Synthesis of Boc vinylketone amino acid derivatives. 
 
 
 
The propargyloxycarbonyl (Poc) protected amino acids were synthesized in anticipation 
of the utilization of ‘click’ chemistry for selective detection.34 The free base amino acids were 
commercially available. To prepare the Poc protected amino acids, propargyl chloroformate was 
incubated with the desired amino acid and sodium hydroxide as the base. Then a standard 
coupling was performed with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI) 
hydrochloride, 1-hydroxybenzotriazole (HOBt) hydrate, 4-methylmorpholine as the base, N,O-
dimethylhydroxylamine hydrochloride, and dichloromethane as the solvent at ambient 
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temperature for 16 hr to generate the Weinreb amide leaving group. Followed by a Grignard 
reaction with vinylmagensium bromide in ether at 0 °C to produce the Poc protected amino acids 
with a vinyl ketone electrophile at the C-terminal position. 
 
Figure 24. Synthesis of Poc vinylketone amino acid derivatives. 
 
An additional set of single amino acid analogues was synthesized to explore other 
electrophilic moieties with the goal of identifying the most suitable electrophile appropriate for 
selective labeling of activation segment cysteine while exploring various distances of the 
electrophilic group. Beginning with the commercially available Boc-protected isoleucine a 
standard coupling was performed with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI) 
hydrochloride, 1-hydroxybenzotriazole (HOBt) hydrate, 4-methylmorpholine as the base, 
ethanolamine, and dichloromethane (DCM) as the solvent at ambient temperature for 16 hr. The 
resultant alcohol was exposed to Appel reaction conditions to substitute the alcohol with a 
halide. A halide source (I2, CBr4, or CCl4), triphenylphosphine, imidazole, and DCM and the 
solvent at 0 °C for 4 hr yielded the alkyl halide electrophilic analogues 22-24. 
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Figure 25. Synthesis of various amino acid—electrophile derivatives. 
 
 
To produce a sulfur analogue for generating a disulfide bond with Cys199 and the Boc-
protected isoleucine, a standard coupling was performed with N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (EDCI) hydrochloride, 1-hydroxybenzotriazole (HOBt) hydrate, 4-
methylmorpholine as the base, cysteinamine, and dichloromethane (DCM) as the solvent at 
ambient temperature for 16 hr.  
To produce a maleimide analogue for covalent attachment with Cys199 and the 
electrophilic maleimide group on the Boc protected isoleucine. A standard coupling was 
performed with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI) hydrochloride, 1-
hydroxybenzotriazole (HOBt) hydrate, 4-methylmorpholine as the base, ethanolamine, and 
dichloromethane (DCM) as the solvent at ambient temperature for 16 hr. The resultant alcohol 
was purified on silica and then made into an electrophilic group with triphenylphosphine, diethyl 
azodicarboxylate (DEAD), and tetrahydrofuran (THF) as the solvent at -78 °C for 4 hr for the 
SN2 reaction with commercially available maleimide to produce 20. 
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3.4.3 Evaluation of single amino acid analogues as PKACα and AKT inhibitors. 
The first set of single amino acid analogue compounds with the vinyl ketone was tested 
for their inhibitory properties in a biochemical fluorescence resonance energy transfer (FRET) 
assay (Z’-LYTE kinase assay, Ser/Thr kit 1 and 6, Invitrogen, assays were run as published in 
reference 34)34 using commercially available recombinant PKACα and AKT1 (Invitrogen, 
P2999). This assay utilizes proprietary peptides that serve as substrates for the target enzyme and 
are labeled with coumarin and fluorescein at opposite ends for FRET action. The kinase 
(PKACα or AKT1) transfers a phosphate to the substrate from ATP. The reaction is halted and 
the FRET signal measured. The detectable FRET signal is only from phosphorylated substrate 
where the coumarin and fluorescein are still connected by the substrate scaffold. 
Unphosphorylated peptide is cleaved by a proprietary protease provided in the kit. The 
proteolytic action prevents FRET from occurring with the unphosphorylated substrate. 
Therefore, a decrease in FRET signaling is indicative of decreased enzymatic action. The 
compounds added that decrease FRET signaling can be interpreted as inhibitors of PKACα or 
AKT1. However, whether these are ATP or substrate competitive inhibitors is, generally, not 
discernable from these data. 
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Figure 26. PKACα inhibition graphs. 
 
 
 
Table 10. PKACα IC50’s by Z’Lyte Assay 
Compound PKACα IC50 (μM) 
3 56.2a 
6 >100 
9 >100 
10 >100 
18 >100 
Table 10. a: value obtained from reference 24.34 
 
6
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3.4.4: Results of Single Amino Acid Analogues  
The four compounds were tested against PKACα in triplicate. These compounds did not 
show any inhibition at concentrations up to 100 μM. This observation could be attributed to a 
number of factors. It is possible the vinyl ketone Michael acceptor is too reactive and is 
essentially used up non-specifically before it can alkylate a residue that inhibits the enzyme. It is 
also possible that the cysteine is not as accessible when the full length peptide is not present and 
therefore the electrophile cannot reach the cysteine, although previous attempts with single 
amino acid analogues by other groups were successful (see Chapter 1). Another possibility that 
more closely matches previously published results is that the reactivity of Cys199 towards 
external electrophiles is significantly reduced in the presence of ATP (at various physiologically 
relevant concentrations, see chapter 1 Type IV inhibitors of PKACα, section 1.3); therefore, the 
inhibitory effect seen by alkylation of Cys199 would not have occurred and the amino acids 
alone would not have sufficient binding affinity to inhibit activity. 
 Three of the single amino acid analogues were also tested against AKT1 in triplicate 
using the Z’Lyte assay. The purpose of testing against AKT1, another AGC kinase, was to 
provide valuable selectivity data. AKT1’s hydrophobic pocket at the P+1 position has been 
demonstrated to be better suited for aromatic moieties and it was hypothesized that we could 
obtain selectivity both for and against AKT1 via this mechanism. AKT1 was selected due to both 
its similar consensus sequence with PKACα (RXRXXSF and RRXS respectively) and its 
availability in our lab. The results are displayed below. 
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Table 11. Summary information of AKT1 and PKACα inhibition. 
Table 11. a: value obtained from reference 24.34 
 
 
 
 
Figure 27. AKT1 inhibition. 
Compound AKT1 IC50 (μM) 95% Confidence Int PKACα IC50 (μM) 
3 0.58a .46-.75 56.2a 
6 1.56 1.36-1.78 >100 
9 12.32 9.89-15.35 >100 
10 - - >100 
14 2.44 1.23-2.76 - 
18 - - >100 
6 9
14
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In all cases, compounds that were tested against both enzymes (3, 6, 9) indicated they 
were more potent inhibitors of AKT1 than PKACα. Compounds 3, 14, 9, and 6 had 0.58, 2.44, 
12.32, and 1.56 mM activity, respectively. It was not unexpected that the phenylalanine 
analogues would have better activity than the glycine analogues. This is particularly true when 
considering that the available data for TPCK, a phenylalanine based chloromethyl ketone 
commercially available and commonly used as a protease inhibitor, was demonstrated to have 
selectivity for AGC kinase cysteines in the activation loop that have a phenylalanine 
hydrophobic pocket adjacent to the cysteine of interest.35  
3.4.5: Discussion of the Single Amino Acid Analogue Results 
 After review of the data and available literature it was determined that, first, the single 
amino acid residues would not provide the desired properties to reliably target Cys199. Second, 
the single amino acid analogues would not provide the selectivity required for activity-based 
protein profiling on either a family or target selective scale (for the kinome). Third, that the vinyl 
ketone is too reactive of an electrophile to be reliably used and stored under mild conditions for 
extended periods of time (a logistical consideration). Lastly, it appears reactivity of Cys199 is 
not as robust as indicated with pure enzyme and it is necessary to increase the amount of time the 
electrophile is in proximity of the thiol side chain for adequate alkylation to occur. Therefore, a 
new hypothesis was needed to address issues of reactivity, selectivity, and binding action. 
3.5 Production and Evaluation of Longer Peptide Probes 
 By returning to the original structure-based design approach of PKI complexed with 
PKACα it was concluded that there are a minimum number of amino acids from the inhibitor 
peptide required for the preparation of an activity based probe with the necessary properties. It 
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was also hypothesized that there was a need for more stable electrophiles and that, despite their 
weaker reactivity, the appropriate placement by the PKI scaffold would be enough for sufficient 
labeling at Cys199. Additionally, new assays were required to address the need to determine if 
labeling was occurring in addition to the inhibitory properties. Therefore the Z’Lyte assay was 
no longer sufficient for the purposes of characterization (as a stand alone indicator), and a new 
method to assist in determining the mechanism of action was required. 
3.5.1 Experimental design. 
It was decided that gel electrophoresis techniques would allow for a more mechanistic 
characterization of new probes (as compared to the FRET assay). The initial experiments focused 
on fluorescence detection techniques using compounds tagged with rhodamine and different 
electrophiles. To perform these experiments, sufficient amounts of probe and a large scale source 
of protein were required. As a result, manual solid phase peptide synthesis to produce the peptide 
scaffold for the probe, solution phase organic synthesis to produce large quantities of a reactive 
rhodamine derivative, solution phase organic synthesis to produce the electrophiles, and 
recombinant protein expression for the preparation of PKACα presented themselves as solutions 
to the problem.  
 The general strategy selected for the production of probe involved a combination of 
synthetic steps that took place both on solid phase and in the solution phase with a (necessary) 
two-phase purification work up. The peptide was to be synthesized on a super acid-sensitive 
resin. The final N-terminal deprotection was to be done on the resin, then a tag could be placed 
on the N-terminus while still on solid phase using basic SN2 conditions. The use of a super acid-
sensitive resin is critical to the successful synthesis of these probes. The super acid-sensitive 
resin allows for orthogonal deprotection from the resin while maintaining the side chain 
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protecting groups on the amino acids. The side chain protecting groups prevent undesired 
coupling at later stages in the synthesis, not just for the Fmoc-based solid phase synthesis.  
 The 2-chloryltrityl chloride (2-CTC) resin was selected to be the solid support system for 
our Fmoc-based peptide chemistry. The 2-CTC resin has a number of desirable properties. It has 
been proven effective in Fmoc-based peptide syntheses.123 The cleaved alcohol resin can be 
regenerated with thionylchloride to produce the original 2-CTC species, if desired.124 It is not 
patent protected and is generally cheaply commercially available from multiple vendors in 
various preparations. Perhaps most importantly, it is super acid-sensitive, which means we can 
use a <3% TFA solution in dichloromethane to remove the peptide from the resin.123 These 
weakly acidic conditions will preserve the side chains of the amino acids necessary as part of the 
PKI scaffold and allow for subsequent orthogonal chemistry.  
 The fluorescent tag rhodamine was selected for the development of the first round of 
peptide-based probes. Many derivatives of rhodamine are available, as it is a common 
fluorophore. However, we needed relatively large quantities of a reactive rhodamine derivative 
to synthesize our probes and commercially available analogues were generally cost prohibitive. 
Therefore, the synthesis began with the generic rhodamine B which is very economical. For a 
linker, N-methylamino butyric acid was coupled. This route was adapted from a previously 
reported synthesis and improved upon it to prepare our rhodamine-NHS ester in large 
quantities.125,126  
 The electrophile was reevaluated and based on available data it was determined to move 
forward with the chloromethyl ketone. The chloromethyl ketone has a variety of pros and cons 
for its usage in ABPP. Very much in its favor is its selectivity for cysteine over other amino 
acids. It is also relatively small and can be incorporated into various scaffolds. Conversely, its 
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synthesis it difficult and requires the use of a potentially explosive diazomethane intermediate.  
As a result the first priority was to identify a different route to the chloromethyl ketone that did 
not require diazomethane.  
3.5.2 Preparation of the Chloromethyl Ketone 
 In an attempt to avoid using diazomethane as the intermediate to the production of 
chloromethyl ketone, a new synthetic route was explored that would allow the production of 
glycine chloromethyl ketone without the need for the specialized equipment to produce 
diazomethane. The initial starting materials benzylamine and epichlorohydrin are commercially 
available. Mixing benzylamine and epichlorohydrin in cyclohexane at ambient temperature for 
16 hrs produces 25. Followed by addition of the Boc protecting group, this is important if one 
desires to acid deprotect in the end and produce the stable HCl salt. The Boc group was added 
using Boc anhydride in dichloromethane at ambient temperature for 16 hr to produce 26. The 
alcohol was oxidized to a ketone by Swern oxidation conditions to produce the doubly protected 
chloromethyl ketone (27). Finally the benzyl group was removed with Pd(OH)/C in ethanol 
(Pd/C was not effective at removing this group), and hydrogen at 1 atm for 16 hr. While this did 
produce the desired chloromethyl ketone in quantities to move forward, we would need large 
quantities and the yield was relatively poor at this time (conditions were not optimized).   
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Figure 28. Alternative route to glycine chloromethyl ketone. 
 
 
 
As a result, the use of diazomethane chemistry to produce the selected chloromethyl 
ketone moiety for incorporation into our probe was necessary. To produce the diazomethane 
intermediate, the mixed anhydride of the Boc-protected amino acid must be produced.127 This is 
done by incubating the Boc-protected amino acid with isobutyl chloroformate in tetrahydrofuran 
with N-methylmorpholine as the base at -20 °C for 0.5 hr. Diazomethane is prepared from a 
stable, commercially available, derivative: Diazald. Diazald is broken down into diazomethane 
with KOH, the resulting diazomethane is then distilled with ether into a separate flask and kept 
cool in an ice bath. The diazomethane ether solution is poured directly into the mixed aldehyde 
produced in the previous steps and allowed to react for 4 hr, while the remaining diazomethane is 
quenched. The Boc protected amino acid with the diazomethane moiety is stable enough for 
purification. This product is treated with 4 N HCl in dioxane and monitored by TLC until 
completion. The resulting HCl salt can be crashed out by triturating with ether allowing for easy 
isolation without the need for column chromatography (Figure 29).127  
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Figure 29. Diazomethane route to chloromethyl ketone formation. 
 
 
 
 
 
 
3.5.3: Preparation of Rhodamine-NHS Ester. 
 The need for an abundant source of fluorophore led to an extensive search of the 
literature for a method to rapidly access large quantities of a reactive rhodamine derivative. What 
was found was a derivative of rhodamine B that would provide a linker and the ability to make 
the NHS ester for nucleophilic substitution onto the N-terminal of the peptide.125,126 Starting with 
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ethylcarbodiimide (EDCI), N-hydroxysuccinimide, and dichloromethane (DCM) as the solvent 
at ambient temperature for 16 hr. The resulting NHS ester 35 is ideal for the SN2 chemistry we 
employed to attached the N-methylamino butyric acid. The secondary amine is critical for the 
rhodamine to maintain its fluorescent characteristics; if it were not a secondary amine it would 
be subject to intramolecular lactam formation and subsequent quenching of the fluorescent 
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character. The resulting acid 34 is then exposed to a second round of standard coupling 
conditions, although this time with N,N′-dicyclohexylcarbodiimide (DCC), N-
hydroxysuccinimide, and dichloromethane (DCM) as the solvent at ambient temperature for 16 
hr. The final product was crashed out of solution with ether and collected as a viscous resin.  
 
 
 
Figure 30. Synthesis of Rhodamine-NHS ester. 
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3.5.4: Preparation of Peptide Scaffold. 
 The traditional approach to large scale peptide synthesis relies on the use of solid-
phase Fmoc based chemistry.123 The super acid sensitive 2-chlorotrityl chloride (2-CTC) resin 
was selected as the solid phase support system. It was hypothesized that incorporating the amino 
acids 18RRNA21 onto the single amino acid Ile(22) (RRNAI) would be adequate for 
demonstrating the feasibility of the probe and testing against the initial activity-based 
experiments. Additionally, the consensus sequence for PKACa is RRXS; thus, by incorporating 
more of the PKI scaffold, the probe now contains the consensus sequence.42,55,128 The 2-CTC 
resin was first swelled with DCM for 5 minutes, then DMF for 5 minutes. Fmoc-Ile-OH was 
added with triethylamine as the base and allowed to react for 1 hr. Once the first amino acid is 
loaded onto the resin, iterative fmoc based chemistry can be used to add the additional amino 
acids. All amino acids were purchased from ChemImpex as Fmoc-protected derivatives. The 
Fmoc is removed with a 20% piperidine solution. There is a subsequent coupling with the next 
amino acid in the sequence. This is followed by another deprotection in 20% piperidine. These 
steps are repeated until the desired peptide is produced.  
 
	   73	  
Figure 31. Solid phase synthesis of the pentapeptide. 
 
 
 
 
3.5.5: Assembly of the PentaPeptide Probe. 
  The glycine chloromethyl ketone was synthesized in the same manner as described above 
(Scheme 5). The glycine was hypothesized to allow for the greatest maneuverability of the 
electrophile to accomodate the trajectory of the thiol group on Cys199, while not interfering with 
the positioning of the important PKI-Ile22 side chain.  
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ester and triethylamine (TEA) in dimethylformamide (DMF). The reaction was stirred for 3 hr, 
washed with DMF five times, then DCM five times.  
The resin-bound product was taken directly to the next step. By attaching the rhodamine 
while on solid phase the N-terminus is effectively capped, which is essentially for subsequent 
reactions, and allows for easy work up. Rhodamine-PKI(18-22)-OH was then cleaved from the 
resin with a 2% TFA in DCM (this preserves the side chain protecting groups). The solvent was 
removed under vacuum (Scheme 8) and the product was characterized by MALDI mass 
spectrometry and taken directly to the next step.  
 
 
Figure 32. Solid phase addition of rhodamine tag and soft cleavage. 
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The next reaction is the coupling of the glycine chloromethyl ketone 32, the peptide is 
preincubated with (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate 
(PyBOP), and diisopropylethylamine (DIEA) in DCM. Then, the glycine chloromethyl ketone 
was added to the solution. The reaction was stirred for 16 h. Solvent was removed and the 
purified on a silica gel flash column, 0-30% over 10 minutes MeOH/DCM. The probe is then 
globally deprotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr,  and triturated with ether to 
afford crude product. This product was then purified on HPLC (95:5 to 75:25 H2O:ACN over 20 
minutes). The two-stage purification has proven to be a necessary extra step for the successful 
isolation of the final product (Scheme 9). Attempts to circumvent the silica column have resulted 
in the inability to isolate final product with sufficient purity to conduct research.  
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Figure 33. Coupling of the electrophile to 37 to generate 38. 
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undergoes cis phosphorylation at Ser338.130 It does undergo autophosphorylation at Thr197; 
however, this is a much slower reaction and does not result in complete conversion to the fully 
phosphorylated protein.131  
In mammalian cells, phosphorylation at Thr197 occurs rapidly and irreversibly by 
PDK1.38,130 Competent E. coli  cells were transformed with the wt or mutant PKACα plasmid and 
grown for 16 hr at 37 °C with ampicillin selection and moderate shaking in a test tube. An 
aliquot was taken into a 1 L Erlenmeyer flask with ampicillin selection and auto-induction media 
and grown at 37 °C for 16 hr with moderate shaking. Following growth, cells were spun down at 
6000 rpm for 10 min, and lysed into buffer (25 mM Tris, pH 8, 300 mM NaCl, and 10 mM 
imidazole) at ambient temperature. Cellular debris was removed by centrifugation at 20,000 rpm 
for 30 min and the soluble fraction was decanted onto a nickel column. Following sample 
loading, the nickel column was washed with 5 column volumes of a non-eluting buffer that 
prevents nonspecific binding to the nickel (25 mM Tris, pH 8, 300 mM NaCl, and 10 mM 
imidazole). Isolated PKACα protein is then eluted with 100 mM imidazole and concentration 
determined by absorption at 280 nm on a spectrophotometer.  Purity was analyzed by Coomassie 
stain (Figure 34 below).  
	   78	  
Figure 34. Coomassie stain of purified recombinant PKACα. 
 
 
3.6.1 Validation of Rhodamine 
 Prior to completion of the fully assembled pentapeptide probe it was necessary to 
determine whether or not the rhodamine analog synthesized could be detected on a GE Typhoon 
gel imaging instrument. Recombinant PKACα was incubated with 25 equivalents of Rhodamine-
NHS (35) for 1 hr at ambient temperature. To the solution was then added a denaturing sample 
buffer and incubated at 100 °C for 5 minutes before being run on a 10% SDS page gel at 170 V 
for 1 hr. The gel was imaged on a GE Typhoon gel imager set for detection of the similar 
TAMARA fluorophore.  
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 As was anticipated, there was robust labeling of all contents of the protein solution. The 
NHS ester (35) is a nonspecific electrophile and will robustly react with all available 
nucleophiles in solution, if allowed to react for sufficient time in suitable conditions.  
Figure 35. Evalutation of 35. 
 
 
3.6.2: Discussion of Rhodamine-NHS Labeling Experiment. 
There is significant labeling in the higher molecular weight regions mostly due to how 
the sample was denatured. The initial experiments did not contain a disulfide reducing agent, 
such as betameracaptoethanol (BME), which was omitted to ensure that there was no reversal of 
any labeling reactions that  may have occurred. This lack of disulfide reducing agent allowed 
significant intermolecular disulfides to persist during the gel electrophoresis and imaging steps. 
The described experiment provided the necessary proof for utilizing the rhodamine derivative 
synthesized in the lab. 
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3.7: Biological Characterization of the pentapeptide (38) as a probe for PKACα. 
 It was decided to examine the new probe for both its ability to inhibit wt PKACα in the 
Z’Lyte kinase assay and its ability to label the protein as wt, mutant, and in complex biological 
mixtures. All gels were cast in house and made to contain 10% acrylamide, following the exact 
procedure detailed in the experimental. HCT-116 cell lysates are known to overexpress AKT 
(Cys310 known to be nucleophilic see Chapter 1, section 1.3), these were procured in and 
supplied by Dr. Richard G Moran’s lab in the pharmacology and toxicology Department of 
VCU.  
 Multiple gel electrophoresis experiments were conducted to characterize the pentapeptide 
probe and its interactions with various substances. The first gel electrophoresis experiment 
shown below examined the labeling of the pentapeptide probe with wt recombinant protein, 
C199A mutant, the HCT-116 cell lysates, and the HCT-116 cell lysates spiked with wt 
recombinant protein. The ladder was purchased from Biorad and run at 1:100 dilution for 
fluorescence experiments and at 1x for colorimetric experiments.  For lanes containing wt 
protein recombinant PKACα was incubated in phosphate buffer (25 mM PO4 pH 7.2) with 
different concentrations of probe for 1 hr at ambient temperature. The samples were quenched 
with a denaturing sample buffer with bromophenol blue marker and incubated at 100 °C for 5 
min. The resulting solution was loaded onto the gel and run at a constant 170 V for 1 hr. The 
C199A mutant was incubated in the same manner and conditions as the wild type protein. The 
HCT-116 cell lysates were incubated in identical conditions. The additional HCT-116 cell lysate 
lanes were spiked with recombinant PKACα prior to incubation with probe. Then, all lanes were 
imaged on a typhoon imager.  
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Figure 36. Examination of Probe 38 with wt PKACα (lanes 2, 3, 6, and 8), C199A (lanes 4 and 
5), and HCT-116 cell lysates (lanes 11-15). 
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3.7.1: Discussion of Figure 36. 
This gel (Figure 36) demonstrates a number of positive characteristics of the probe and 
provides significant data with which to move forward. Due to the nature of how gels work, it can 
be concluded that the probe does in fact covalently label the protein in an irreversible manner. 
The labeling by the probe was robust and easily detected. The probe did not label non-selectively 
in the HCT-116 cell lysates, meaning that there is not aberrant labeling throughout the lane. 
What is particularly interesting is the location of the single band in lanes 13 and 15, which 
contain 30 mM of probe 38 and 16 μg of lysates. This band strongly correlates with the 
molecular weight of AKT1, and matches some of this labs previous results.34 It is also important 
to note that the cysteine in AKT1 was found to be nucleophilic (see chapter 1, section 1.3). Probe 
38 displays remarkable selectivity in a complex biological mixture. Additionally, high selectivity 
for the upper band was retained in extreme excess of recombinant protein, it is possible that bio 
reagents (such as ATP) in the lysate are inhibiting labeling of PKACα. The probe did however 
label the C199A mutant of PKACα, which was unexpected in that the probe was designed to 
only react with Cys199. It may be possible that the probe is alkylating another residue. There is 
precedent with Lysine-72 being alkylated by a fluorosulphone analog, by Taylor et al.132 
However, Lys72 is not located in the substrate-binding site. There is another cysteine residue. 
However, it is not located near the substrate-binding site either. 
3.7.2: Activity-based ATP effects on labeling. 
To further examine the characteristics observed in the gel above and to test the hypothesis 
that ATP may be inhibiting labeling, another gel (Figure 29) was run. Only recombinant PKACα 
was run on this gel and various biologically relevant conditions were examined. Physiologically 
relevant levels of magnesium chloride were examined: the Mg2+ cation is required for efficient 
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catalytic activity and substrate turnover.80,82,93  ATP was examined at 1 equivalent to the enzyme 
(~5.8 μM). These conditions were introduced prior to incubation with the probe. Additionally, 
fluoresceine-maleimide and Rhodamine NHS-ester were utilized as well. The incubation 
conditions for each of the probes were identical and are as follows. Recombinant PKACα was 
incubated in phosphate buffer (25 mM PO4 pH 7.2) with different concentrations of probe and 
physiologically relevant substances for 1 hr at ambient temperature. The samples were quenched 
with a denaturing sample buffer with bromophenol blue marker and incubated at 100 °C for 5 
minutes. The resulting solution was loaded onto the gel and run at a constant 170 V for 1 hr. 
Figure 37. Examination of A = 38, B = fluoresceine-maleimide, and C = 35. 
 
3.7.3: Results and Discussion of Figure 37. 
 As was demonstrated in the previous experiment, robust labeling occurs when 
recombinant protein and probe are incubated together without any other additives. However, 
when ATP is introduced (1 equivalent) to the incubation conditions, a slight reduction in labeling 
Probe
Probe Conc (µM)
Recombinant PKACa 5µg
MgCl2 (µM)
ATP (equivalents)
-      -      A     A    A   A     A     A   A      -     -     -    B    C   -
-      -     31  62  154 62   62    62 154   -     -     -    10    5   -
-     +      +     +    +   +     +      +   +      -     -     +     +    +   -
-     -       -      -     -    -    10k    6   6      -     -     +     +    +   -
-     -       -      -     -    1     1      1   1      -     -     +     +    +   -
75kDa
25kDa
PKACα
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is noted (lane 6). Upon addition of 10 mM MgCl2, labeling is completely abolished (lane 7). 
Addition of 1 equivalent of MgCl2 causes a reduction in labeling (lanes 8 and 9). Fluoresceine-
Maleimide and Rhodamine-NHS both label robustly; however, fluoresceine-maleimide appears 
to only label one band of PKACα (lane 13). The rhodamine-NHS labels nonspecifically (lane 
14).  
 Both a divalent metal ion (such as Mg2+) and ATP are required for efficient phosphate 
transfer to a substrate (it will occur in the absence of, but not efficiently).80 The addition of 1 
equivalent of ATP incurred a minor reduction in labeling efficiency by the probe. This is an 
unfortunate observation in that physiologically relevant concentrations of ATP are significantly 
higher than those examined in the gel (3-10 mM).133 Also, addition of the MgCl2 salt at 10 mM 
concentration completely abolished labeling (this is the salt concentration used in the inhibition 
assays to be discussed below). While robust labeling is observed, the probe will not label in 
active-like conditions, which excludes it from being classified as an activity-based probe for 
PKACα; however, selective labeling of what appears to be AKT in the cell lysates is a positive 
result. 
 
3.7.4: Inhibition of PKACα with RAC-1-280. 
To determine whether or not the probe was an effective inhibitor of wt PKACα, the 
Z’Lyte kinase inhibition assay kit was utilized. The IC50 of probe 38 was determined to be 6.9 
μM. While the IC50 was higher than would be expected for a covalent inhibitor, it is clear from 
the gel experiments labeling is most likely inhibited in conditions that would allow for 
phosphoryl transfer. It may be that the same protective features the previous Type IV irreversible 
inhibitors (see Chapter 1, section 1.3) encountered with ATP in the inhibition assay are at work. 
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As well as from MgCl2, the inhibition assay conditions are run at 10 mM MgCl2 (Invitrogen 
Z’LYTE manufacturer protocol). This concentration of MgCl2 was shown to completely abolish 
labeling. Therefore, the IC50 may only be indicative of the reversible peptide. The intention was 
that this data, in conjunction with the mechanistic data gleaned from the in vitro gel experiments, 
would validate the probe. The IC50 data plus the lack of selectivity for PKACa in a complex 
biological mixture leads to a hypothesis that more of the inhibitor peptide sequence PKI was 
needed to obtain selectivity for PKACα and to produce an activity-based probe.  
3.7.5: DFG Sequence Alignment. 
 To determine the broad applicability of the method to the kinome, a sequence alignment 
was performed on the eukaryote protein kinome. It was determined that 99 human protein 
kinases share a similar cysteine in the activation loop. Among them is AKT1 (discussed in 
Chapter 1, section 1.3), and the homologous PKG (from the same family of AGC kinases).  The 
results of the alignment are shown in the experimental (Chapter 4, Figure 69). The cysteine that 
corresponds to the position in PKACα is highlighted in a red box. Other cysteines in the 
activation loop are highlighted in orange text and present potential targets by a similar strategy; 
that is a substrate based small molecule/peptide with an appropriately placed electrophile could 
have the potential to react with these cysteines in an activity-dependent manner. The alignment 
and analysis was performed with ClustalX 2.1 and the kinome fasta file was obtained from 
kinase.com. 
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3.7.6: Discussion of the Pentapeptide Experiments. 
 The pentapeptide analogue (Rh-PKI(18-22)-G-(CMK)) provided significant strides in the 
production of active-site directed probes for the lab and established protocols for labeling and 
imaging various samples. The rhodamine derivative synthesized was proven effective at labeling 
and detection. The synthesis that was modified to obtain large quantities of the rhodamine-NHS 
proved to be easily replicated and to have agreeable yields. The glycine chloromethyl ketone 
moiety was shown to effectively label recombinant PKACα. The synthesis of the entire probe 
was a significant step as well and the two-stage purification was shown to be necessary and this 
synthesis is easily applied to other peptides and compatible electrophiles. This is the synthetic 
method that was carried forward to the remaining probes. The probe also displayed remarkable 
selectivity in HCT-116 cell lysates, albeit not for PKACα, but it is important to note that the 
chloromethyl ketone moiety will readily react with free sulfurs and the level of selectivity 
observed is a significant result. Additionally, the band that is labeled occurs at a molecular 
weight consistent with the molecular weight of AKT, which has a nucleophilic cysteine (Cys310) 
that has been demonstrated to react with various electrophiles (see chapter 1, section 1.3). 
 The characterization of (Rh-PKI(18-22)-G-(CMK)) also revealed a number of negative 
attributes. Labeling can easily be abolished with physiologically relevant concentrations of 
MgCl2. ATP appears to have a protective effect on (Rh-PKI(18-22)-G-(CMK)) labeling of wt 
PKACα. (Rh-PKI(18-22)-G-(CMK)) does not label PKACα in HCT-116 cell lysates (to a 
detectable level), even when the sample was spiked with excess PKACα. The IC50 determined by 
the Z’Lyte kinase assay was indicative of reversible kinetics (high IC50 and a hill slope of 1). The 
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data would suggest that, despite (Rh-PKI(18-22)-G-(CMK)) being an active-site directed probe, 
it is not an activity-based probe in that it actually is prohibited from labeling in conditions 
conducive to catalytic activity.  
 It was decided at this point to synthesize a larger portion of PKI in order to gain affinity 
for the catalytic subunit and subsequently increase labeling. PKI(14-22)-Amide has been shown 
to retain suitable affinity for PKACα (Ki 36 nM) while being synthetically accessible at 9 amino 
acids in length. Therefore, the next analogue synthesized was Rh-PKI(14-22)-Gly-(CMK) 
3.8: Preparation of PKI(14-22)Gly-CMK 
 The same order of operations was utilized to complete the synthesis of PKI(14-22)Gly-
CMK. The 2-CTC resin proved to be a valuable resin for this synthetic route and resin preloaded 
with Ile was purchased from ChemImpex. The same batch of glycine chloromethyl ketone 
produced utilizing the diazomethane intermediate was used. The synthetic route we chose to 
make our rhodamine NHS ester provided us a route that enabled large scale production; 
therefore, we did not have to synthesize more for the production of this probe as the previous 
batch was sufficient. An additional step was added to the peptide synthesis, an acetyl capping 
step to cap off any uncoupled N-termini after each coupling step. 
Schemes 10 and 11 depict the production of the PKI(14-22)-GlyCMK probe. Briefly, 2-
chlorotrityl chloride (2-CTC) resin preloaded with Ile was purchased from ChemImpex (200-400 
mesh, Catalog #03472). Peptide couplings were carried out manually via standard Fmoc amino 
acid protection chemistry. Amino acids were activated and added to resin with (benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) and diisopropylethylamin 
(DIEA). The resin was swelled with DCM (5 min) then DMF (5 min).  All amino acids were 
added by the general procedure that follows (with the exception of Arg, which underwent double 
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couplings): Fmoc deprotection (20% piperidine in DMF, 3 x 5 min), wash with DMF 3x, amino 
acid coupling (PyBOP, DIEA 0.1 M in DMF, 1 hr, 2x for Arg), wash with DMF 3x, acetyl cap 
(pyridine:acetic anhydride 20:20, 0.15 M in DMF, 30 min). After the final deprotection (Gly 14) 
with 20% piperidine in DMF, the resin-bound product was taken directly to the next step.  
 
 
Figure 38. Iterative solid phase synthesis of 39. 
 
While the peptide is still on the resin it was treated with a solution of RhodamineNHS 
ester and triethylamine (TEA) in dimethylformamide (DMF). The reaction was stirred for 3 h, 
washed with DMF 5x, then DCM 5x. The resin-bound product was taken directly to the next 
step. By attaching the rhodamine while on the solid phase the N-terminus is capped, which is 
essential for subsequent reactions, and allows for easy work up. Rhodamine-PKI(18-22)-OH was 
then cleaved from the resin with a weakly acidic solution of TFA in DCM (2% v/v). The solvent 
was removed under vacuum and product taken directly to the next step. The next reaction is the 
H2N Gly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-O
Cl
Cl
2-Chlorotrityl 
chloride resin 
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coupling of the glycine chloromethyl ketone 32, where the peptide is preincubated with 
(Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) and 
diisopropylethylamine (DIEA) in DCM. Then the glycine chloromethyl ketone was added to the 
solution. The reaction was stirred for 16 hr. Solvent was removed and the purified on a silica gel 
flash column, 0-30% over 10 minutes MeOH/DCM. The probe is then globally deprotected 
followed by trituration with ether to afford crude product. Product purified on HPLC. 
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Figure 39. Mixed solid phase and solution phase chemical assembly of 41. 
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3.9: Biological Characterization of Rh-PKI(14-22)-G-(CMK). 
 In a similar setup, the longer length probe was examined for its ability to label PKACα. 
The limit of detection for protein amounts was examined. The saturability of labeling was 
examined with non-covalent Myr-PKI(14-22)-Amide, which examines a number of 
characteristics and will be discussed after in section 3.9.2. The labeling of the cysteine to alanine 
mutant (C199A) examined the residue being labeled. Oxidation of the cysteine was attempted in 
order to mimic the endogenous regulatory mechanism of glutathiolation. Labeling under 
different pH conditions examined the differences in the two bands. The Coomassie stained gels 
and fluorescent gels of applicable experiments underwent secondary analysis due to their overlap 
and the predominant band species was determined and examined. Additionally, the protein 
production was modified to better represent physiological conditions (see section 3.9.11). All 
gels were cast in house and made to contain 10% acrylamide, the exact procedure is detailed in 
Chapter 4, the biological experimental section. 
3.9.1: Protein—Probe Limit of Detection. 
 Many gel electrophoresis experiments were conducted with the nonapeptide-based probe. 
The first, of note, is detailed below where the limit of detection of protein in the presence of 
excess probe was examined. Protein concentration was determined by absorbance at 280 nM and 
diluted such that it was 1 mg/mL in phosphate buffer (25 mM PO4 pH 7.2). The probe was made 
as a 10 mM stock in DMSO and diluted accordingly for appropriate final concentrations in the 
gel experiments. The gel was cast as 1.5 mm thick and the wells were a total volume of 20 μL. 
The samples were quenched with a denaturing sample buffer (made in-house and described in 
the experimental) and incubated at 100 °C for 5 minutes. The denaturing sample buffer did not 
contain a disulfide reducing agent (such as betamercaptoethanol, BME).  
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Figure 40. Protein concentration detection analysis. 
 
 
 
3.9.2: Results and Discussion of Figure 40. 
 The Rh-PKI(14-22)-G-(CMK) probe displays robust labeling of isolated recombinant 
PKACα at varying amounts. The last prominent labeling signal is observed at 2 μg of 
recombinant protein; 1 μg and less does not provide as potent signal. The lack of disulfide 
reducing agent is apparent in the upper portions of the gel (indicating higher molecular weight); 
these are most likely intermolecular disulfide bonds. The double banding of recombinant 
PKACα is observed again. The extended length of the peptide recognition scaffold did not 
provide the level of selectivity desired for single band images at all observable protein 
concentrations. It is clear that optimization is necessary moving forward for a gel image that 
consists of only one band. 
 
 
Recombinant PKACα (µg)
41 (30µM)
0    10     9     8      7      6     5     4      3      2      1     .5   .25   .1    0
-      +      +     +      +      +     +     +     +      +      +      +     +    +     -
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3.9.3: Mutant labeling experiments. 
 In order to fully characterize the mechanism of action of the Rh-PKI(14-22)-G-(CMK) 
probe, additional gels were run to examine the effects of other changes. In Figure 41 below, the 
labeling characteristics of the probe were examined against the cysteine mutant of PKACα 
(C199A) and limit of detection experiments were included with a lower concentration of probe. 
Both protein concentrations were determined by absorbance at 280 nm and diluted such that it 
was 1 mg/mL in phosphate buffer (25 mM PO4 pH 7.2). The probe was made as a 10 mM stock 
in DMSO and diluted accordingly for appropriate final concentrations in the gel experiments. 
The gel was cast as 1.5 mm thick and the wells were a total volume of 20 μL. The samples were 
quenched with a denaturing sample buffer (made in house and detailed in the biological 
experimental section) and incubated at 100°C for 5 minutes. This time the denaturing sample 
buffer did contain a disulfide reducing agent (betamercaptoethanol, BME). Coomassie staining 
was performed with blue G250 in a H2O/MeOH/AcOH solution, and destained with a 
H2O/MeOH/AcOH solution.  
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Figure 41. Labeling analysis with wild-type and C199A PKACα. 
 
3.9.4: Results and Discussion of Figure 41. 
 The Rh-PKI(14-22)-G-(CMK) probe displays robust labeling of isolated recombinant 
PKACα at the reduced concentration (3 μM). However, robust labeling occurred with the C199A 
mutant. It is possible that labeling is occurring at a different residue, e.g., Lysine-72 is in 
proximity and has been shown to react with nucleophiles placed in close proximity; this is, 
however, unlikely because lysine-72 resides more in the nucleotide-binding site than the 
substrate-binding pocket. There is another lysine residue more appropriately placed, Lysine-83, 
and may be a target of an appropriately placed electrophile. The distance from the alpha-carbon 
at the P+2 position is 5.6 Å to Lys83 and it is 8.3 Å to Cys199. This observation is interesting 
Recombinant PKACα (µg)
C199A (µg)
41 (µM)
75kDa
25kDa
PKACα
-      10   9    8     7    6     -     -      -
-       -     -     -     -     -     5    4      -
-       -    3     3     3    3    -     3      -
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and not necessarily an exclusion for qualification of an activity-based probe. The C199A mutant 
does retain activity and such a probe would still label in an activity-dependent manner. What is 
fortunate from this experiment, however, is the high molecular weight impurity in the C199A 
samples. These two spots give points of reference for alignment, and as a result a secondary 
analysis was performed by overlapping the Coomassie stained gel and the fluorescent image, 
detailed below. 
 
 
 
 
Figure 42. Coomassie and fluorescence image overlap from Figure 41. 
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3.9.5: Saturability with Myr-PKI(14-22)-Amide. 
To further characterize the mechanism of action of the Rh-PKI(14-22)-G-(CMK) probe 
additional gels were run to examine the effects of competition with a known inhibitor with a 
known mechanism of action. In Figure 44 below, the labeling characteristics of the probe were 
examined against the wild-type recombinant PKACα and increasing concentrations of the 
reversibile inhibitor Myr-PKI(14-22)-Amide (IC50 = 49.9 nM). Protein concentrations were 
determined by absorbance at 280 nm and diluted such that it was 1 mg/mL in phosphate buffer 
(25 mM PO4 pH 7.2). The probe was made as a 10 mM stock in DMSO and diluted accordingly 
for appropriate final concentrations in the gel experiments. The gel was cast as 1.5 mm thick and 
the wells were a total volume of 20 μL. The samples were prepared for gel electrophoresis as 
above and Coomassie stain performed as above.  
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Figure 43. Saturability of labeling. 
 
 
3.9.6: Results and discussion of the saturability experiment. 
 The labeling lane (lane 3), which lacks any inhibitor, displays robust labeling. Increasing 
the concentration of Myr-PKI(14-22)-Amide, an active-site directed reversible inhibitor, reduces 
labeling in a dose dependent manner. DMSO did not inhibit labeling; therefore, the decrease in 
labeling can be attributed to Myr-PKI(14-22)-Amide. The Coomassie stain gel image matches 
the fluorescence image. The dose dependent decrease in signal appears to be linear for both 
bands (upper and lower), indicating the labeling of each band is occurring in the active site.  
 
 
PKACα
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    -       -        3      3      3      3     3     -
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3.9.7 Cysteine oxidation with glutathione. 
The mechanism of action of the Rh-PKI(14-22)-G-(CMK) probe must be further 
characterized to understand what is happening on a molecular level; therefore, additional gels 
were run to examine the effects of cysteine oxidation with glutathione. In Figure 44 below, the 
labeling characteristics of the probe were examined against the wild-type recombinant PKACα 
and with oxidative conditions to mimic the endogenous regulatory mechanism of 
glutathiolaytion at Cys199. PKACα concentration was determined as described above. The 
probe was made as a 10 mM stock solution in DMSO and diluted accordingly for appropriate 
final concentrations in the gel experiments. The gel was cast as 1.5 mm thick and the wells were 
a total volume of 20 μL. Prior to incubation with probe, the appropriate lanes were incubated for 
1 hr with relevant reagents (diamide, glutathione (GSH), and diamide with GSH). Then the 
samples were incubated with probe for an additional 1 hr. The samples were prepared for gel 
electrophoresis as described above, imaging and staining was performed as described above. 
 
 
	   99	  
 
Figure 44. Examination of the effects of cysteine oxidation on labeling. 
 
 
 
 
 
 
3.9.8: Results and discussion of the cysteine oxidation experiment (Figure 44). 
The control labeling lane (lane 3) displays robust labeling. GSH alone has no observable 
impact on labeling of wild-type recombinant PKACα. When diamide is introduced, the bottom 
band was selectively knocked out. When diamide and GSH are both introduced, again the bottom 
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band was selectively knocked out. The Coomassie image matches the fluorescent image and 
indicates equal protein loading. The selective knockout of labeling for the bottom band is an 
interesting result that has a number of possible explanations. The unphosphorylated form of the 
protein at Thr197 has a disordered activation loop. Therefore, it is possible that Cys199 is more 
easily accessible when the activation loop is disordered and, as a result, oxidizes much easier 
than the ordered species. It is also possible that oxidation at Cys199 was incomplete. However, 
the methods to perform this oxidation were previously reported by Taylor et al.37 Another 
possibility is that oxidation is occurring but it is not inhibiting labeling: i.e., that is it is labeling 
two different residues one for each band. This last hypothesis was further examined in the next 
discussed gel. 
3.9.9: Labeling analysis in different pH conditions. 
The residue(s) that the Rh-PKI(14-22)-G-(CMK) probe is alkylating must be further 
characterized to understand what is happening on a molecular level; therefore, additional gels 
were run to examine the effects of pH changes to labeling. In Figure 45 below, the labeling 
characteristics of the probe were examined against the wild-type recombinant PKACα and with 
phosphate buffer solutions of increasing acidity. The PKACα concentration was determined and 
adjusted appropriately as described above. The probe was made as a 10 mM stock solution in 
DMSO and diluted accordingly for appropriate final concentrations in the gel experiments. The 
gel was cast as 1.5 mm thick and the wells were a total volume of 20 μL. Then the samples were 
incubated with probe for 1 hr. The individual samples were prepared for gel electrophoresis as 
described above. Imaging and staining was conducted as described above. 
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Figure 45. Analysis of pH effects on labeling. 
 
 
3.9.10: Results and Discussion of Figure 45. 
The Rh-PKI(14-22)-G-(CMK) probe displays robust labeling of isolated recombinant 
PKACα at the standard buffer pH of 7.2. However, the labeling subsequently reduces with the 
corresponding reduction in pH. The reduction in labeling is noted for both band species in a 
similar fashion for each decrease in pH. At a concentration of 300 nM of probe, only the labeling 
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at pH 7.2 is detectable. A similar reduction of labeling is observed with the off target bovine 
serum albumin (BSA). Because the labeling is affected by pH changes for both bands in a similar 
manner, the data suggest that the two bands are labeled at the same residue, as their isoelectric 
points respond at the same rate to pH changes. This reduces the likelihood (the possibility 
mentioned in the cysteine oxidation gel discussed above) that two different residues were being 
labeled. Fortunately, with the BSA producing two spots, points of reference for alignment were 
available and as a result a secondary analysis was performed by overlapping the Coomassie 
stained gel and the fluorescent image, detailed below. 
 
 
 
 
 
Figure 46. Overlap of fluorescence and Coomassie gel images from Figure 46. 
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3.9.11: Analysis of PDK1 phosphorylation on PKACα and labeling. 
 To examine the effect of phosphorylation of Thr197 on labeling with Rh-PKI(14-22)-G-
(CMK) recombinant PKACα was phosphorylated in vitro. To promote phosphorylation at 
Thr197, the enzyme that performs this catalytic action in vivo (3-phosphoinositide-dependent 
protein kinase 1, PDK1) was purchased from Invitrogen. Recombinant PKACα was diluted and 
mixed with appropriate amounts of PDK1. In Figure 47, the labeling characteristics of the probe 
were examined against the wild-type recombinant PKACα and with recombinant PKACα that 
was treated with PDK1. Both protein solution concentrations were determined as described 
above. The probe was made as a 10 mM stock solution in DMSO and diluted accordingly for 
appropriate final concentrations in the gel experiments. The gel was cast as 1.5 mm thick and the 
wells were a total volume of 20 μL. Then the samples were incubated with probe for 1 hr. The 
samples were prepared for gel electrophoresis as described above. Imaging and staining was 
performed as described above. 
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Figure 47. PKACα treated with PDK1 analyzed with 41. 
 
 
3.9.12 Results and Discussion of Figure 47. 
Probe 41 again displayed robust labeling of isolated recombinant PKACα at the standard 
buffer pH of 7.2. Rh-PKI(14-22)-G-(CMK) revealed that by treatment of PKACα with PDK1, a 
single band can be produced in the gel. This confirmed the hypothesis of the two bands differing 
by a phosphate moiety. However, the method by which we produced the protein was inefficient 
(only made 100 μg on the first run) and relies on outside sources of PDK1, which proved cost 
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inefficient. Therefore, it was determined that a method to produce large enough quantities for 
activity-based experiments of PKACα was necessary. Additionally, probe 41 did not display the 
selective qualities necessary for the activity-based probe and it was determined that the 
chloromethyl ketone moiety remained too reactive. As a result, a switch to an electrophile with a 
reduced reactivity profile was selected.   
3.9.13: Discussion of the Biological Characterization of 41. 
 The nonapeptide analogue 41 enabled extensive characterization of the interactions 
between the specifically placed chloromethyl ketone moiety and different isoforms of PKACα. 
The probe demonstrated selectivity for pThr197 PKACα over Thr197 PKACα. The labeling was 
saturable as was demonstrated with Myr-PKI(14-22)-Amide. The probe did not respond to the 
C199A mutant, as was expected. The probe did not respond to the glutathiolation experiments, as 
was also expected. It is possible that it is labeling another amino acid. The phosphorylation of 
Thr197 was successful and produced enough to confirm the hypothesis. 
 Based upon these observations, it was decided to synthesize a different derivative of PKI 
in order to gain selectivity for the catalytic subunit and ideally increase specific labeling at 
Cys199 in an activity-dependent manner. PKI(14-22) has already demonstrated itself to be a 
good length and so it was decided not to change the recognition scaffold. It was, instead, decided 
to change the reactivity of the electrophile. The hypothesis was that, by reducing the reactivity of 
the electrophile, selective labeling would be achieved in both isolated and complex biological 
mixtures.  
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3.10: The fluoromethyl ketone electrophile 
 The fluoromethyl ketone moiety is less reactive than the chloromethyl ketone. Its 
synthesis is a little more complicated in that the free base of glycine fluoromethyl ketone, for 
example, is not stable and therefore a multistep synthesis is necessary.134,135 A multistep synthesis 
for the production of glycine fluoromethyl ketone has been published and the results were 
reproduced in this lab.135 The scheme is depicted below with the yields obtained in this lab, all 
spectral data matched the previously reported values and are detailed in the experimental section. 
The protected glycine fluoromethyl ketone was used in the same capacity as the glycine 
chloromethyl ketone in terms of appending to the peptide scaffold. 
 
Figure 48. Synthesis of fluoromethyl ketone. 
 
 
The chemistry scheme in Figures 49-50 depict the production of the PKI(14-22)-G-
(FMK) probe. Briefly, 2-Chlorotrityl Chloride (2-CTC) resin preloaded with Ile was purchased 
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from ChemImpex (200-400 mesh, Catalog #03472). Peptide couplings were carried out manually 
via standard fmoc amino acid protection chemistry. Amino acids were activated and added to 
resin with (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) and 
diisopropylethylamin (DIEA). The resin was swelled with DCM (5 min) then DMF (5 min).  All 
amino acids were added by the general procedure that follows (with the exception of Arg, which 
underwent double couplings): Fmoc deprotection (20% piperidine in DMF, 3 x 5 min), wash 
with DMF 3x, amino acid coupling (PyBOP, DIEA 0.1 M in DMF, 1 hr, 2x for Arg), wash with 
DMF 3x, acetyl cap (pyridine:acetic anhydride 20:20, 0.15 M in DMF, 30 min). After the final 
deprotection (Gly 14) with 20% piperidine in DMF, the resin-bound product was taken directly 
to the next step.  
Figure 49. Production of peptide on resin. 
 
 
H2N Gly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-O
Cl
Cl
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Peptide Synthesis
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While the peptide is still on the resin it was treated with a solution of Rhodamine-NHS 
ester and triethylamine (TEA) in dimethylformamide (DMF). The reaction was stirred for 3 h, 
washed with DMF 5x, then DCM 5x. The resin-bound product was taken directly to the next 
step. Rhodamine-PKI(14-22)-OH was then cleaved from the resin with a 2% TFA in DCM. The 
solvent was then removed under vacuum. Product taken directly to the next step.  
The subsequent reaction is the addition of the electrophile by coupling of the glycine 
fluoromethyl ketone 47. Briefly, the peptide is preincubated with (Benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), and diisopropylethylamine 
(DIEA) in DCM. Then the glycine fluoromethyl ketone was added to the solution. The reaction 
was stirred for 16 h. Solvent was removed and purified on a silica gel flash column, 0-30% over 
10 minutes MeOH/DCM. The probe is then globally deprotected with 95:2.5:2.5 TFA:TIS:H2O 
(5 mL) for 1 hr,  then triturated with ether to afford crude product. The crude product was 
purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). 
 
 
 
 
 
	   109	  
Figure 50. Assembly of Rh-PKI(14-22)-G-(FMK). 
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3.11: Expression of Phosphorylated PKACα 
 To adequately examine a probe for activity-based protein profiling (ABPP), relatively 
large quantities of isolated protein are required for activity-based experiments. Previously, it was 
determined that in order to examine the physiologically relevant form of PKACα 
(phosphorylated at Thr197) we needed to devise a method that would produce pThr197 PKACα 
as the only species (at least by probe detection limits). The PDK1 plasmid was a generous gift 
from Justin Rettenmaier at the University of California, San Francisco. However, useful 
quantities could not be isolated from E. coli due to poor solubility and low expression levels. 
Therefore, the initial method of mixing the isolated proteins would not work when attempting to 
produce in-house PDK1.  
3.11.1: Crude lysate mixture method. 
 The next experiment to produce pThr197 PKACα involved the generation of PDK1 
lysates, without purifying, as the source of PDK1. Briefly, competent E. coli cells were 
transformed with the PDK1 plasmid and grown for 16 hr at 37 °C  with ampicillin and moderate 
shaking in a test tube. An aliquot was taken into a 1 L Erlenmeyer flask with ampicillin selection 
and auto-induction media and grown at 37 °C for 16 hr with moderate shaking. Following 
growth, cells were spun down at 6000 rpm for 10 min, and lysed into MOPS buffer (50 mM 
MOPS, pH 7.4, 100 mM NaCl, 10 mM BME, 10 mM MgCl2, and 1 mM ATP) at ambient 
temperature. Cellular debris was removed by centrifugation at 20,000 rpm for 30 min. The 
supernatant was taken onto the next step without further purification.  
Simultaneously, competent E. coli cells were transformed with the wt-PKACα plasmid 
and grown for 16 hr at 37 °C with ampicillin and moderate shaking in a test tube. An aliquot was 
taken into a 1 L Erlenmeyer flask with ampicillin selection and auto-induction media and grown 
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at 37°C for 16 hr with moderate shaking. Following growth, cells were spun down at 6000 rpm 
for 10 min, and lysed into buffer (25 mM tris, pH 8, 300 mM NaCl, and 10 mM imidazole) at 
ambient temperature. Cellular debris was removed by centrifugation at 20,000 rpm for 30 min 
and the soluble fraction was decanted onto a nickel column. Following sample loading, the 
nickel column was washed with 5 column volumes of a non-eluting buffer (25 mM tris, pH 8, 
300 mM NaCl, and 10 mM imidazole). Isolated PKACα protein is then eluted with 100 mM 
imidazole and concentration determined by absorption at 280 nm on a spectrophotometer.   
The purified PKACα was then added directly to the lysates which were made from the 
PDK1 transformed E. coli cells and lysed into MOPS buffer. The solution was allowed to react 
for 90 minutes at ambient temperature. Then the solution was buffer exchanged into buffer for 
the nickel column (25 mM tris, pH 8, 300 mM NaCl, and 10 mM imidazole), and decanted onto 
a nickel column. The same procedure was followed for purifying PKACα as stated above.  
3.11.2: Gel of Pure PKACα treated with PDK1 lysates. 
In Figure 51, below, the labeling characteristics of the probe were examined against the 
wild-type recombinant PKACα that was treated with PDK1 lysates. The final PKACα solution 
concentration was determined by absorbance at 280 nm and diluted to 1 mg/mL in phosphate 
buffer (25 mM PO4 pH 7.2). Appropriate amounts of protein were added to reaction vessels 
(epindorf tubes). The probe was made as a 10 mM stock solution in DMSO and diluted 
accordingly for appropriate final concentrations in the gel experiments. The gel was cast as 1.5 
mm thick and the wells were a total volume of 20 μL. The samples were incubated with probe 
for 1 hr. The samples were prepared for gel electrophoresis as described above. Fluorescence 
imaging and Coomassie staining were performed as described above. 
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Figure 51. Examination of labeling on treated PKACα. 
 
 
3.11.3: Results and Discussion of Figure 51. 
The Rh-PKI(14-22)-G-(CMK) probe again displayed robust labeling of isolated 
recombinant PKACα at the standard buffer pH of 7.2. Additionally, Rh-PKI(14-22)-G-(CMK) 
labeled the treated with lysates PKACα in a similar way to the treated with commercial PDK1. 
This confirmed the hypothesis of treating with PDK1 to obtain the phosphorylated species as the 
predominant form. Unfortunately, it is a rather crude method for producing the protein and the 
results were not immediately reproducible. Therefore, it was necessary to explore an alternative 
route of producing PKACα pThr197. 
PKACα (2 µg)
Treated PKACα (2 µg)
Treated Lysates of PKACα (2 µL)  -    -     -     -     -     -     +    +
 -    -     -     +    +     -     -     -
 -    +    +     -    -     -     -      -
 -    -     +     -    +    -     -     +48 (5 µM)
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3.11.4 Co-expression of PKACα and PDK1. 
To co-express the two proteins they must each be selected for in the bacterial growth 
media. Therefore, the original plasmid PDK1 had to be switched to a compatible vector. The 
PDK1 plasmid was isolated with a QIAprep Spin Mini Prep Kit (procedure in the experimental 
section). A pRSF Duet Plasmid (Kan resistant) was isolated from an overnight culture with the 
same kit. The PDK1 plasmid was digested with BglII and NdeI restriction enzymes and the 
pRSF Duet plasmid with Bam HI and NdeI. The resulting solutions were run on agarose gel (cast 
in house, see experimental) and the appropriate bands were imaged with ethidium bromide and 
excised with a scalpel (Figure 40 below). They were ligated together with a DNA ligase enzyme. 
The resulting solution was used to transform competent E. coli cells (detailed in experimental). 
After subsequent incubation, the new plasmid was isolated with a QIA Spin Mini Prep Kit and 
then transfected into cells already expressing PKACα. The same process was done with cells 
expressing the mutant C199A PKACα. 
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Figure 52. Agarose gel electrophoresis of PDK1 plasmid and pRSF duet. 
 
 
 
 
 
 
 
 
 
 
 
 
!
PDK1 pRSF Duet
PDK1
pRSF Duet
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3.11.5: Labeling of coexpressed PKACα and PDK1. 
In Figure 53, below, the labeling characteristics of the probe were examined against the 
wild-type, and C199A, recombinant PKACα that was coexpressed with PDK1. The final 
PKACα solution concentration was determined by absorbance at 280 nm and diluted to 1 mg/mL 
in phosphate buffer (25 mM PO4 pH 7.2). The probe was made as a 10 mM stock solution in 
DMSO and diluted accordingly for appropriate final concentrations in the gel experiments. The 
gel was cast as 1.5 mm thick and the wells were a total volume of 20 μL. Then the samples were 
incubated with probe for 1 hr. The samples were quenched with a denaturing sample buffer 
(made in house and detailed in the biological experimental section) and incubated at 100°C for 5 
minutes. The denaturing sample buffer contained a disulfide reducing agent 
(betamercaptoethanol, BME). Fluorescent images were taken on an Amersham 600 Imager. 
Coomassie staining was performed with blue G250 in a H2O/MeOH/AcOH solution, and 
destained with a H2O/MeOH/AcOH solution. Images of the Coomassie stained gel were taken on 
an Amersham 600 Imager. 
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Figure 53. Examination of coexpressed PKACα and PDK1 labeling with 48. 
 
 
 
3.11.6: Results and Discussion of Figure 53. 
The Rh-PKI(14-22)-G-(CMK) probe again displayed robust labeling of isolated 
recombinant PKACα at the standard buffer pH of 7.2. This time only one band is observed. This 
confirmed the utility of the coexpression platform. However, it is now abundantly clear that the 
conditions for expression can be tuned with the isolated PKACα to promote 
phosphorylation.42,83,129-131 In effect, a method was developed to easily produce large quantities of 
PKACα phosphorylated at Thr197 without the close monitoring of conditions. 
 
 Coexpressed PKACα (2 µg)
 Coexpressed C199A PKACα (2 µg)
 Coexpressed R194A PKACα (8 µg)
Fluorosceine-Maleimide (50 µM)
48 (2.3 µM)    -    -    +      -     +    -     -    +     -     -
   -    -     -      -     -    +     -     -     +    -
   -   +     +     -     -    -     -     -      -     -
   -    -     -     +     +   +    -     -      -     -
   -    -     -      -     -    -     +    +     +     -
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3.12: Biological Characterization of 48. 
In a similar setup to the chloromethyl ketone derivative, the fluoromethyl ketone probe 
was examined for its ability to label PKACα. Saturability of labeling was examined with non-
covalent Myr-PKI(14-22)-Amide. The labeling of the cysteine to alanine mutant (C199A) was 
examined to examine the residue being labeled. Oxidation of the cysteine was attemped to mimic 
the endogenous regulatory mechanism of glutathiolation. Labeling with increasing 
concentrations of ATP and MgCl2 was examined as was labeling in many complex biological 
mixtures such as: MCF7 cells, MDA-MB-231 cells, bovine heart tissue lysates, mouse heart 
tissue lysates, and E. coli lysates. All gels were cast in house and made to contain 10% 
acrylamide, the exact procedure is detailed in the biological experimental section. 
3.12.1: Activity-Based Experiment: Probe labeling saturation. 
To analyze the labeling characteristics of the Rh-PKI(14-22)-G-(FMK) (48) probe 
saturation gels were run to examine the effects of competition with a known inhibitor with a 
known mechanism of action. In Figure 54 below, labeling of PKACα with probe 48 was 
competed off with incrementally increasing concentrations of commercially available Myr-
PKI(14-22)-Amide (IC50 = 49.9 nM) . Protein concentration and probe concentrations were 
prepared and determined as described above. The samples were prepared for gel electrophoresis 
as described above. Fluorescence imaging and Coomassie staining were performed as described 
above. 
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Figure 54. Saturability of labeling of probe 48. 
 
Compound 48 displayed robust labeling of isolated enzyme. The labeling was reduced in 
a dose dependent manner by competition with Myr-PKI(14-24)-Amide. As increasing amount of 
reversible inhibitor are added, non specific labeling is not observed. The Coomassie stain gel 
image matches the fluorescence image.  
 
 
 
 
  
 
 
 
PKACα (µg)
48 (µM)
PKI (14-22) (µM)
2     2      2     2     2     2     -
0    2.3   2.3  2.3  2.3  2.3   -
0     0     0.2   1    10   58    -
75 kDa
75 kDa
PKACα
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3.12.2: Activity-Based Experiment: Cysteine Oxidation. 
In Figure 55 below, the labeling characteristics of the probe were examined against the 
wild-type recombinant PKACα and with oxidative conditions to mimic the endogenous 
regulatory mechanism of glutathiolaytion at Cys199. Prior to incubation with probe, the 
appropriate lanes were incubated for 1 and 4 hr with Ellman’s reagent (a generic cysteine 
oxidizer). Then the samples were incubated with probe for an additional 1 hr. The gel cast, 
detection, staining, and imaging were the same as above. 
 
 
 
Figure 55. Cysteine oxidation effect on labeling by Ellman’s reagent. 
 
 
 
 
 
  
PKACα (µg)
48 (µM)
Ellman's Reagent (mM)
Time (hours)
      2         2          2          2
      0        2.3       2.3       2.3
      0         0          2          2
      0         0          1          4
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Probe 48 displayed robust labeling in the control lane (lane 2). Ellman’s reagent (2 mM) 
inhibited labeling over the course of 4 hr. The activation loop cysteine is held in conformation 
when Thr197 is phosphorylated and as a result the oxidation at Cys199 takes longer to occur.  
 
3.12.3: Selectivity Experiment: C199A Mutant. 
 To analyze the effects of probe 48 on labeling the C199A mutant of PKACα and further 
confirm the mechanism of labeling, the gel below was run (Figure 56) where conditions were the 
same as above. Imaging, detection, and staining were repeated same as above.  
 
 
Figure 56. Selectivity labeling experiment with wild-type and mutant PKACα. 
 
 Probe 48 displayed selectivity for the wild-type PKACα over the C199A mutant. Robust 
labeling was detected in the control lane (lane 2), and no detectable labeling occurred in lane 4 
which contains the C199A mutant.  
 
 
PKACα (µg)
C199A (µg)
48 (µM)
      2         2          0          0
      0        2.3        0         2.3
      0         0          2          2
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3.12.4: Activity-Based: Effects of ATP and MgCl2 on Labeling Efficiency. 
 Previous results from this lab indicated that these probes have decreased labeling 
efficiency in physiological conditions. To examine this hypothesis, probe 48 was incubated with 
wild-type PKACα with increasing concentrations of ATP and in the buffer used for the Z’LYTE 
kinase assay (high MgCl2 concentration 10 mM, buffer B).133 
Figure 57. Labeling in the presence of ATP and MgCl2. 
 
 Probe 48 displays positive labeling characteristics with low levels of ATP (0.25 – 1 mM) 
in lanes 4 and 5. However, when the concentration is increased to 2 mM, labeling is decreased, 
but not abolished, which is a significant first for these types of probes. The effect of the kinase 
buffer B did not affect labeling in a significant manner.  
 
-     +     +     +    +     +      +
-     A     A     A    A    A      B
-      -     +     +    +     +      +
-      -      -  0.25   1     2      2
PKACα (2 µg)
Buffer
48 (300 nM)
ATP (mM)
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3.12.5: Additional investigation into Cys199 labeling mechanism of action. 
 Trypsin digest mass spectrometry was utilized to confirm the location of binding of probe 
48 to PKACα. Briefly, unmodified or treated PKACα was buffer exchanged into a lysis buffer 
((25 mM Tris pH 7.6, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 10 mM 
DTT). The protein solution was mixed with trypsin at a ratio of 20:1 protein to protease. The 
resulting solution was incubated at 37 oC for 24 hr (in a sealed eppendorf tube). The sample was 
analyzed by MALDI mass spectrometry with CHCA matrix (Sigma) on a Voyager DE-ProTM 
MALDI TOF Mass Spectrometer.  
 
Table 12: Trypsin Digest Mass Spec Results 
Table 12: Mass found was the PKACα sequence + Probe Fragment (NAIG) + Na+. Exact mass 
of probe fragment (NAIG) was calculated to be 371.2169.  
 
 
 
 
 
 
 
Mass$Calculated Mass$Found
Untreated 2215.0893 2215.6430
Treated$with$RAC727116 2609.2960 2609.5996
PKACα/Tryspin/Fragment:/TWpTLCGTPEYLAPEIILSK
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3.12.6: Examination in Complex Biological Mixture: MCF7 Lysates. 
 Once the labeling mechanism of action had been extensively characterized and shown to 
display characteristics consistent with an activity-based probe, selectivity in complex biological 
mixtures was the necessary next step. MCF7 cells (a breast cancer cell line) were grown in T75 
flasks with RPMI buffer and 10% FBS (no antibiotic). Once confluent, the cells were collected 
by centrifugation and the RPMI media exchanged with phosphate buffer. Cells were lysed with a 
Dounce homogenizer and debris removed by centrifugation. Concentrations were determined by 
Bradford assay (detailed procedure and results in experimental).  
Figure 58. Labeling in MCF7 cell lysates. 
 
PKACα (µg)
MCF7 (µg)
48 (µM)
cAMP (1 mM)
-       2         2    -       -        -      -
-        -         -  100  100    100  100
-        -       0.3   -    0.3       -   0.3
-        -         -     -      -        -      +
PKACα
75 kDa
25 kDa
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 Probe 48 displayed robust labeling of the control PKACα lane (lane 3). The cell lysates 
were treated with/without probe and with/without cAMP to ensure release of the catalytic 
subunit from the holoenzyme. A single band was observed in both MCF7 cell lanes (lanes 5 and 
7); however, the molecular weight does not match that of PKACα and more closely matches the 
homologous PKG (~76 kDa).  
3.12.7: Examination in Complex Biological Mixture: MDA-MB-231 Lysates. 
 The MCF7 cells were revealed to have very little total amounts of PKA.136 MDA-MB-
231 cancer cells do have large quantities of PKA (contained in the holoenzyme).136 Therefore, 
MDA-MB-231 cells were examined with probe 48. MDA-MB-231 cells (another breast cancer 
cell line) were grown in T75 flasks with RPMI buffer, 1% ampicillin, and 10% FBS. Once 
confluent, the cells were collected by centrifugation and the RPMI media exchanged with 
phosphate buffer with 1x Rouche Protease inhibitor cocktail. Cells were lysed with a Dounce 
homogenizer and debris removed by centrifugation. Concentration determined by Bradford assay 
(detailed procedure and results in experimental). 
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Figure 59. Examination of MDA-MB-231 Lysates with compound 48. 
 
 Probe 48 effectively labels recombinant PKACα in the control lane (lane 3). There is 
selective labeling in the lysates. The band does not correspond with the molecular weight of 
PKACα. Myr-PKI(14-22)-Amide does not competitively knock out labeling at equivalents up to 
50x. 
 
 
 
 
 
PKACα (µg)
MDA-MB-231 (µg)
48 (0.3 µM)
PKI (µM)
cAMP (1 mM)
-      -      -   100  100 100 100 100
-      2     2    -        -      -     -      -
-      -     +    -        +     +    +     +
-      -      -     -        -    0.3   3   30
-      -      -    +        +     +    +     +
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3.12.7: Examination in Complex Biological Mixture: Bovine heart lysates. 
 Early work with PKACα was performed with tissue samples.44,114 Specifically, bovine 
heart was used extensively. Testing the hypothesis that PKA is not abundant enough in the 
samples for adequate labeling, bovine heart tissue was examined. Briefly, bovine heart tissue was 
cut into equal parts of 10 g pieces. One piece was incubated with protease inhibitor and the 
lysates were produced with a tissue homogenizer. The debris was removed by sequential 
centrifugation. Lysate concentrations were determined by Bradford assay and probe incubation 
performed as previously described. A PKACα pThr197 specific antibody was used for Western 
blot (detailed procedure available in experimental). 
 
 
 
Figure 60. Examination of bovine heart lysates with compound 48. 
 
 
 
 
 
PKACα (µg)
Bovine Heart Lysates (µg)
48 (µM)
  0   800 700 600 500 400 300 200 100 40
 0.2 0.2  0.2  0.2  0.2  0.2  0.2  0.2  0.2  0.2
 2     0      0     0    0     0     0     0     0    0
PKACα
Lysates
Mirror
Image
Western Blot with pT197 Specific Antibody
PKACα
Lysates
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 The dense nature of these tissues allowed for the facile production of concentrated 
lysates. A significant load of lysates was analyzed and probe 48 did display selective labeling. 
However, the band is similar to that observed in the MDA-MB-231 lysates and does not 
correspond with PKACα. Moreover, the antibody detection indicates the band being observed by 
fluorescence is not that being labeled by antibody.  
3.12.9: Examination in Complex Biological Mixture: Mouse heart lysates. 
 To examine the possibility of species variance in PKACα production and labeling, mouse 
heart lysates were prepared in the same manner as above. Protein concentration determined by 
Bradford, and antibody detection with a PKACα pThr197 antibody, all as described above.  
 
Figure 61. Examination of mouse heart lysates with compound 48. 
 
 A similar labeling profile was noted in the mouse heart lysates as with the bovine heart 
lysates. That is, heavy lysate loads were found in each lane with selective labeling of one band 
that does not correspond with the expected molecular weight. The antibody reveals a similar 
result as that of bovine: the band labeled is not the band that corresponds with PKACα. 
 
PKACα (2 µg)
Lysates (400 µg)
48 (µM)
cAMP (µM)
-        +     +       -        -       -
-         -      -       +       +      +
-         -     0.3     -      0.3   0.3
-         -      -        -       -     100
75 kDa
25 kDa
PKACα
Recombinant
PKACα
PKACα
Western Blot with pThr197 PKA Antibody
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3.12.10: Discussion of Biological Characterization of Probe 48. 
 The fluoromethyl ketone probe was examined extensively by multiple mechanisms and 
variables. The saturability of labeling by competition with Myr-PKI(14-22)-Amide was 
examined. The labeling was reduced with increasing concentrations of the reversible inhibitor in 
a dose dependent manner. Cysteine oxidation’s effect on labeling with the use of Ellman’s 
reagent to oxidize Cys199 was examined.137 Upon treatment with Ellman’s reagent for 4 hrs 
labeling was effectively abolished. Rh-PKI(14-22)-G(FMK) (48) did not detectably label the 
C199A mutant of PKACα. The trypsin digest mass spec indicated that a residue in the activation 
loop is being modified. The IC50 of the probe was determined to be 11 nM (as determined by 
Invitrogen). Thse results were very favorable for a selective probe that labels the catalytic 
subunit in an activity-dependent manner. As a result, the probe was examined in a number of 
biological systems. 
 The first system examined was MCF7 cell lysates. The procedure for growing up these 
cells and producing lysates is detailed in the experimental. The MCF7 cell line is a breast cancer 
cell line. When we examined the labeling in these lysates, the probe displayed remarkable 
selectivity. However, this singular band did not correspond with PKACα and as a result we set 
out to examine a different biological system with potentially greater amounts of PKA. 
 Cell lysates were reexamined to test the hypothesis that there was not enough PKA for 
labeling. The MDA-MB-231 cell line was selected due to it having demonstrated robust 
production of PKA. The growing conditions were similar to the MCF7 cell line but with protease 
inhibitor in the lysate solution, which may have influenced the labeling. However, the band does 
not match PKACα in molecular weight, nor is it labeled by antibody.  
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Bovine heart was readily available from the local butcher, and early PKA work in the 
literature dealt with PKA isolated from bovine hearts (Chapter 2). The tissue was marinated in 
protease inhibitor and homogenized. The debris was removed by sequential centrifugation and 
concentration determined by Bradford assay. A detailed work up is described in the experimental 
section. While selective labeling occurred again, the molecular weight again did not match that 
would be expected from PKA, it was slightly higher. The Western blot with anti-PKACα 
confirmed that the labeled band does not correspond with the PKA identified with antibody, and 
does seem to be the same band labeled in the MDA-MB-231 lysates. 
 We reexamined the labeling of the probe in mouse heart lysates. The mouse hearts were a 
generous gift from Dr. Jolene Windle. The tissue was marinated in protease inhibitor and 
homogenized. The debris was removed by sequential centrifugation and concentration 
determined by Bradford assay. A detailed work up is described in the experimental section. 
Again, selective labeling was observed on a band not consistent with the molecular weight of 
PKACα but similar to that observed in bovine heart and MDA-MB-231 cell lysates (3 species 
covered). In an effort to determine the identity of the labeled peptide, biotinylated analogues 
were synthesized for pull-down experiments.  
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3.13: Development of a Biotinylated Peptide Probe. 
 To determine the identity of the fluorescently labeled protein, biotinylated analogues 
were designed for pull-down experiments. The full length probe was assembled in the same 
fashion as Rh-PKI(14-22)-G-FMK and the scheme is depicted below (a detailed procedure is 
available in the experimental section). Biotin-NHS was synthesized according to a previously 
described route and the spectral data matched previously reported values.138 The synthetic 
scheme is depicted below. 
 
 
Figure 62. Synthesis of Biotin-NHS. 
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Figure 63. Synthesis of Biotin-PKI(14-22)-G-(FMK). 
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3.13.1: Biological Characterization of 51, Biotin-PKI(14-22)-G-(FMK). 
 The biotinylated probe did not detectably label recombinant PKACα in conditions that 
paralleled that of the fluorescently labeled probe (300 nM). Later experiments show minimal 
labeling and will be discussed in a later section. The hypothesis at the time was that there was a 
difference between PKACα produced recombinately and endogenously expressed PKACα. As a 
result, the pull-down experiment was performed and the results are detailed below.  
 Briefly, mouse heart lysates were passed through a streptavidin column to remove 
endogenously biotinylated proteins from the untreated lysates. Then the eluent was diluted 10 
fold into phosphate buffer and incubated with 300 nM of biotin-PKI(14-22)-G-(FMK) for 1 hr. 
The solution was then incubated with the column for 1 hr and subsequently eluted with a biotin 
solution. A detailed procedure is available in the experimental. 
 
 
Figure 64. Western blot of the pull-down sample with pThr197 antibody. 
 
recombinant PKACα (.2µg)
Pull Down sample
-        +
+       -
PKA Thr197 Antibody
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Figure 65. Western blot of the pull-down sample with streptavidin-HRP. 
 
 
Figure 66. Coomassie stain of pull-down sample, major bands highlighted. 
 
 
 
Recombinant PKACα (0.2 µg)
Pull-Down Sample
-            +  
+           -
Avidin-HRP
Recombinant PKACα (0.2 µg)
Pull-Down Sample
-            +  
+           -
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3.13.2: Results and Discussion of the Biological Characterization of 51. 
 The IC50 of biotin-PKI(14-22)-G-(FMK) was determined to be 149 nM (by Invitrogen). 
The results of the pull-down experiment reveal that PKACα was pulled down. But, in addition 
another prominent protein with a much higher molecular weight was observed. The streptavidin-
hrp blot indicates a relative larger quantity of the higher molecular weight protein. Similarly, the 
Coomassie stain image appears to indicate that the higher molecular weight protein is present in 
larger quantities (reminiscent of the results obtained when examining the MCF7 cell line). When 
the IC50 is considered along with the pull-down results, it is reasonable to assume the probe does 
not covalently interact with PKACα on a level of selectivity necessary for ABPP of PKA. It was 
hypothesized that the linker was not long enough and so another analogue was designed to 
extend the linker between biotin and the recognition scaffold.  
3.13.3: Addition of a linker. 
 The 8-(Fmoc-amino)octanoic acid (AOC) linker is solid-phase chemistry compatible and 
has been utilized in similar probes as a linker. The synthesis was carried out on a peptide 
synthesizer and assembly of the probe was similar to that of the previous probes. A detailed 
procedure is available in the experimental section. The probe was analyzed under similar 
conditions; however, labeling was demonstrated at relatively high concentrations. 
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Figure 67. Synthesis of Biotin-Aoc-PKI(14-22)-G-(FMK). 
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3.13.4: Biological Characterization of Compound 54. 
 To examine the labeling efficiency of the new probe and test the limits of detection. The 
probe was incubated with recombinant PKACα and detected by streptavidin-HRP ECL substrate 
on an Amersham 600 imager (detailed experimental available in Chapter 4).  
 
Figure 68. Detection of recombinant PKACα labeled with 51 (lanes 3-5)and 54 (lanes 6-8). 
 
3.13.5: Results and Discussion of the Biotinylated Derivatives. 
 The IC50 of the biotin-AOC-PKI(14-22)-(FMK) probe against PKACα was determined to 
be 14.1 nM (by Invitrogen). This confirmed the hypothesis that the linker length was not long 
enough. Without the linker, the IC50 was 149 nM. The IC50 is also indicative of increased binding 
over the reversible inhibitor (IC50 = 49 nM, determined by Invitrogen). However, labeling of 
recombinant protein remained an issue: even at high concentrations, only trace labeling was 
PKACα (2 µg)
51 (µM)
54 (µM)
-     +    +     +      +     +     +      +
-      -  0.5    1      2      -      -       -
-      -     -     -       -    0.5    1      2
	   137	  
detectable. No labeling was detected in MDA-MB-231 lysates (only endogenous biotinylated 
peptides were shown by Western blot), and no labeling of commercial bovine PKACα was 
obersved. The biotinylated peptide-based probes did not label in a manner consistent with the 
fluorescently labeled probes. This suggests that the rhodamine is influencing the position of the 
electrophile such that labeling is occurring more robustly than non-interfering tags. 
3.14: Results, Discussion, and Future Directions. 
The active site of protein kinases has been shown to be influenced by certain post-
translational modifications, as was suggested by others.40,128,137,139-141 While this work did not 
produce an activity-based probe suitable for activity-based protein profiling of PKACα in 
complex biological mixtures, it did produce probes capable of investigating the active-site of 
PKACα, as demonstrated by the selectivity for pThr197 and sensitivity to cysteine oxidation. 
Additionally, the probes are capable of assessing those post-translational modifications in a 
concerted, in vitro, manner without the use of multiple proteomic techniques. The reactivity of 
Cys199 has not been systematically studied, although, these probes are capable of such 
characterization. In addition, ABPs may have been developed for proteins of interest by probe 38 
and probes 48 and 51 (as evidenced by their proteome wide selectivity and interactions with a 
PKI fragment) and further investigations into these ABPs is warranted. This represents a large 
step forward in the characterization of active site substrate-binding dynamics in the kinome. 
A sequence alignment of the human kinome revealed that a total of ninety-nine kinases 
carry a cysteine in the position similar to PKACα–C199 (see Figure 69). These kinases are 
mainly clustered in the AGC family and the CaMK family. Access to the cysteine in these 
kinases is restricted by selectivity filters in the P+1 binding site and the substrate-binding groove, 
allowing selective targeting of each cysteine and kinase with a high affinity peptide scaffold. 
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High affinity inhibitory peptides are known for several of the kinases in Figure 69, including 
AKT, PKG, AMPK, CaMKI, CHK2, and multiple isoforms of PKC. The activation loop 
cysteines in several of these kinases, including AKT1-C310, RSK1-C220, S6K1-C254, and 
MSK1-C214, have been shown to react with electrophiles. The flexible, efficient, and modular 
synthetic method presented here will allow the incorporation of a variety of electrophiles and 
detection tags into these peptides to prepare additional substrate competitive inhibitor probes for 
the kinases in Figure 69.  
While an ABP probe was not developed for PKACα specifically, a general strategy for 
developing substrate competitive inhibitor probes for kinases that targets the activation loop was 
developed and implemented. Work to further enhance peptide-based probe labeling and 
selectivity for PKACα (modification of the electrophile reactivity and position) in complex 
biological mixtures, and the use of it to study PKACα activity in diverse biological systems is 
currently underway in our lab.   
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Chapter 4. Experimentals 
4.1 ClustalX Sequence Alignment 
Kinome activation loop (DFG-APE) sequence alignment: 
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Other_IRE__IRE1 DFGLCKK-------LAVG-------------------------------------------------------RHSFSRRSGVPGTEGWIA-PE    31
Other_IRE__IRE2 DFGLCKK-------LPAG-------------------------------------------------------RCSFSLHSGIPGTEGWMA-PE    31
AGC_AKT__AKT1 DFGLCKE-------GIKDG-A---------------------------------------------------------TMKTFCGTPEYLA-PE    28
AGC_AKT__AKT2 DFGLCKE-------GISDG-A---------------------------------------------------------TMKTFCGTPEYLA-PE    28
AGC_AKT__AKT3 DFGLCKE-------GITDA-A---------------------------------------------------------TMKTFCGTPEYLA-PE    28
AGC_SGK__SGK DFGLCKE-------NIEHN-S---------------------------------------------------------TTSTFCGTPEYLA-PE    28
AGC_SGK__SGK3 DFGLCKE-------GIAIS-D---------------------------------------------------------TTTTFCGTPEYLA-PE    28
AGC_SGK__SGK2 DFGLCKE-------GVEPE-D---------------------------------------------------------TTSTFCGTPEYLA-PE    28
AGC_PKC_Alpha_PKCa DFGMCKE-------HMMDG-V---------------------------------------------------------TTRTFCGTPDYIA-PE    28
AGC_PKC_Alpha_PKCb DFGMCKE-------NIWDG-V---------------------------------------------------------TTKTFCGTPDYIA-PE    28
AGC_PKC_Alpha_PKCg DFGMCKE-------NVFPG-T---------------------------------------------------------TTRTFCGTPDYIA-PE    28
AGC_PKC_Eta_PKCh DFGMCKE-------GICNG-V---------------------------------------------------------TTATFCGTPDYIA-PE    28
AGC_PKC_Eta_PKCe DFGMCKE-------GILNG-V---------------------------------------------------------TTTTFCGTPDYIA-PE    28
AGC_PKC_Delta_PKCd DFGMCKE-------NIFGE-S---------------------------------------------------------RASTFCGTPDYIA-PE    28
AGC_PKC_Delta_PKCt DFGMCKE-------NMLGD-A---------------------------------------------------------KTNTFCGTPDYIA-PE    28
AGC_PKC_Iota_PKCi DYGMCKE-------GLRPG-D---------------------------------------------------------TTSTFCGTPNYIA-PE    28
AGC_PKC_Iota_PKCz DYGMCKE-------GLGPG-D---------------------------------------------------------TTSTFCGTPNYIA-PE    28
AGC_PKN__PKN1 DFGLCKE-------GMGYG-D---------------------------------------------------------RTSTFCGTPEFLA-PE    28
AGC_PKN__PKN2 DFGLCKE-------GMGYG-D---------------------------------------------------------RTSTFCGTPEFLA-PE    28
AGC_PKN__PKN3 DFGLCKE-------GIGFG-D---------------------------------------------------------RTSTFCGTPEFLA-PE    28
AGC_RSK_MSK_MSK1 DFGLSKE-------FVADETE---------------------------------------------------------RAYSFCGTIEYMA-PD    29
AGC_RSK_MSK_MSK2 DFGLSKE-------FLTEEKE---------------------------------------------------------RTFSFCGTIEYMA-PE    29
AGC_RSK_p70_p70S6K DFGLCKE-------SIHDG-T---------------------------------------------------------VTHTFCGTIEYMA-PE    28
AGC_RSK_p70_p70S6Kb DFGLCKE-------SIHEG-A---------------------------------------------------------VTHTFCGTIEYMA-PE    28
AGC_RSK_RSK_RSK1 DFGLSKE-------AIDHD-K---------------------------------------------------------RAYSFCGTIEYMA-PE    28
AGC_RSK_RSK_RSK2 DFGLSKE-------SIDHE-K---------------------------------------------------------KAYSFCGTVEYMA-PE    28
AGC_RSK_RSK_RSK3 DFGLSKE-------AIDHE-K---------------------------------------------------------KAYSFCGTVEYMA-PE    28
AGC_RSK_RSK_RSK4 DFGLSKE-------SVDQE-K---------------------------------------------------------KAYSFCGTVEYMA-PE    28
AGC_PKA__PRKX DFGFAKK-------LVD-------------------------------------------------------------RTWTLCGTPEYLA-PE    25
AGC_PKA__PRKY DFGFAKK-------LVD-------------------------------------------------------------RTWTLCGTPEYLA-PE    25
AGC_PKA__PKACa DFGFAKR-------VKG-------------------------------------------------------------RTWTLCGTPEYLA-PE    25
AGC_PKA__PKACb DFGFAKR-------VKG-------------------------------------------------------------RTWTLCGTPEYLA-PE    25
AGC_PKA__PKACg DFGFAKR-------VKG-------------------------------------------------------------RTWTLCGTPEYLA-PE    25
AGC_PKG__PKG1 DFGFAKK-------IGFGK-----------------------------------------------------------KTWTFCGTPEYVA-PE    27
AGC_PKG__PKG2 DFGFAKK-------IGSGQ-----------------------------------------------------------KTWTFCGTPEYVA-PE    27
AGC_MAST__MAST1 DFGLSKM-------GLMSLTTNLYEGHIE-----------------------------------------KDAREF--LDKQVCGTPEYIA-PE    43
AGC_MAST__MAST4 DFGLSKV-------GLMSMTTNLYEGHIE-----------------------------------------KDAREF--LDKQVCGTPEYIA-PE    43
AGC_MAST__MAST2 DFGLSKI-------GLMSLTTNLYEGHIE-----------------------------------------KDAREF--LDKQVCGTPEYIA-PE    43
AGC_MAST__MAST3 DFGLSKI-------GLMSMATNLYEGHIE-----------------------------------------KDAREF--IDKQVCGTPEYIA-PE    43
AGC_DMPK_GEK_MRCKb DFGSCLK-------MN-------------------------------------------------------DDGTV--QSSVAVGTPDYIS-PE    29
AGC_DMPK_GEK_MRCKa DFGSCLK-------LM-------------------------------------------------------EDGTV--QSSVAVGTPDYIS-PE    29
AGC_DMPK_GEK_DMPK2 DFGSCLR-------LN-------------------------------------------------------TNGMV--DSSVAVGTPDYIS-PE    29
AGC_DMPK_GEK_DMPK1 DFGSCLK-------LR-------------------------------------------------------ADGTV--RSLVAVGTPDYLS-PE    29
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CAMK_MAPKAPK_MNK_MNK2 DFDLGSG-------IKLNGDCSPIS-----------------------------------------------TP----ELLTPCGSAEYMA-PE    35
CAMK_RSKb_MSKb_Domain2_MSK1 DFGFARL-------KPPD------------------------------------------------------NQ----PLKTPCFTLHYAA-PE    28
CAMK_RSKb_MSKb_Domain2_MSK2 DFGFARL-------RPQSP-----------------------------------------------------GV----PMQTPCFTLQYAA-PE    29
CAMK_RSKb_RSKb_Domain2_RSK2 DFGFAKQ-------LRAE------------------------------------------------------NG----LLMTPCYTANFVA-PE    28
CAMK_RSKb_RSKb_Domain2_RSK3 DFGFAKQ-------LRAE------------------------------------------------------NG----LLMTPCYTANFVA-PE    28
CAMK_RSKb_RSKb_Domain2_RSK1 DFGFAKQ-------LRAG------------------------------------------------------NG----LLMTPCYTANFVA-PE    28
CAMK_RSKb_RSKb_Domain2_RSK4 DFGFAKQ-------LRGE------------------------------------------------------NG----LLLTPCYTANFVA-PE    28
CAMK_PKD__PKD1 DFGFARI-------IGE-------------------------------------------------------KS----FRRSVVGTPAYLA-PE    27
CAMK_PKD__PKD3 DFGFARI-------IGE-------------------------------------------------------KS----FRRSVVGTPAYLA-PE    27
CAMK_PKD__PKD2 DFGFARI-------IGE-------------------------------------------------------KS----FRRSVVGTPAYLA-PE    27
CAMK_RAD53__CHK2 DFGHSKI-------LGE-------------------------------------------------------TS----LMRTLCGTPTYLA-PE    27
CAMK_CAMK-Unique__STK33 DFGLAVK-------KQSRS-----------------------------------------------------EA----MLQATCGTPIYMA-PE    29
CAMK_CAMKL_AMPK_AMPKa1 DFGLSNM-------M-------------------------------------------------------SDGE----FLRTSCGSPNYAA-PE    27
CAMK_CAMKL_AMPK_AMPKa2 DFGLSNM-------M-------------------------------------------------------SDGE----FLRTSCGSPNYTA-PE    27
CAMK_CAMKL_BRSK_BRSK2 DFGMASL-------Q-------------------------------------------------------VGDS----LLETSCGSPHYAC-PE    27
CAMK_CAMKL_BRSK_BRSK1 DFGMASL-------Q-------------------------------------------------------VGDS----LLETSCGSPHYAC-PE    27
CAMK_CAMKL_MARK_MARK2 DFGFSNE-------F-------------------------------------------------------TFGN----KLDTFCGSPPYAA-PE    27
CAMK_CAMKL_MARK_MARK1 DFGFSNE-------F-------------------------------------------------------TVGN----KLDTFCGSPPYAA-PE    27
CAMK_CAMKL_MARK_MARK3 DFGFSNE-------F-------------------------------------------------------TVGG----KLDTFCGSPPYAA-PE    27
CAMK_CAMKL_MARK_MARK4 DFGFSNE-------F-------------------------------------------------------TLGS----KLDTFCGSPPYAA-PE    27
CAMK_CAMKL_QIK_QIK DFGFGNF-------F-------------------------------------------------------KSGE----LLATWCGSPPYAA-PE    27
CAMK_CAMKL_QIK_SIK DFGFGNF-------Y-------------------------------------------------------KSGE----PLSTWCGSPPYAA-PE    27
CAMK_CAMKL_QIK_QSK DFGFSNL-------F-------------------------------------------------------TPGQ----LLKTWCGSPPYAA-PE    27
CAMK_CAMKL_NuaK_NuaK1 DFGLSNL-------Y-------------------------------------------------------QKDK----FLQTFCGSPLYAS-PE    27
CAMK_CAMKL_NuaK_NuaK2 DFGLSNL-------Y-------------------------------------------------------HQGK----FLQTFCGSPLYAS-PE    27
CAMK_CAMKL_MELK_MELK DFGLCAK-------P-------------------------------------------------------KGNKDY--HLQTCCGSLAYAA-PE    29
CAMK_CAMKL_NIM1_NIM1 DFGFSTV-------S-------------------------------------------------------KKGE----MLNTFCGSPPYAA-PE    27
CAMK_CAMKL_SNRK_SNRK DFGFSNK-------F-------------------------------------------------------QPGK----KLTTSCGSLAYSA-PE    27
CAMK_CAMKL_HUNK_HUNK DFGLSNC-------AG------------------------------------------------------ILGYSD--PFSTQCGSPAYAA-PE    30
CAMK_TSSK__SSTK DFGFGR---------------------------------------------------------------QAHGYPD--LSTTYCGSAAYAS-PE    28
CAMK_TSSK__TSSK3 DFGFAKV--------------------------------------------------------------LPKSHRE--LSQTFCGSTAYAA-PE    29
CAMK_TSSK__TSSK2 DFGFSKR-------C----------------------------------------------------LRDSNGRII--LSKTFCGSAAYAA-PE    32
CAMK_TSSK__TSSK1 DFSFSKR-------C----------------------------------------------------LRDDSGRMA--LSKTFCGSPAYAA-PE    32
CAMK_TSSK__TSSK4 DFGFAKM-------VPSNQPVGCSPS-----------------------------------------YRQVNCFSH--LSQTYCGSFAYAC-PE    43
CAMK_PIM__PIM3 DFGSGAL-------LK--------------------------------------------------------DT----VYTDFDGTRVYSP-PE    26
CAMK_PIM__PIM1 DFGSGAL-------LK--------------------------------------------------------DT----VYTDFDGTRVYSP-PE    26
CAMK_PIM__PIM2 DFGSGAL-------LH--------------------------------------------------------DE----PYTDFDGTRVYSP-PE    26
CAMK_CAMKL_PASK_PASK DFGSAAY-------LER-------------------------------------------------------GK----LFYTFCGTIEYCA-PE    27
Other_CAMKK_Meta_CaMKK2 DFGVSNE-------FK--------------------------------------------------------GSDA--LLSNYVGTPAFMA-PE    28
Other_CAMKK_Meta_CaMKK1 DFGVSNQ-------FE--------------------------------------------------------GNDA--QLSSTAGTPAFMA-PE    28
CAMK_CAMKL_LKB_LKB1 DLGVAEA-------LHP------------------------------------------------------FAADD--TCRTSQGSPAFQP-PE    30
CAMK_CAMKL_CHK1_CHK1 DFGLATV-------FRY------------------------------------------------------NNRER--LLNKMCGTLPYVA-PE    30
Other_AUR__AurC DFGWSVH-------TPLP------------------------------------------------------------ERKTMCGTLDYLP-PE    26
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Other_AUR__AurB DFGWSVH-------APSL------------------------------------------------------------RRKTMCGTLDYLP-PE    26
Other_AUR__AurA DFGWSVH-------APSS------------------------------------------------------------RRTTLCGTLDYLP-PE    26
Other_PLK__PLK3 DFGLAAR-------LEPPE------------------------------------------------------Q----RKKTICGTPNYVA-PE    28
Other_PLK__PLK2 DFGLAAR-------LEPLE------------------------------------------------------H----RRRTICGTPNYLS-PE    28
Other_PLK__PLK1 DFGLATK-------VEYDG------------------------------------------------------E----RKKTLCGTPNYIA-PE    28
Other_PLK__PLK4 DFGLATQ-------LKMPH------------------------------------------------------E----KHYTLCGTPNYIS-PE    28
CAMK_DAPK__DAPK1 DFGLAHK-------IDFGNEF-----------------------------------------------------------KNIFGTPEFVA-PE    27
CAMK_DAPK__DAPK3 DFGIAHK-------IEAGNEF-----------------------------------------------------------KNIFGTPEFVA-PE    27
CAMK_DAPK__DAPK2 DFGLAHE-------IEDGVEF-----------------------------------------------------------KNIFGTPEFVA-PE    27
CAMK_DAPK__DRAK1 DFGLSRI-------LKNSEEL-----------------------------------------------------------REIMGTPEYVA-PE    27
CAMK_DAPK__DRAK2 DFGMSRK-------IGHACEL-----------------------------------------------------------REIMGTPEYLA-PE    27
CAMK_MLCK__caMLCK DFGLARR-------YKPREKL-----------------------------------------------------------KVNFGTPEFLA-PE    27
CAMK_MLCK__SgK085 DFGLARR-------YKPREKL-----------------------------------------------------------KVNFGTPEFLA-PE    27
CAMK_MLCK__skMLCK DFGLARR-------YNPNEKL-----------------------------------------------------------KVNFGTPEFLS-PE    27
CAMK_MLCK__smMLCK DFGLARR-------LENAGSL-----------------------------------------------------------KVLFGTPEFVA-PE    27
CAMK_MLCK__TTN EFGQARQ-------LKPGDNF-----------------------------------------------------------RLLFTAPEYYA-PE    27
CAMK_Trio__Trio DFGDAVQ-------LNTTYYI-----------------------------------------------------------HQLLGNPEFAA-PE    27
CAMK_Trio__Trad DLEDAVQ-------ISGHFHI-----------------------------------------------------------HHLLGNPEFAA-PE    27
CAMK_Trio__SPEG DFGNAQE-------LTPGEPQ-----------------------------------------------------------YCQYGTPEFVA-PE    27
CAMK_Trio__Obscn DFGFAQN-------ITPAELQ-----------------------------------------------------------FSQYGSPEFVS-PE    27
CAMK_Trio__Domain2_SPEG DFGSAQP-------YNPQALRP---------------------------------------------------------LGHRTGTLEFMA-PE    29
CAMK_Trio__Domain2_Obscn DLGNAQS-------LSQEKVLP---------------------------------------------------------SDKFKDYLETMA-PE    29
CMGC_CDK_CDC2_CDK2 DFGLARA-------FG-----------------------------------------------------VP-VRT----YTHEVVTLWYRA-PE    28
CMGC_CDK_CDC2_CDK3 DFGLARA-------FG-----------------------------------------------------VP-LRT----YTHEVVTLWYRA-PE    28
CMGC_CDK_CDC2_CDC2 DFGLARA-------FG-----------------------------------------------------IP-IRV----YTHEVVTLWYRS-PE    28
CMGC_CDK_CDK5_CDK5 DFGLARA-------FG-----------------------------------------------------IP-VRC----YSAEVVTLWYRP-PD    28
CMGC_CDK_TAIRE_PCTAIRE1 DFGLARA-------KS-----------------------------------------------------IP-TKT----YSNEVVTLWYRP-PD    28
CMGC_CDK_TAIRE_PCTAIRE2 DFGLARA-------KS-----------------------------------------------------VP-TKT----YSNEVVTLWYRP-PD    28
CMGC_CDK_TAIRE_PCTAIRE3 DFGLARA-------KS-----------------------------------------------------VP-TKT----YSNEVVTLWYRP-PD    28
CMGC_CDK_TAIRE_PFTAIRE1 DFGLARA-------KS-----------------------------------------------------VP-SHT----YSNEVVTLWYRP-PD    28
CMGC_CDK_TAIRE_PFTAIRE2 DFGLARA-------KS-----------------------------------------------------IP-SQT----YSSEVVTLWYRP-PD    28
CMGC_CDK_CDK4_CDK4 DFGLARI-------YS-----------------------------------------------------Y--QMA----LTPVVVTLWYRA-PE    27
CMGC_CDK_CDK4_CDK6 DFGLARI-------YS-----------------------------------------------------F--QMA----LTSVVVTLWYRA-PE    27
CMGC_CDK_CDK10_CDK10 DFGLARA-------YG-----------------------------------------------------VP-VKP----MTPKVVTLWYRA-PE    28
CMGC_CDK_PITSLRE_PITSLRE DFGLARE-------YG-----------------------------------------------------SP-LKA----YTPVVVTLWYRA-PE    28
CMGC_CDK_CDK7_CDK7 DFGLAKS-------FG-----------------------------------------------------SP-NRA----YTHQVVTRWYRA-PE    28
CMGC_CDK__CCRK DFGLARV-------FS-----------------------------------------------------PDGSRL----YTHQVATRWYRA-PE    29
CMGC_CDK_CRK7_CHED DFGLARL-------YS-----------------------------------------------------SEESRP----YTNKVITLWYRP-PE    29
CMGC_CDK_CRK7_CRK7 DFGLARL-------YN-----------------------------------------------------SEESRP----YTNKVITLWYRP-PE    29
CMGC_CDK_CDK9_CDK9 DFGLARA-------FSL----------------------------------------------------AKNSQPN--RYTNRVVTLWYRP-PE    32
CMGC_CDK_CDK8_CDK8 DMGFARL-------FN-----------------------------------------------------SPLKPLA--DLDPVVVTFWYRA-PE    31
CMGC_CDK_CDK8_CDK11 DMGFARL-------FN-----------------------------------------------------SPLKPLA--DLDPVVVTFWYRA-PE    31
CMGC_MAPK_ERK_Erk1 DFGLAR--------I-AD--------------------------------------------------PEHDHTG---FLTEYVATRWYRA-PE    31
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CMGC_MAPK_ERK_Erk2 DFGLAR--------V-AD--------------------------------------------------PDHDHTG---FLTEYVATRWYRA-PE    31
CMGC_MAPK_ERK_Erk5 DFGMARG-------L-CT--------------------------------------------------SPAEHQY---FMTEYVATRWYRA-PE    32
CMGC_MAPK_nmo_NLK DFGLAR-----------V--------------------------------------------------EELDESR---HMTQEVVTQYYRA-PE    29
CMGC_MAPK_JNK_JNK1 DFGLAR---------------------------------------------------------------TAGTSF---MMTPYVVTRYYRA-PE    27
CMGC_MAPK_JNK_JNK3 DFGLAR---------------------------------------------------------------TAGTSF---MMTPYVVTRYYRA-PE    27
CMGC_MAPK_JNK_JNK2 DFGLAR---------------------------------------------------------------TACTNF---MMTPYVVTRYYRA-PE    27
CMGC_MAPK_p38_p38a DFGLAR---------------------------------------------------------------HTDD-----EMTGYVATRWYRA-PE    25
CMGC_MAPK_p38_p38b DFGLAR---------------------------------------------------------------QADE-----EMTGYVATRWYRA-PE    25
CMGC_MAPK_p38_p38g DFGLAR---------------------------------------------------------------QADS-----EMTGYVVTRWYRA-PE    25
CMGC_MAPK_p38_p38d DFGLAR---------------------------------------------------------------HADA-----EMTGYVVTRWYRA-PE    25
CMGC_MAPK_Erk7_Erk7 DFGLARS-------LGDL--------------------------------------------------PEGPEDQ---AVTEYVATRWYRA-PE    33
CMGC_MAPK_ERK_Erk3 DFGLAR---------IMD--------------------------------------------------PHYSHKG---HLSEGLVTKWYRS-PR    31
CMGC_MAPK_ERK_Erk4 DFGLAR---------IVD--------------------------------------------------QHYSHKG---YLSEGLVTKWYRS-PR    31
CMGC_RCK__MAK DFGLAR---------------------------------------------------------------ELRSQP---PYTDYVSTRWYRA-PE    27
CMGC_RCK__ICK DFGLAR---------------------------------------------------------------EIRSKP---PYTDYVSTRWYRA-PE    27
CMGC_RCK__MOK DFGSCR---------------------------------------------------------------SVYSKQ---PYTEYISTRWYRA-PE    27
CMGC_CDKL__CDKL2 DFGFART-------LAA-----------------------------------------------------P-GEV----YTDYVATRWYRA-PE    28
CMGC_CDKL__CDKL3 DFGFART-------LAA-----------------------------------------------------P-GDI----YTDYVATRWYRA-PE    28
CMGC_CDKL__CDKL1 DFGFARL-------LTG-----------------------------------------------------P-SDY----YTDYVATRWYRS-PE    28
CMGC_CDKL__CDKL4 DFGFAQI-------LI------------------------------------------------------P-GDA----YTDYVATRWYRA-PE    27
CMGC_CDKL__CDKL5 DFGFARN-------LSEG----------------------------------------------------N-NAN----YTEYVATRWYRS-PE    29
CMGC_GSK__GSK3A DFGSAKQ-------LVR-------------------------------------------------------GEP----NVSYICSRYYRA-PE    27
CMGC_GSK__GSK3B DFGSAKQ-------LVR-------------------------------------------------------GEP----NVSYICSRYYRA-PE    27
CMGC_CLK__CLK1 DFGSATY-------DDEH-------------------------------------------------------------HSTLVSTRHYRA-PE    25
CMGC_CLK__CLK4 DFGSATY-------DDEH-------------------------------------------------------------HSTLVSTRHYRA-PE    25
CMGC_CLK__CLK2 DFGSATF-------DHEH-------------------------------------------------------------HSTIVSTRHYRA-PE    25
CMGC_CLK__CLK3 DFGSATF-------DHEH-------------------------------------------------------------HTTIVATRHYRP-PE    25
CMGC_SRPK__SRPK2 DLGNACW-------VHKH-------------------------------------------------------------FTEDIQTRQYRS-IE    25
CMGC_SRPK__MSSK1 DLGNACW-------VHKH-------------------------------------------------------------FTEDIQTRQYRA-VE    25
CMGC_SRPK__SRPK1 DLGNACW-------VHKH-------------------------------------------------------------FTEDIQTRQYRS-LE    25
CMGC_DYRK_Dyrk1_DYRK1B DFGSSCQ-------LGQR-------------------------------------------------------------IYQYIQSRFYRS-PE    25
CMGC_DYRK_Dyrk1_DYRK1A DFGSSCQ-------LGQR-------------------------------------------------------------IYQYIQSRFYRS-PE    25
CMGC_DYRK_Dyrk2_DYRK2 DFGSSCY-------EHQR-------------------------------------------------------------VYTYIQSRFYRA-PE    25
CMGC_DYRK_Dyrk2_DYRK3 DFGSSCF-------EYQK-------------------------------------------------------------LYTYIQSRFYRA-PE    25
CMGC_DYRK_Dyrk2_DYRK4 DFGSSCY-------EHQK-------------------------------------------------------------VYTYIQSRFYRS-PE    25
CMGC_DYRK_HIPK_HIPK1 DFGSASH-------VSKA-------------------------------------------------------V-----CSTYLQSRYYRA-PE    26
CMGC_DYRK_HIPK_HIPK2 DFGSASH-------VSKA-------------------------------------------------------V-----CSTYLQSRYYRA-PE    26
CMGC_DYRK_HIPK_HIPK3 DFGSASH-------VSKT-------------------------------------------------------V-----CSTYLQSRYYRA-PE    26
CMGC_DYRK_HIPK_HIPK4 DFGSASI-------FSEVR-----------------------------------------------------YV-----KEPYIQSRFYRA-PE    28
CMGC_DYRK_PRP4_PRP4 DFGSASH-------VADN-------------------------------------------------------D-----ITPYLVSRFYRA-PE    26
Other_CK2__CK2a1 DWGLAEF-------YH------------------------------------------------------PGQEYN-----VRVASRYFKG-PE    27
Other_CK2__CK2a2 DWGLAEF-------YH------------------------------------------------------PAQEYN-----VRVASRYFKG-PE    27
Other_NKF1__SgK069 DFGHTRP-------RG------------------------------------------------------TLLRLA--GPPIPYTAPELCA-PP    30
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Other_NKF1__SgK110 DLGLTRP-------EG------------------------------------------------------SPTPAP--PVPLPTAPPELCL-LL    30
Other_NKF1__SBK DFGMTRR-------VG------------------------------------------------------CRVKRV--SGTIPYTAPEVCQ-AG    30
Other_IKK__IKKa DLGYAKD-------VDQGS-----------------------------------------------------------LCTSFVGTLQYLA-PE    27
Other_IKK__IKKb DLGYAKE-------LDQGS-----------------------------------------------------------LCTSFVGTLQYLA-PE    27
Other_IKK__IKKe DFGAARE-------LDDDE-----------------------------------------------------------KFVSVYGTEEYLH-PD    27
Other_IKK__TBK1 DFGAARE-------LEDDE-----------------------------------------------------------QFVSLYGTEEYLH-PD    27
STE_STE11__MAP3K2 DFGASKR-------LQTIC---------------------------------------------------LSGTG----MKSVTGTPYWMS-PE    31
STE_STE11__MAP3K3 DFGASKR-------LQTIC---------------------------------------------------MSGTG----MRSVTGTPYWMS-PE    31
STE_STE11__MAP3K8 DFGCARR-------LAWAG---------------------------------------------------LNGTHS-DMLKSMHGTPYWMA-PE    34
STE_STE11__MAP3K5 DFGTSKR-------LAGIN---------------------------------------------------PC-------TETFTGTLQYMA-PE    28
STE_STE11__MAP3K7 DFGTSKR-------LAGVN---------------------------------------------------PC-------TETFTGTLQYMA-PE    28
STE_STE11__MAP3K6 DFGTSKR-------LAGIT---------------------------------------------------PC-------TETFTGTLQYMA-PE    28
STE_STE11__MAP3K4 DFGCSVK-------LKNNA---------------------------------------------------QTMPG---EVNSTLGTAAYMA-PE    32
STE_STE11__MAP3K1 DFGAAAR-------LASKG---------------------------------------------------TGAG---EFQGQLLGTIAFMA-PE    32
STE_STE20_FRAY_OSR1 DFGVSAF-------LATGG---------------------------------------------------DITR--NKVRKTFVGTPCWMA-PE    33
STE_STE20_FRAY_STLK3 DFGVSAF-------LATGG---------------------------------------------------DVTR--NKVRKTFVGTPCWMA-PE    33
STE_STE20_STLK_STLK5 GLRSNLS-------MISHG---------------------------------------------------QRQRVVHDFPKYSVKVLPWLS-PE    35
STE_STE20_STLK_STLK6 GLSHLHS-------LVKHG---------------------------------------------------QRHRAVYDFPQFSTSVQPWLS-PE    35
STE_STE20_KHS_KHS1 DFGVAAK-------ITAT-----------------------------------------------------IAK-----RKSFIGTPYWMA-PE    28
STE_STE20_KHS_KHS2 DFGVSAQ-------ITAT-----------------------------------------------------IAK-----RKSFIGTPYWMA-PE    28
STE_STE20_KHS_GCK DFGVSGE-------LTAS-----------------------------------------------------VAK-----RRSFIGTPYWMA-PE    28
STE_STE20_KHS_HPK1 DFGISAQ-------IGAT-----------------------------------------------------LAR-----RLSFIGTPYWMA-PE    28
STE_STE20_MSN_ZC1/HGK DFGVSAQ-------LDRT-----------------------------------------------------VGR-----RNTFIGTPYWMA-PE    28
STE_STE20_MSN_ZC3/MINK DFGVSAQ-------LDRT-----------------------------------------------------VGR-----RNTFIGTPYWMA-PE    28
STE_STE20_MSN_ZC2/TNIK DFGVSAQ-------LDRT-----------------------------------------------------VGR-----RNTFIGTPYWMA-PE    28
STE_STE20_MSN_ZC4/NRK DFGVSAQ-------VSRT-----------------------------------------------------NGR-----RNSFIGTPYWMA-PE    28
STE_STE20_NinaC_MYO3B DFGVSAQ-------LTST-----------------------------------------------------RLR-----RNTSVGTPFWMA-PE    28
STE_STE20_NinaC_MYO3A DFGVSAQ-------LTST-----------------------------------------------------RHR-----RNTSVGTPFWMA-PE    28
STE_STE20_MST_MST1 DFGVAGQ-------LTDT-----------------------------------------------------MAK-----RNTVIGTPFWMA-PE    28
STE_STE20_MST_MST2 DFGVAGQ-------LTDT-----------------------------------------------------MAK-----RNTVIGTPFWMA-PE    28
STE_STE20_YSK_MST3 DFGVAGQ-------LTDT-----------------------------------------------------QIK-----RNTFVGTPFWMA-PE    28
STE_STE20_YSK_YSK1 DFGVAGQ-------LTDT-----------------------------------------------------QIK-----RNTFVGTPFWMA-PE    28
STE_STE20_YSK_MST4 DFGVAGQ-------LTDT-----------------------------------------------------QIK-----RNTFVGTPFWMA-PE    28
STE_STE20_SLK_SLK DFGVSAK-------NTRT-----------------------------------------------------IQR-----RDSFIGTPYWMA-PE    28
STE_STE20_SLK_LOK DFGVSAK-------NLKT-----------------------------------------------------LQK-----RDSFIGTPYWMA-PE    28
STE_STE20_TAO_TAO2 DFGSASI-------MAP--------------------------------------------------------------ANSFVGTPYWMA-PE    24
STE_STE20_TAO_TAO1 DFGSASM-------ASP--------------------------------------------------------------ANSFVGTPYWMA-PE    24
STE_STE20_TAO_TAO3 DFGSASM-------ASP--------------------------------------------------------------ANSFVGTPYWMA-PE    24
STE_STE20_PAKA_PAK1 DFGFCAQ-------ITPE-----------------------------------------------------QSK-----RSTMVGTPYWMA-PE    28
STE_STE20_PAKA_PAK3 DFGFCAQ-------ITPE-----------------------------------------------------QSK-----RSTMVGTPYWMA-PE    28
STE_STE20_PAKA_PAK2 DFGFCAQ-------ITPE-----------------------------------------------------QSK-----RSTMVGTPYWMA-PE    28
STE_STE20_PAKB_PAK4 DFGFCAQ-------VSKE-----------------------------------------------------VPR-----RKSLVGTPYWMA-PE    28
STE_STE20_PAKB_PAK5 DFGFCAQ-------VSKE-----------------------------------------------------VPK-----RKSLVGTPYWMA-PE    28
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STE_STE20_PAKB_PAK6 DFGFCAQ-------ISKD-----------------------------------------------------VPK-----RKSLVGTPYWMA-PE    28
STE_STE7__MAP2K1 DFGVSGQ-------LIDSM---------------------------------------------------ANS---------FVGTRSYMS-PE    26
STE_STE7__MAP2K2 DFGVSGQ-------LIDSM---------------------------------------------------ANS---------FVGTRSYMA-PE    26
STE_STE7__MAP2K5 DFGVSTQ-------LVNSI---------------------------------------------------AKT---------YVGTNAYMA-PE    26
STE_STE7__MAP2K6 DFGISGY-------LVDSV---------------------------------------------------AKTI--------DAGCKPYMA-PE    27
STE_STE7__MAP2K3 DFGISGY-------LVDSV---------------------------------------------------AKTM--------DAGCKPYMA-PE    27
STE_STE7__MAP2K4 DFGISGQ-------LVDSI---------------------------------------------------AKTR--------DAGCRPYMA-PE    27
STE_STE7__MAP2K7 DFGISGR-------LVDSK---------------------------------------------------AKTR--------SAGCAAYMA-PE    27
Other_NKF4__CLIK1 DFGLSKV-------CAGLAPR-----G---------------------------------KEGNQDNKNVNVNK---YWLSSACGSDFYMA-PE    45
Other_NKF4__CLIK1L DFGLSKV-------CS--------------------------------------------ASGQNPEEPVSVNK---CFLSTACGTDFYMA-PE    39
Other_ULK__ULK1 DFGFARY-------LQSN-----------------------------------------------------------MMAATLCGSPMYMA-PE    27
Other_ULK__ULK2 DFGFARY-------LHSN-----------------------------------------------------------MMAATLCGSPMYMA-PE    27
Other_ULK__ULK3 DFGFAQH-------MSPW-----------------------------------------------------------DEKHVLRGSPLYMA-PE    27
Other_ULK__ULK4 NFCLAKV-------EGENLEEFFALVAA--------------------------------EEGGGDNGENVLKK---SMKSRVKGSPVYTA-PE    51
Other_ULK__Fused DFGFARA-------MSTN-------------------------------------------------------T---MVLTSIKGTPLYMS-PE    28
Other_NEK__NEK1 DFGIARV-------LNSTVE----------------------------------------------------------LARTCIGTPYYLS-PE    28
Other_NEK__NEK5 DFGIARV-------LNNSME----------------------------------------------------------LARTCIGTPYYLS-PE    28
Other_NEK__NEK3 DFGSARL-------LSNPMA----------------------------------------------------------FACTYVGTPYYVP-PE    28
Other_NEK__NEK4 DLGIARV-------LENHCD----------------------------------------------------------MASTLIGTPYYMS-PE    28
Other_NEK__NEK2 DFGLARI-------LNHDTS----------------------------------------------------------FAKTFVGTPYYMS-PE    28
Other_NEK__NEK9 DYGLAKK-------LNSEYS----------------------------------------------------------MAETLVGTPYYMS-PE    28
Other_NEK__NEK8 DFGISKI-------LSSK---------------------------------------------------------------S---TPCYIS-PE    20
Other_NEK__NEK6 DLGLGRF-------FSSETT----------------------------------------------------------AAHSLVGTPYYMS-PE    28
Other_NEK__NEK7 DLGLGRF-------FSSKTT----------------------------------------------------------AAHSLVGTPYYMS-PE    28
Other_NEK__NEK11 DFGVSRL-------LMGSCD----------------------------------------------------------LATTLTGTPHYMS-PE    28
Other_NEK__NEK10 DFGLAKQ-------KQENSK----------------------------------------------------------LT-SVVGTILYSC-PE    27
Other_TLK__TLK1 DFGLSKI-------MDDDSYG----------------------------------------------------VDGMDLTSQGAGTYWYLP-PE    34
Other_TLK__TLK2 DFGLSKI-------MDDDSYNS---------------------------------------------------VDGMELTSQGAGTYWYLP-PE    35
CAMK_Trbl__Trb1 SLEDTHI-------MKGED----------------------------------------------------------DALSDKHGCPAYVS-PE    28
CAMK_Trbl__Trb2 SLEDAYI-------LRGDD----------------------------------------------------------DSLSDKHGCPAYVS-PE    28
CAMK_Trbl__Trb3 NLEDSCV-------LTGPD----------------------------------------------------------DSLWDKHACPAYVG-PE    28
CAMK_CAMK-Unique__SgK495 NFCLGKH-------LVSEG----------------------------------------------------------DLLKDQRGSPAYIS-PD    28
Other_NKF3__SgK223 NFLKAKQ-------KPG-G----------------------------------------------------------TPNLQQKKSQARLA-PE    27
Other_NKF3__SgK269 NFSQAKQ-------KS--H----------------------------------------------------------LVDPEILRDQSRLA-PE    26
Other_NAK__AAK1 DFGSATN-------KFQNP--------------------------------------------------QTEGVNAVEDEIKKYTTLSYRA-PE    36
Other_NAK__BIKE DFGSATN-------KFLNP--------------------------------------------------QKDGVNVVEEEIKKYTTLSYRA-PE    36
Other_NAK__GAK DFGSATT-------ISHYPDYS-------W---------------------------------------SAQRRALVEEEITRNTTPMYRT-PE    40
Other_PEK_PEK_PEK DFGLVT-------AMDQDEEEQT----------------------------------------------VLTPMPAYARHTGQVGTKLYMS-PE    40
Other_PEK__PKR DFGLVT-------SLKND-----------------------------------------------------------GKRTRSKGTLRYMS-PE    27
Other_PEK_GCN2_GCN2 DFGLATDHLAFSADSKQDDQTGD----------------------------------------------LIKSDPS-GHLTGMVGTALYVS-PE    46
Other_WEE__Wee1 D-EDDW--ASNKVMFKIGDLGH-------------------------------------------------V--TRISSPQVEEGDSRFLA-NE    39
Other_WEE__Wee1B ENEADWF-LSANVMYKIGDLGH-------------------------------------------------A--TSINKPKVEEGDSRFLA-NE    41
Other_WEE__MYT1 D---FG------LLVELGTAG---------------------------------------------------------AGEVQEGDPRYMA-PE    27
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TKL_STKR_Type1_ALK1 DLGLAVM-------HSQ---GSD---------------------------------------------------YLDIGNNPRVGTKRYMA-PE    32
TKL_STKR_Type1_ALK2 DLGLAVM-------HSQ---STN---------------------------------------------------QLDVGNNPRVGTKRYMA-PE    32
TKL_STKR_Type1_ALK4 DLGLAVR-------HDA---VTD---------------------------------------------------TIDIAPNQRVGTKRYMA-PE    32
TKL_STKR_Type1_TGFbR1 DLGLAVR-------HDS---ATD---------------------------------------------------TIDIAPNHRVGTKRYMA-PE    32
TKL_STKR_Type1_ALK7 DLGLAVK-------HDS---ILN---------------------------------------------------TIDIPQNPKVGTKRYMA-PE    32
TKL_STKR_Type1_BMPR1A DLGLAVK-------FNS---DTN---------------------------------------------------EVDVPLNTRVGTKRYMA-PE    32
TKL_STKR_Type1_BMPR1B DLGLAVK-------FIS---DTN---------------------------------------------------EVDIPPNTRVGTKRYMP-PE    32
TKL_STKR_Type2_ACTR2 DFGLALK-------FEA---GKS---------------------------------------------------AGD--THGQVGTRRYMA-PE    30
TKL_STKR_Type2_ACTR2B DFGLAVR-------FEP---GKP---------------------------------------------------PGD--THGQVGTRRYMA-PE    30
TKL_STKR_Type2_TGFbR2 DFGLSLR-------LDP---TLS---------------------------------------------------VDDLANSGQVGTARYMA-PE    32
TKL_STKR_Type2_MISR2 DLGLALV-------LPG--LTQPPAW--------------------------------------------TPTQPQGPAAIMEAGTQRYMA-PE    40
TKL_STKR_Type2_BMPR2 DFGLSMR-------LTGNRLVRP-----------------------------------------------G---EEDNAAISEVGTIRYMA-PE    36
RGC_RGC__ANPa DYGLESF-------R-----DLD-----------------------------------------------------PEQGHTVYAKKLWTA-PE    28
RGC_RGC__ANPb DYGLASF-------RS----TAE-----------------------------------------------------PDDSHALYAKKLWTA-PE    29
RGC_RGC__HSER DFGCNSI-------LP----PK---------------------------------------------------------------KDLWTA-PE    19
RGC_RGC__CYGD DHGHGRL-------LE----AQK-----------------------------------------------------VLPEPPRAEDQLWTA-PE    29
RGC_RGC__CYGF DYGFNDI-------LE----MLR-----------------------------------------------------LSEEESSMEELLWTA-PE    29
TK_Abl__ABL DFGLSRL-------MT----GDT---------------------------------------------------YT-AHAGA-KFPIKWTA-PE    29
TK_Abl__ARG DFGLSRL-------MT----GDT---------------------------------------------------YT-AHAGA-KFPIKWTA-PE    29
TK_Tec__BTK DFGLSRY-------VL----DDE---------------------------------------------------YT-SSVGS-KFPVRWSP-PE    29
TK_Tec__BMX DFGMTRY-------VL----DDQ---------------------------------------------------YV-SSVGT-KFPVKWSA-PE    29
TK_Tec__TEC DFGMARY-------FL----DDQ---------------------------------------------------YT-SSSGA-KFPVKWCP-PE    29
TK_Tec__TXK DFGMTRY-------VL----DDE---------------------------------------------------YV-SSFGA-KFPIKWSP-PE    29
TK_Tec__ITK DFGMTRF-------VL----DDQ---------------------------------------------------YT-SSTGT-KFPVKWAS-PE    29
TK_Src__HCK DFGLARV-------IE----DNE---------------------------------------------------YT-AREGA-KFPIKWTA-PE    29
TK_Src__LYN DFGLARV-------IE----DNE---------------------------------------------------YT-AREGA-KFPIKWTA-PE    29
TK_Src__LCK DFGLARL-------IE----DNE---------------------------------------------------YT-AREGA-KFPIKWTA-PE    29
TK_Src__BLK DFGLARI-------ID----S-E---------------------------------------------------YT-AQEGA-KFPIKWTA-PE    28
TK_Src__SRC DFGLARL-------IE----DNE---------------------------------------------------YT-ARQGA-KFPIKWTA-PE    29
TK_Src__YES DFGLARL-------IE----DNE---------------------------------------------------YT-ARQGA-KFPIKWTA-PE    29
TK_Src__FYN DFGLARL-------IE----DNE---------------------------------------------------YT-ARQGA-KFPIKWTA-PE    29
TK_Src__FGR DFGLARL-------IK----DDE---------------------------------------------------YN-PCQGS-KFPIKWTA-PE    29
TK_Src__FRK DFGLARV-------FKV---DNEDI-------------------------------------------------YE-SRHEI-KLPVKWTA-PE    32
TK_Src__BRK DFGLARL-------IK----EDV---------------------------------------------------Y--LSHDH-NIPYKWTA-PE    28
TK_Src__SRM DFGLARL-------LK----DDI---------------------------------------------------YS-PSSSS-KIPVKWTA-PE    29
TK_Csk__CSK DFGLTKE-------AS----STQ---------------------------------------------------DT-G-----KLPVKWTA-PE    25
TK_Csk__CTK DFGLAKA-------ER----KGL---------------------------------------------------DS-S-----RLPVKWTA-PE    25
TK_Fer__FER DFGMSRQ-------ED----GGV---------------------------------------------------YS-SSG-LKQIPIKWTA-PE    29
TK_Fer__FES DFGMSRE-------EA----DGV---------------------------------------------------YA-ASGGSRQVPVKWTA-PE    30
TK_FGFR__FGFR2 DFGLARD-------INN---IDY---------------------------------------------------YK-KTTNG-RLPVKWMA-PE    30
TK_FGFR__FGFR3 DFGLARD-------VHN---LDY---------------------------------------------------YK-KTTNG-RLPVKWMA-PE    30
TK_FGFR__FGFR1 DFGLARD-------IHH---IDY---------------------------------------------------YK-KTTNG-RLPVKWMA-PE    30
TK_FGFR__FGFR4 DFGLARG-------VHH---IDY---------------------------------------------------YK-KTSNG-RLPVKWMA-PE    30
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TK_Ret__RET DFGLSRD-------VYE---EDS---------------------------------------------------YV-KRSQG-RIPVKWMA-IE    30
TK_VEGFR__KDR DFGLARD-------IYK---DPD---------------------------------------------------YV-RKGDA-RLPLKWMA-PE    30
TK_VEGFR__FLT1 DFGLARD-------IYK---NPD---------------------------------------------------YV-RKGDT-RLPLKWMA-PE    30
TK_VEGFR__FLT4 DFGLARD-------IYK---DPD---------------------------------------------------YV-RKGSA-RLPLKWMA-PE    30
TK_PDGFR__FMS DFGLARD-------IMN---DSN---------------------------------------------------YI-VKGNA-RLPVKWMA-PE    30
TK_PDGFR__KIT DFGLARD-------IKN---DSN---------------------------------------------------YV-VKGNA-RLPVKWMA-PE    30
TK_PDGFR__PDGFRa DFGLARD-------IMH---DSN---------------------------------------------------YV-SKGST-FLPVKWMA-PE    30
TK_PDGFR__PDGFRb DFGLARD-------IMR---DSN---------------------------------------------------YI-SKGST-FLPLKWMA-PE    30
TK_PDGFR__FLT3 DFGLARD-------IMS---DSN---------------------------------------------------YV-VRGNA-RLPVKWMA-PE    30
TK_Tie__TIE2 DFGLSR----------G---QEV---------------------------------------------------YV-KKTMG-RLPVRWMA-IE    27
TK_Tie__TIE1 DFGLSR----------G---EEV---------------------------------------------------YV-KKTMG-RLPVRWMA-IE    27
TK_Alk__ALK DFGMARD-------IYR---ASY---------------------------------------------------Y--RKGGCAMLPVKWMP-PE    30
TK_Alk__LTK DFGMARD-------IYR---ASY---------------------------------------------------Y--RRGDRALLPVKWMP-PE    30
TK_Sev__ROS DFGLARD-------IYK---NDY---------------------------------------------------Y--RKRGEGLLPVRWMA-PE    30
TK_InsR__INSR DFGMTRD-------IYE---TDY---------------------------------------------------Y--RKGGKGLLPVRWMA-PE    30
TK_InsR__IGF1R DFGMTRD-------IYE---TDY---------------------------------------------------Y--RKGGKGLLPVRWMS-PE    30
TK_InsR__IRR DFGMTRD-------VYE---TDY---------------------------------------------------Y--RKGGKGLLPVRWMA-PE    30
TK_DDR__DDR1 DFGMSRN-------LYA---GDY---------------------------------------------------Y--RVQGRAVLPIRWMA-WE    30
TK_DDR__DDR2 DFGMSRN-------LYS---GDY---------------------------------------------------Y--RIQGRAVLPIRWMS-WE    30
TK_Trk__TRKB DFGMSRD-------VYS---TDY---------------------------------------------------Y--RVGGHTMLPIRWMP-PE    30
TK_Trk__TRKC DFGMSRD-------VYS---TDY---------------------------------------------------Y--RVGGHTMLPIRWMP-PE    30
TK_Trk__TRKA DFGMSRD-------IYS---TDY---------------------------------------------------Y--RVGGRTMLPIRWMP-PE    30
TK_Musk__MUSK DFGLSRN-------IYS---ADY---------------------------------------------------Y--KANENDAIPIRWMP-PE    30
TK_Ror__ROR1 DLGLSRE-------IYS---ADY---------------------------------------------------Y--RVQSKSLLPIRWMP-PE    30
TK_Ror__ROR2 DLGLFRE-------VYA---ADY---------------------------------------------------Y--KLLGNSLLPIRWMA-PE    30
TK_CCK4__CCK4 ALGLSKD-------VYN---SEY---------------------------------------------------Y--HFR-QAWVPLRWMS-PE    29
TK_Axl__AXL DFGLSKK-------IYN---GDY---------------------------------------------------Y--RQGRIAKMPVKWIA-IE    30
TK_Axl__MER DFGLSKK-------IYS---GDY---------------------------------------------------Y--RQGRIAKMPVKWIA-IE    30
TK_Axl__TYRO3 DFGLSRK-------IYS---GDY---------------------------------------------------Y--RQGCASKLPVKWLA-LE    30
TK_Met__MET DFGLARD-------MYD---KEY---------------------------------------------------YSVHNKTGAKLPVKWMA-LE    32
TK_Met__RON DFGLARD-------ILD---REY---------------------------------------------------YSVQQHRHARLPVKWMA-LE    32
TK_Ryk__RYK DNALSRD-------LFP---MDY---------------------------------------------------H--CLGDNENRPVRWMA-LE    30
TK_Ack__ACK DFGLMRA-------LPQN--DDH---------------------------------------------------Y--VMQEHRKVPFAWCA-PE    31
TK_Ack__TNK1 DFGLVRP-------LGGA--RGR---------------------------------------------------Y--VMGGPRPIPYTWCA-PE    31
TK_EGFR__EGFR DFGLAKL-------LGAE--EKE---------------------------------------------------Y--HAE-GGKVPIKWMA-LE    30
TK_EGFR__HER2/ErbB2 DFGLARL-------LDID--ETE---------------------------------------------------Y--HAD-GGKVPIKWMA-LE    30
TK_EGFR__HER4/ErbB4 DFGLARL-------LEGD--EKE---------------------------------------------------Y--NAD-GGKMPIKWMA-LE    30
TK_EGFR__HER3/ErbB3 DFGVADL-------LPPD--DKQ---------------------------------------------------L--LYS-EAKTPIKWMA-LE    30
TK_Syk__SYK DFGLSKA-------LRAD--ENY---------------------------------------------------Y--KAQTHGKWPVKWYA-PE    31
TK_Syk__ZAP70 DFGLSKA-------LGAD--DSY---------------------------------------------------Y--TARSAGKWPLKWYA-PE    31
TK_Eph__EphA3 DFGLSRV-------LEDDP-EAA---------------------------------------------------Y--TTR-GGKIPIRWTS-PE    31
TK_Eph__EphA5 DFGLSRV-------LEDDP-EAA---------------------------------------------------Y--TTR-GGKIPIRWTA-PE    31
TK_Eph__EphA4 DFGMSRV-------LEDDP-EAA---------------------------------------------------Y--TTR-GGKIPIRWTA-PE    31
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TK_Eph__EphA6 DFGLSRV-------LEDDP-EAA---------------------------------------------------Y--TTT-GGKIPIRWTA-PE    31
TK_Eph__EphA7 DFGLSRV-------IEDDP-EAV---------------------------------------------------Y--TTT-GGKIPVRWTA-PE    31
TK_Eph__EphB1 DFGLSRY-------LQDDTSDPT---------------------------------------------------Y--TSSLGGKIPVRWTA-PE    33
TK_Eph__EphB2 DFGLSRF-------LEDDTSDPT---------------------------------------------------Y--TSALGGKIPIRWTA-PE    33
TK_Eph__EphB3 DFGLSRF-------LEDDPSDPT---------------------------------------------------Y--TSSLGGKIPIRWTA-PE    33
TK_Eph__EphB4 DFGLSRF-------LEENSSDPT---------------------------------------------------Y--TSSLGGKIPIRWTA-PE    33
TK_Eph__EphA8 DFGLSRV-------LEDDP-DAA---------------------------------------------------Y--TTT-GGKIPIRWTA-PE    31
TK_Eph__EphA2 DFGLSRV-------LEDDP-EAT---------------------------------------------------Y--TTS-GGKIPIRWTA-PE    31
TK_Eph__EphA1 DFGLTRL-------LDD--FDGT---------------------------------------------------Y--ETQ-GGKIPIRWTA-PE    30
TK_Eph__EphB6 RLGHS-------------------------------------------------------------------------PQ-GPSCLLRWAA-PE    19
TK_Eph__EphA10 GFGRGP---------RDRS-EAV---------------------------------------------------Y--TTM-SGRSPALWAA-PE    29
TK_Fak__FAK DFGLSRY-------MED---STY---------------------------------------------------Y--KAS-KGKLPIKWMA-PE    29
TK_Fak__PYK2 DFGLSRY-------IED---EDY---------------------------------------------------Y--KAS-VTRLPIKWMS-PE    29
TK_JakA__JAK1 DFGLTKA-------IET---DKE---------------------------------------------------YYTVKDDR-DSPVFWYA-PE    31
TK_JakA__TYK2 DFGLAKA-------VPE---GHE---------------------------------------------------YYRVREDG-DSPVFWYA-PE    31
TK_JakA__JAK2 DFGLTKV-------LPQ---DKE---------------------------------------------------YYKVKEPG-ESPIFWYA-PE    31
TK_JakA__JAK3 DFGLAKL-------LPL---DKD---------------------------------------------------YYVVREPG-QSPIFWYA-PE    31
TK_Lmr__LMR1 DYGLAHC-------KYR---EDY-----------------------------------------------------FVTADQLWVPLRWIA-PE    30
TK_Lmr__LMR3 DYGLAHS-------NYK---EDY-----------------------------------------------------YLTPERLWIPLRWAA-PE    30
TK_Lmr__LMR2 DYGIGFS-------RYK---EDY-----------------------------------------------------IETDDKKVFPLRWTA-PE    30
TK_JakB__Domain2_JAK1 DPGIPIT-------VLS------------------------------------------------------------RQEC--IERIPWIA-PE    24
TK_JakB__Domain2_TYK2 DPGVGLG-------ALS------------------------------------------------------------REER--VERIPWLA-PE    24
TK_JakB__Domain2_JAK2 DPGISIT-------VLP------------------------------------------------------------KDIL--QERIPWVP-PE    24
TK_JakB__Domain2_JAK3 DPGVSPA-------VLS------------------------------------------------------------LEML--TDRIPWVA-PE    24
TKL_LISK_LIMK_LIMK2 DFGLSRL-------IVEERKRAPMEKATTKK--------------------------------------RTLRKNDRKKRYTVVGNPYWMA-PE    48
TKL_LISK_LIMK_LIMK1 DFGLARL-------MVDEKTQP------EGL--------------------------------------RSLKKPDRKKRYTVVGNPYWMA-PE    42
TKL_LISK_TESK_TESK1 DFGLAEK-------IPVYREGA------------------------------------------------------RKEPLAVVGSPYWMA-PE    32
TKL_LISK_TESK_TESK2 DFGLAEK-------IPDVSMGS------------------------------------------------------EK--LAVVGSPFWMA-PE    30
TKL_MLK_HH498_HH498 DFGESRF-------LQSLD-ED--------------------------------------------------------NMTKQPGNLRWMA-PE    29
TKL_MLK_TAK1_TAK1 DFGTACD-------IQT-------------------------------------------------------------HMTNNKGSAAWMA-PE    25
TKL_MLK_LZK_DLK DFGTSKE-------LSD---KS--------------------------------------------------------TKMSFAGTVAWMA-PE    27
TKL_MLK_LZK_LZK DFGTSKE-------LSD---KS--------------------------------------------------------TKMSFAGTVAWMA-PE    27
TKL_MLK_MLK_MLK1 DFGLARE-------WH----RT--------------------------------------------------------TKMSAAGTYAWMA-PE    26
TKL_MLK_MLK_MLK3 DFGLARE-------WH----KT--------------------------------------------------------TQMSAAGTYAWMA-PE    26
TKL_MLK_MLK_MLK4 DFGLARE-------WH----RT--------------------------------------------------------TKMSTAGTYAWMA-PE    26
TKL_MLK_MLK_MLK2 DFGLARE-------WH----KT--------------------------------------------------------TKMSAAGTYAWMA-PE    26
TKL_MLK_MLK_ZAK DFGASRF-------HN----HT--------------------------------------------------------THMSLVGTFPWMA-PE    26
TKL_RAF__BRAF DFGLATV-------KSRWSGSH--------------------------------------------------------QFEQLSGSILWMA-PE    30
TKL_RAF__RAF1 DFGLATV-------KSRWSGSQ--------------------------------------------------------QVEQPTGSVLWMA-PE    30
TKL_RAF__ARAF DFGLATV-------KTRWSGAQ--------------------------------------------------------PLEQPSGSVLWMA-AE    30
TKL_RAF__KSR1 LFGISGV-------VREGRREN--------------------------------------------------------QLKLSHDWLCYLA-PE    30
TKL_RAF__KSR2 LFSISGV-------LQAGRRED--------------------------------------------------------KLRIQNGWLCHLA-PE    30
TKL_RIPK__ANKRD3 DFGLAKC-------NGLS-H-----------------------------------------------------SHDLSMDGLFG-TIAYLP-PE    31
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TKL_RIPK__SgK288 DFGLSKW-------MEQSTR-----------------------------------------------------MQYIERSALRG-MLSYIP-PE    32
TKL_RIPK__RIPK2 DFGLSKW-------RMMSLS-----------------------------------------------------QSRSSKSAPEGGTIIYMP-PE    33
TKL_RIPK__RIPK3 DFGLSTF-------QGGS--------------------------------------------------------QSGTGSGEPGGTLGYLA-PE    30
TKL_RIPK__RIPK1 DLGLASF-------KMWSKLNN------EE---------------------------------------HNELREVDGTAKKNGGTLYYMA-PE    41
TKL_IRAK__IRAK1 DFGLARF-------SRFAG-SSP------------------------------------------------SQSSMVARTQTVRGTLAYLP-EE    37
TKL_IRAK__IRAK3 DFAMAHF-------R--S--HLE------------------------------------------------HQSCTINMTSSSSKHLWYMP-EE    34
TKL_IRAK__IRAK2 HP-MAHL-------CP----VNK------------------------------------------------RSKYTMMKTHLLRTSAAYLP-ED    33
TKL_IRAK__IRAK4 DFGLARA-------S--------------------------------------------------------EKFAQTVMTSRIVGTTAYMA-PE    30
Other_NRBP__NRBP1 VAPDTIN-------NH------------------------------------------------------------VKTCREEQKNLHFFA-PE    26
Other_NRBP__NRBP2 ALPDDLR-------SP------------------------------------------------------------IRAEREELRNLHFFP-PE    26
Other_Wnk__Wnk1 DLGLATL-------KR------------------------------------------------------------ASFAKSVIGTPEFMA-PE    26
Other_Wnk__Wnk3 DLGLATL-------MR------------------------------------------------------------TSFAKSVIGTPEFMA-PE    26
Other_Wnk__Wnk2 DLGLATL-------KR------------------------------------------------------------ASFAKSVIGTPEFMA-PE    26
Other_Wnk__Wnk4 DLGLATL-------KR------------------------------------------------------------ASFAKSVIGTPEFMA-PE    26
CK1_CK1__CK1a DFGLAKK-------YRDN---------------------------------------------------RTRQHIPYREDKNLTGTARYAS-IN    35
CK1_CK1__CK1a2 DFGLAKK-------YRDN---------------------------------------------------RTRQHIPYREDKHLIGTVRYAS-IN    35
CK1_CK1__CK1d DFGLAKK-------YRDA---------------------------------------------------RTHQHIPYRENKNLTGTARYAS-IN    35
CK1_CK1__CK1e DFGLAKK-------YRDA---------------------------------------------------RTHQHIPYRENKNLTGTARYAS-IN    35
CK1_CK1__CK1g3 DFGLAKE-------YIDP---------------------------------------------------ETKKHIPYREHKSLTGTARYMS-IN    35
CK1_CK1__CK1g1 DFGLAKE-------YIDP---------------------------------------------------ETKKHIPYREHKSLTGTARYMS-IN    35
CK1_CK1__CK1g2 DFGLAKE-------YIDP---------------------------------------------------ETKKHIPYREHKSLTGTARYMS-IN    35
CK1_TTBK__TTBK2 DFGLARQ-------FTN----------------------------------------------------SCGDVRPPRAVAGFRGTVRYAS-IN    34
CK1_TTBK__TTBK1 DFGLARQ-------YTN----------------------------------------------------TTGDVRPPRNVAGFRGTVRYAS-VN    34
CK1_VRK__VRK1 DYGLAYR-------YCPE---------------------------------------------------GVHKEYKEDPKRCHDGTIEFTS-ID    35
CK1_VRK__VRK2 DYGLSYR-------YCPN---------------------------------------------------GNHKQYQENPRKGHNGTIEFTS-LD    35
CK1_VRK__VRK3 GYGFAFR-------YCPS---------------------------------------------------GKHVAYVEGSRSPHEGDLEFIS-MD    35
Other_NKF5__SgK307 NLEYMLE-------SEDR---------------------------------------------------GVQRDLTRVPLP--TQLYNWAA-PE    33
Other_NKF5__SgK424 ----------------------------------------------------------------------------------------------
Other_NAK__MPSK1 SMNQACIH------VEGSR-----------------------------------------------------QALTLQDWAAQRCTISYRA-PE    34
Other_PEK__HRI DFGLACT-----DILQKNTDWTN------------------------------------------------RNGKRTPTHTSRVGTCLYAS-PE    40
Other_TTK__TTK DFGIANQ-------MQPDTTS--------------------------------------------------------VVKDSQVGTVNYMP-PE    30
STE_STE-Unique__COT DFGLSVQ-------MTED----------------------------------------------------------VYFPKDLRGTEIYMS-PE    28
STE_STE-Unique__NIK DFGHAVC-------LQPDGLG-----------------------------------------------------KSLLTGDYIPGTETHMA-PE    33
Other_CDC7__CDC7 NFNIHSSISHESPAVKLMKQSKTVDVLSRKLATKKKAISTKVMNSAVMRKTASSCPASLTCDCYATDKVCSICLSRRQQVAPRAGTPGFRA-PE    93
TK_TK-Unique__SuRTK106 -LGLAYE-------VYTRG----------------------------------------------------------AISSTQTIPLKWLA-PE    27
TKL_LRRK__LRRK2 DYGIAQY------CCRMG-------------------------------------------------------------IKTSEGTPGFRA-PE    26
Other_Other-Unique__SgK496 DLGFCKP--------------------------------------------------------------------EAMMSGSIVGTPIHMA-PE    25
Other_MOS__MOS DFGCSEK-------LEDLLCFQTP-------------------------------------------------------SYPLGGTYTHRA-PE    31
Other_TBCK__TBCK KFGLYH--------MTAHG----------------------------------------------------------DDVDFPIGYPSYLA-PE    27
TKL_LRRK__LRRK1 DYGISRQ------SFHEG-------------------------------------------------------------ALGVEGTPGYQA-PE    26
Other_Other-Unique__KIS DFGLSFK--------EGN------------------------------------------------------------QDVKYIQTDGYRA-PE    25
TKL_TKL-Unique__MLKL ELRKTQTS------MSLG---------------------------------------------------------TTREKTDRVKSTAYLS-PQ    30
Other_Bud32__PRPK DFGLS---------FIS-------------------------------------------------------------ALPEDKGVDLYVL-EK    23
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Figure 69. Human kinome DFG-APE sequence alignment. 
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Other_NKF2__PINK1 DFGCCLADESIGLQLPFSS-----------------------------------------------------------WYVDRGGNGCLMA-PE    34
Other_TOPK__PBK DVGVSLP-------LDEN-------------------------------------------------------MTVTDPEACYIGTEPWKP-KE    31
AGC_MAST__MASTL DFGLSK---------VT-------------------------------------------------------------LNRDINMMDILTT-PS    23
Other_Other-Unique__RNAseL DFDKS---------------------------------------------------------------------------------IKWAGDPQ    13
TKL_MLK_ILK_ILK DVKFSFQ------------------------------------------------------------------------CPGRMYAPAWVA-PE    21
Other_Other-Unique__SgK071 DLSSNVL-------MTDKAKWN-------------------------------------------------------IRAEEDPFRKSWMA-PE    31
STE_STE-Unique__Domain2_GCN2 DYSISKR-------LAD-------------------------------------------------------------ICKEDVFEQTRVRFSD    26
Other_SCY1__SCYL2 DFCVSST-------NPSEQE-----------------------------------------------------PKFPCKEWDPNLPSLCLPNPE    34
Other_SCY1__SCYL1 DYMYSAQ--------GNGGG---------------------------------------------------------PPRKGIPELEQYDP-PE    28
Other_SCY1__SCYL3 --GMET------------------------------------------------------------------------VCKVSQATPEFLRSIQ    20
Other_Other-Unique__SgK196 QYLLTSN-------FS-------------------------------------------------------------ILANDLDALPLVNHSSG    26
Other_VPS15__PIK3R4 DFASFKPTYLPEDNPADFNYFFDTSRRR----------------------------------------TCYIAPERFVDGGMFATELEYMRDPS    54
Other_BUB__BUB1 DLGQSID-------MKLFPKG--------------------------------------------------------TIFTAKCETSGFQC-VE    30
Other_BUB__BUBR1 DFSYSVD--------LRVQLD--------------------------------------------------------VFTLSGFRTVQILEGQK    30
Other_Other-Unique__SgK493 DLDDAR--------VEETP-----------------------------------------------------------CAGSTDCILEFPARNF    27
Other_Other-Unique__SgK396 DFDFTKS-------VSQR-----------------------------------------------------------ASVNMMVGDLSLMS-PE    27
Other_Slob__Slob DLENS-------------------------------------------------------------------------LLGLPSFYRSYFSQFR    21
Other_Haspin__Haspin -YTLNGK-------SSTIP-----------------------------------------------------------SCGLQVSIIDYTLSRL    27
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4.2 General Chemical Methods:  
Chemical reagents and solvents were purchased from Sigma-Aldrich (MO, USA), Alfa-Aesar 
(MA, USA), Fisher Scientific (PA, USA). Amino acids and coupling reagents were purchased 
from Chem-Impex. Analytical Thin Layer Chromatography (TLC) was performed using silica 
gel GHLF plates (Analtech Inc., DE, USA). Flash Chromatography was performed on 
TELEDYN ISCO CombiFlash® Rf instrument using RediSep Rf Normal-phase Flash Columns 
(4g, 12g, 24g, or 40g). 1H NMR and 13C NMR were recorded on a Bruker Topspin 400MHz 
using Chloroform-d and deuterated DMSO. All chemical shifts are reported as δ in units of parts 
per million (ppm) relative to chloroform and DMSO residual peaks at 7.26 and 2.50 respectively 
(1H) and 77.16 and 39.52 respectively (13C). The multiplicity (s = singlet, d = doublet, dd = 
doublet of doublets, t = triplet, q = quartet, m = muliplet), coupling constants(s) (Hz). 
Electrospray ionization (ESI) mass spectra were obtained from Perkin Elmer Flexar 
UPLC/AxION2 TOF Mass Spectrometer. Matrix-Assisted Laser Desorption/Ionization 
(MALDI) spectra were obtained from Voyager DE-ProTM MALDI TOF Mass Spectrometer.  
4.2.1 
 
 
 
((prop-2-yn-1-yloxy)carbonyl)-L-phenylalanine (12). To a vial add 8 mL H2O, 467.52 mg 
NaOH, and 660.8 mg phenylalanine (freebase form). To the solution add 0.39 mL 
propargylcarbamate. Allot to react for 16 hr at ambient tempterature. Wash with 2 N 
H
N
O
O
O OH
12
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HCl/EtOAc, collect organic layer. (438 mg, 43.8%). Rf (90:10 DCM:MeOH)= 0.47. Crude 
product taken forward to Weinreb Amide formation.   
 
4.2.2 
 
((prop-2-yn-1-yloxy)carbonyl)-L-isoleucine (16). To a vial add 8 mL H2O, 467.52 mg NaOH, 
and 616 mg isoleucine (freebase form). To the solution add 0.39 mL propargylcarbamate. Allot 
to react for 16 hr at ambient tempterature. Wash with 2 N HCl/EtOAc, collect organic layer. (463 
mg, 46.3%). Rf (90:10 EtOAc:Hexanes)= 0.44. Crude product taken forward to Weinreb Amide 
formation. 
 
4.3 General Procedure for the Formation of Weinreb Amide Intermediates. 
To a vial was added 1 equivalent of amino acid (Boc or Poc protected). To the vial was added 
DCM (.25 M final concentration of amino acid). To the solution was added N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide (EDCI, 1.2 equivalents), 1-Hydroxybenzotriazole 
(HOBt) hydrate (1 equivalent), and  4-methylmorpholine (4 equivalents). This solution was 
allowed to react for 15 minutes at ambient T. To the solution was then added N,O-
Dimethylhydroxylamine hydrochloride (1.1 equivalents) and allowed to react for 16 hr. The 
reaction solution was washed with 1N HCl once, then with saturated NaCO3, then the organic 
solvent was collected and solvent removed in vacuo. The crude product was purified by flash 
H
N OH
O
O
O
16
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chromatography on silica by CombiFlash instrument (0-100% EtOAc:Hexanes over 20 column 
volumes).  
 
4.3.1 
 
 
tert-butyl (S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (2). (2g, 87%) 
1H NMR (400 MHz, CDCl3) δ 7.28 (m, 2H) 7.22 (d, J=7.2, 1H), 7.17 (d, J=7.6, 2H), 5.14 (br, 
1H), 4.95 (br, 1H), 3.65 (s, 3H), 3.16 (s, 3H), 3.05 (dd, J1=6.2, J2=13.5, 1H), 2.89 (m, 1H), 1.39 
(s, 9H). 
 
4.3.2 
 
tert-butyl ((2S,3S)-1-(methoxy(methyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (5). (574 
mg 67%) 1H NMR (400 MHz, CDCl3) δ 5.2 (s, 1H), 4.6 (s, 1H),  3.7 (s, 3H), 3.2 (s, 3H), 2.1 (s, 
1H), 1.7 (m, 1H), 1.5 (m 1H), 1.4 (s, 9H), 1.0 (m, 1H), 1.9 (m, 6H). 
H
N
O
O
O
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4.3.3 
 
 
 
 
tert-butyl (2-(methoxy(methyl)amino)-2-oxoethyl)carbamate (8). (302 mg, 77%) 1H NMR (400 
MHz, CDCl3) δ 5.2 (s, 1H), 4.0 (s, 2H), 3.6 (s, 3H), 3.1 (s, 3H), 1.4 (s, 9H). 
 
4.3.4 
 
 
 
prop-2-yn-1-yl(S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (13). 
(0.312 g, 61% yield). 1H NMR (400MHz, CD3OD) δ 7.23-7.29 (m, 5H), 4.89 (m, 1H), 4.60 (s, 
2H), 3.73 (s, 3H), 3.17 (s, 3H), 3.04 (dd, J1=5.9, J2=13.3, 1H), 2.86 (m, 2H).  
 
 
 
H
N N
O
O
O O
8
H
N
O
O
O N O
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4.3.5 
 
 
((prop-2-yn-1-yloxy)carbonyl)-L-isoleucine (17). (480 mg, 94%) 1H NMR (400 MHz, CDCl3) δ 
5.3 (d, 1H, J=9), 4.6 (m, 3H), 3.7 (s, 3H), 3.1 (s, 3H), 2.4 (s, 1H), 2.0 (s, 1H), 1.7 (m, 1H), 1.5 
(m, 1H), 1.0 (m, 1H), 0.9 (m, 6H). 
 
4.4 General Procedure for Grignard Reactions with Weinreb Amides. 
The appropriate Weinreb amide (above) (1 equivalent) was dissolved in anhydrous THF (.3 M). 
The solution was then cooled to -40 °C in a dry ice/ACN bath and purged with argon before 1M 
vinyl magnesium bromide in Ether (5 equivalents) was added dropwise (over 5 minutes). After 
3h stirring at -40 °C, the reaction mixture was poured into cold 3N HCl, and extracted three 
times with ethyl acetate. The combined organic layers were dried over anhydrous sodium 
sulphate and concentrated in vacuo. The crude product was purified over silica gel 
chromatography to obtain the desired product.  
 
 
 
 
 
H
N N
O
O
O O
17
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4.4.1 
 
 
 
tert-butyl (S)-(3-oxo-1-phenylpent-4-en-2-yl)carbamate (3). (156 mg, 67%) 1H NMR (400MHz, 
CDCl3) δ 7.25 (m, 3H) 7.10 (d, J=7.4, 2H), 6.41 (m, 2H), 5.83 (d, J=10.4, 1H), 5.22 (m, 1H), 
4.86 (q, J=9, 1H), 3.14 (dd, J1=6.4, J2=13.8, 1H), 2.98 (dd, J1=8.0, J2=15.4, 1H), 1.42 (s, 9H). 
13C NMR (100MHz, CDCl3) δ 197.9, 155.2, 136.0, 133.5, 130.2, 129.6, 128.6, 127.1, 79.9, 58.3, 
38.2, 28.4. HRMS (ESI) C16H21NO3 m/z [M+Na
+] found 298.1415, expected 298.1419.  
 
4.4.2 
 
tert-butyl ((4S,5S)-5-methyl-3-oxohept-1-en-4-yl)carbamate (6). (34 mg, 45%) 1H NMR 
(400MHz, CDCl3) δ 6.4 (m, 2H), 5.8 (d, 1H, J=10.32), 5.1 (s, 1H), 4.5 (m, 1H), 1.8 (m, 1H), 1.5 
(s, 1H), 1.3 (m, 2H), 1.4 (s, 9H), 1 (m, 3H), 0.8 (m, 3H). 13C NMR (100MHz, CDCl3) δ 199.2, 
155.9, 134.2, 129.7, 79.7, 61.9, 37.8, 28.4, 24.3, 16.3, 11.7. 
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4.4.3 
 
tert-butyl ((3S,4S)-3-methyl-5-oxoheptan-4-yl)carbamate (10). To a solution of 6 was added 
Pd/C (0.1 mol%) with H2(g) at ATM and ambient temperature for 16 hr. The solution was 
filtered through celite and solvent removed in vacuo. (22 mg, Quantitative) 1H NMR (400MHz, 
CDCl3) δ 5.0 (s, 1H), 4.2 (s, 1H), 2.4 (m, 1H), 1.8 (s, 1H), 1.4 (s, 3H), 1.3 (s, 9H), 1.0 (m, 3H), 
0.9 (d, 3H, J=6.8), 0.8 (m, 3H). 13C NMR (100MHz, CDCl3) δ 210.5, 155.9, 79.6, 63.6, 37.2, 
34.3, 28.3, 24.2, 16.1, 11.6, 7.5. 
 
4.4.4 
 
 
tert-butyl (2-oxobut-3-en-1-yl)carbamate (9). (34 mg, 45%) 1H NMR (400MHz, CDCl3) δ 6.3 
(m, 2H), 5.9 (d, 1H J=8.2), 5.2 (s, 1H), 4,2 (s, 2H), 1.4 (s, 9H). 13C NMR (100MHz, CDCl3) δ 
205.3, 155.4, 79.6, 62.9, 36.4, 34.1, 28.3. 
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4.4.5 
 
prop-2-yn-1-yl (S)-(3-oxo-1-phenylpent-4-en-2-yl)carbamate (14). (135.7 mg, 38%) 1H NMR 
(400MHz, CD3OD) δ 7.22-7.28 (m, 5H), 6.61 (dd, J1=10.1, J2=12.4, 1H), 6.36 (d, J=17.4, 1H), 
5.87 (d, J=11.4, 1H), 4.72 (m, 1H), 4.60 (s, 2H), 3.24 (dd, J1=5.5, J2=13.9, 1H), 2.87 (m, 2H).  
 
4.4.6 
 
 
prop-2-yn-1-yl ((4S,5S)-5-methyl-3-oxohept-1-en-4-yl)carbamate (18). (50.86 mg, 33%) Rf 
(50:50 Hexanes:EtOAc) = 0.68.  1H NMR (400MHz, CDCl3) δ 6.4 (m, 1H), 6.3 (m, 1H), 5.8 (d, 
1H, J=10.28), 5.4 (s, 1H), 4.6 (m, 3H), 2.4 (s, 1H), 2.0 (m, 1H), 1.3 (m, 2H), 1.2 (m, 1H), 0.9 (d, 
3H, J=6.8), 0.8 (m, 3H).  13C NMR (100MHz, CDCl3) δ 198.3, 155.5, 133.9, 130.0, 78.1, 74.7, 
62.4, 52.8, 37.6, 24.2, 16.1, 11.6. 
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4.5 Synthesis of Remaining Single Amino Acid Analogues 
4.5.1 
 
 
tert-butyl ((2S,3S)-1-((2-hydroxyethyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (19). (936 
mg, 93.6%). To a dry reaction vessel add 841.9 mg of Boc-Ile-OH and 18.2 mL of anhydrous 
DCM. To the solution at .85 mL NMM, 906.7 mg EDCI, 590.5 mg HOBt, and was allowed to 
equilibrate for 15 minutes. To the reaction solution was added ethanolamine (0.26 mL) dropwise 
over 1 minute. Solution allowed to react for 16 hr at ambient temperature. The crude product was 
purified over silica gel chromatography to obtain the desired product. 1H NMR (400MHz, 
CDCl3) δ 6.8 (s, 1H), 5.2 (s, 1H), 3.9 (t 1H, J1=7.08, J2=8.28), 3.7 (s, 2H), 3.4 (m, 2H) 3.3 (s, 
1H), 1.8 (s, 1H), 1.5 (s, 1H), 1.4 (s, 9H), 1.1 (m, 1H), 0.9 (m, 6H). 
 
4.5.2 
 
 
 
tert-butyl((2S,3S)-1-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-3-methyl-1-
oxopentan-2-yl)carbamate (20). (93.33 mg, 31%). To a dry reaction vessel, add anhydrous THF, 
H
N N
H
O
O
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flush with argon, and cool to -78°C under argon. To the THF slowly add triphenyl phosphine 
Ph3P and allow to equilibrate for 5 minutes. To the solution, slowly add diethyl azodicarboxylate 
(DEAD) and allow to equilibrate for 5 minutes. To the solution, add 19 and allow to equilibrate 
for 5 minutes. To the solution, add maleimide, stir, allow to reach ambient temperature, and let 
react for 16 hrs. Solvent removed in vacuo. The crude product was purified over silica gel 
chromatography to obtain the desired product.   1H NMR (400MHz, CDCl3) δ 6.6 (s, 2H), 6.2 (s, 
1H), 4.8 (m, 1H), 4.2 (s, 1H), 3.8 (m, 2H), 3.6 (m, 2H), 3.4 (s, 2H), 1.8 (s, 1H), 1.5 (s, 2H), 1.4 
(s, 9H), 08 (m, 6H). 13C NMR (100MHz, CDCl3) δ 174.3, 171.0, 168.9, 134.4, 72.3, 67.1, 58.2, 
38.1, 36.5, 24.7, 14.7, 11.5. 
 
 
4.5.3 
 
tert-butyl ((2S,3S)-1-((2-mercaptoethyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (21). 
(102.93 mg, 51%). To a dry reaction vessel add 159.6 mg of Boc-Ile-OH and 3.45 mL of 
anhydrous DCM. To the solution add 17 mL NMM, 172.5 mg EDCI, 112.1 mg HOBt, and was 
allowed to equilibrate for 15 minutes. To the reaction solution was added cysteinamine (058.6 
mg) slowly. Solution allowed to react for 16 hr at ambient temperature. The reaction mixture was 
poured into cold 1N HCl, and extracted three times with ethyl acetate. The combined organic 
layers were dried over anhydrous sodium sulphate and concentrated in vacuo. The crude product 
was purified over silica gel chromatography to obtain the desired product.  1H NMR (400MHz, 
H
N N
H
O
O
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CDCl3) δ 6.3 (s, 1H), 4.9 (s, 1H), 3.8 (t, 1H J1=6.48, J2=8.52), 3.4 (m, 2H), 2.6 (m, 2H), 1.8 (s, 
1H), 1.4 (s, 9H), 0.8 (m, 6H). 13C NMR (100MHz, CDCl3) δ 201.3, 171.8, 155.7, 65.2, 42.3, 
39.3, 37.2, 28.3, 24.5, 15.8, 11.4. 
 
 
4.5.4 
 
 
 
tert-butyl ((2S,3S)-1-((2-iodoethyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (22). 
Procedure adapted from Helmboldt, H. et al.142 (37 mg, 27%) To a dry reaction vessel add 
anhydrous DCM (1 mL), flush with argon, and cool to 0°C under argon. To the DCM slowly add 
triphenyl phosphine (Ph3P, 99.6 mg) and allow to equilibrate for 5 minutes. To the solution 
slowly add imidazole (25.9 mg) and allow to equilibrate for 5 minutes. To the solution slowly 
add I2 allow to equilibrate for 15 minutes. To the solution add 19, stir, allow to reach ambient 
temperature, and let react for 4 hrs. Solvent removed in vacuo. Taken back up in non polar 
solvent and passed through celite. The crude product was purified over silica gel chromatography 
to obtain the desired product. 1H NMR (400MHz, CDCl3) δ 6.4 (s, 1H), 5.0 (s, 1H), 3.9 (t, 1H 
J1=2.4, J2=6.4), 3.6 (m, 1H), 3.5 (m, 1H), 3.2 (m, 2H), 1.8 (s, 1H), 1.4 (s, 9H), 0.8 (m, 6H). 13C 
NMR (100MHz, CDCl3) δ 171.7, 155.8, 80.1, 59.5, 41.8, 37.0, 28.3, 24.8, 15.7, 11.4, 4.6. 
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4.5.5 
 
tert-butyl ((2S,3S)-1-((2-bromoethyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (23). 
Procedure adapted from Bora, I. et al.143 (47.65 mg, 51%). To a dry reaction vessel add 0.5 mL of 
DCM. To the DCM add 77.18 mg of 19. To the solution add 102.8 mg of CBr4. Cool to 0°C. To 
the solution slowly add 81.3 mg of Ph3P over 20 minutes. Allow to react for 4hr. Pour solution 
into excess hexanes and filter out the salt precipitate. Remove solvent in vacuo. The crude 
product was purified over silica gel chromatography to obtain the desired product. 1H NMR 
(400MHz, CDCl3) δ 6.7 (s, 1H), 5.1 (s, 1H), 4.0 (t, 1H J1=2.4, J2=6.4), 3.7 (m, 1H), 3.6 (m, 1H), 
3.4 (m, 2H), 1.9 (s, 1H), 1.5 (s, 9H), 0.9 (m, 6H). 13C NMR (100MHz, CDCl3) δ 171.7, 155.8, 
80.1, 59.5, 41.1, 37.1, 31.9, 28.3, 24.8, 15.7, 11.4. 
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4.5.6 
 
 
 
tert-butyl ((2S,3S)-1-((2-chloroethyl)amino)-3-methyl-1-oxopentan-2-yl)carbamate (24). 
Procedure adapted from Bora, I. et al.143 (55.72 mg, 68%). To a dry reaction vessel add 0.5 mL of 
DCM. To the DCM add 77.18 mg of 19. To the solution add 47.7 mg of CCl4. Cool to 0°C. To 
the solution slowly add 81.3 mg of Ph3P over 20 minutes. Allow to react for 4hr. Pour solution 
into excess hexanes and filter out the salt precipitate. Remove solvent in vacuo. The crude 
product was purified over silica gel chromatography to obtain the desired product. 1H NMR 
(400MHz, CDCl3) δ 6.6 (s, 1H), 5.0 (s, 1H), 4.0 (t, 1H J1=2.4, J2=6.4), 3.7 (m, 1H), 3.6 (m, 1H), 
3.4 (m, 2H), 1.9 (s, 1H), 1.5 (s, 9H), 0.9 (m, 6H). 13C NMR (100MHz, CDCl3) δ 171.7, 155.8, 
80.1, 59.4, 43.6, 41.1, 37.1, 28.3, 24.8, 15.7, 11.4. 
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4.6 Alternative Route to Chloromethyl Ketone. 
4.6.1 
 
 
1-(benzylamino)-3-chloropropan-2-ol (25). Procedure adapted from patent US6362188.144 
(1.75g, 88%) To a solution of benzylamine (1.08927g) in cyclohexane (1M, 10.17 mL) was 
added epichlorohydrin (1 equivalent, 0.82 mL). The solution was allowed to react and precipitate 
collected by vacuum filtration and wash with cold cyclohexane. Product taken directly to next 
step. 
 
4.6.2 
 
tert-butyl benzyl(3-chloro-2-hydroxypropyl)carbamate (26). Procedure adapted from Org. Lett 
2010, 12, 2746-2749.145 (358.2 mg, 45%). To a solution of 25 in DCM (0.25M) was added 1 
equivalent of Boc anhydride. The solution was allowed to react for 30 minutes and then the 
solvent was removed in vacuo. The crude product was purified over silica gel chromatography to 
obtain the desired product as a white crystalline solid. Spectral data matched previously 
reported.146 
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4.6.3 
 
tert-butyl benzyl(3-chloro-2-oxopropyl)carbamate (27). Procedure adapted from JOC 2001, 66, 
8661.146 (98 mg, quantitative). Swern oxidation: to a dry vial add anhydrous DCM (3.3 mL) at      
-78°C. To the DCM add oxalyl chloride (0.03 mL). Seperately prepare a solution of DMSO in 
DCM (1 mL). Add the DMSO solution to the oxalyl chloride solution slowly over 10 minutes. 
Prepare a third solution of 26 in DCM (1 mL). Add the alchol containing solution to the mother 
liqour dropwise over 10 minutes, stir for 20 minutes. Prepare a solution of excess TEA (4.5 
equivalents) in DCM, and add dropwise. Stir for 30 minutes. Wash with H2O and extract with 
DCM 3X. Collect organic layers and remove solvent in vacuo to produe product of sufficient 
purity to move forward (one spot by TLC, RF = .77 in 70:30 EtOAc:Hexanes). 1H NMR 
(400MHz, CDCl3) δ 7.2 (m, 5H), 4.5 (s, 1H), 4.5 (s, 1H), 4.1 (s, 1H), 4.08 (s, 1H), 4.0 (s, 1H), 
3.9 (s, 1H), 1.4 (s, 9H). 146 
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4.6.4 
 
tert-butyl (3-chloro-2-oxopropyl)carbamate (28). First attempt with Pd/C at atmospheric pressure 
(H2) and ambient temperature did not produce any effect. The addition of PdOH/C (25% w/w) 
did produce multiple spots. Only a small fraction was able to be recovered as pure product after 
celite and silica column workup (~10%).  
 
 
 
 
4.7 Diazomethane route to Chloromethyl ketones 
 
4.7.1 
 
(2S,3S)-2-((tert-butoxycarbonyl)amino)-3-methylpentanoic (isobutyl carbonic) anhydride (29). 
Procedure adapted from J. Med. Chem 1995, 38, 1015-1021.127 To a dry round bottom flask was 
added 12.5 mL of anhydrous THF. To the THF was added Boc-Ile-OH (1.15645g) and 1 
HN
O
Cl
OO
O
H
N O
O
O
O
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equivalent of NMM (0.55 mL). To the solution was added isobutylchloroformate (0.78 mL). 
Crude used in next step. 
 
 
4.7.2 
 
 
(3S,4S)-1-chloro-4-methyl-2-oxohexan-3-aminium chloride (30). To the solution of 29 prepared 
in the previous step was added a solution of diazomethane in ether (formed in situ with a 
minidiazald kit according to manufacturers instructions). The solution was allowed to react for 5 
hr and allowed to reach ambient temperature. Then the remaining diazomethane was quenched 
with glacial acetic acid (~1 mL until no more bubbling occurred). The diazo intermediate was 
isolated by silicia chromatography and then treated with 4 equivalents of HCl (4N in dioxane) 
and allowed to react for 5 hrs. ~75% solvent removed under vacuum and the remaining was 
tritutated with ether to crash out the product. 1H NMR (400MHz, CD3OD) δ 4.6 (s, 2H), 4.4 (s, 
1H), 3.3 (s, 3H), 2.2 (m, 1H), 1.4 (m, 1H), 1.3 (m, 1H), 1.2 (d, 3H, J=6.88), 1.0 (m, 3H). 
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4.7.3 
 
 
2-((tert-butoxycarbonyl)amino)acetic (isobutyl carbonic) anhydride (31). Procedure adapted 
from J. Med. Chem 1995, 38, 1015-1021.127 To a dry round bottom flask was added 12.5 mL of 
anhydrous THF. To the THF was added Boc-Gly-OH (0.87590g) and 1 equivalent of NMM 
(0.55 mL). To the solution was added isobutylchloroformate (0.78 mL). Crude used in next step. 
 
 
 
4.7.4 
 
3-chloro-2-oxopropan-1-aminium chloride (32). To the solution of 31 prepared in the previous 
step was added a solution of diazomethane in ether (formed in situ with a minidiazald kit 
according to manufacturers instructions). The solution was allowed to react for 5 hr and allowed 
to reach ambient temperature. Then the remaining diazomethane was quenched with glacial 
acetic acid (~1 mL until no more bubbling occurred). The diazo intermediate was isolated by 
silicia chromatography and then treated with 4 equivalents of HCl (4N in dioxane) and allowed 
to react for 5 hrs. ~75% solvent removed under vacuum and the remaining was tritutated with 
ether to crash out the product. 1H NMR (400MHz, CD3OD) δ 4.6 (s, 2H), 4.2 (s, 2H), 3.3 (s, 3H). 
O
H
N O
O
O
O
O
H3N
O
ClCl
	   168	  
 
4.8 Synthesis of Rhodamine derivatives 
4.8.1 
3,6-bis(diethylamino)-9-(2-(((2,5-dioxopyrrolidin-1-yl)oxy)carbonyl)phenyl)xanthylium 
(33): To a solution of rhodamine B (5.0 g, 10.44 mmol) and EDC (3.0 g, 15.66 mmol) in DCM 
(250 mL) was added N-hydroxysuccinimide (1.3 g, 11.48 mmol). The reaction was stirred at 
ambient temperature for 12 hr. Solvent was removed and the product was purified via flash 
chromatography (silica DMC:MeOH 9:1). Yield 75.4% (4.3 g, 7.9 mmol). Analytical data (1H 
NMR, 13C NMR, mass spec) matched the previously reported data.125 
 
4.8.2 
 
 
9-(2-((3-carboxypropyl)(methyl)carbamoyl)phenyl)-3,6-bis(diethylamino)xanthylium (34): 
To a solution of 33 (2.9 g, 5.29 mmol) and DIEA (2.7 g, 21.16 mmol) in I (52.9 mL) was added 
4-methylaminebutyric acid hydrochloride (1.2 g, 7.94 mmol). The reaction was stirred at ambient 
O NN
O
O
N O
O
33
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O
N OH
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temperature for 16 hr. Solvent was removed under vacuum and product was isolated by 
extraction (H2O/CHCl3). The organic layers were combined, dried, and taken directly to next 
step. Yield 87.5%. MS (MALDI) C32H40N3O4 calculated 542.3013 found 542.5626. Analytical 
data (1H NMR, mass spec) matched the previously reported data.126 
 
4.8.3 
 
 
3,6-bis(diethylamino)-9-(2-((4-((2,5-dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)(methyl) 
carbamoyl)phenyl)xanthylium (35): To a solution of 34 (2.2 g, 4.00 mmol) and DCC (1.1 g, 
5.2 mmol) in DMF (35 mL) was added N-Hydroxysuccinimide (0.5 g, 4.00 mmol). The reaction 
was stirred at ambient temperature for 16 hr. The filtrate was collected then triturated with 
diethyl ether, centrifuged, and solvent decant. The product, collected in the bottom of the 
centrifuge tube as an oil, was taken to next step. Yield 85.6%. MS (MALDI) C37H43N4O6 
calculated 639.3177 found 639.8263. 1H-NMR (400 MHz, CD3Cl): δ 7.98 (s, 1H), 7.65 (m, 2H), 
7.52 (m, 1H), 7.34 (m, 1H), 7.22 (d, 1H J = 9.5 Hz), 6.94 (d, 2H J = 9.6 Hz), 6.76 (s, 2H), 3.61 
(m, 8H), 3.27 (t, 2H J = 7.0 Hz), 2.92 (s, 3H) 2.85 (m, 6H), 2.17 (t, 2H J = 7.0 Hz), 1.29 (t, 12H J 
= 7.0 Hz); 13C NMR (125 MHz, CDCl3): δ 172.27, 169.21, 168.51, 167.77, 162.51, 157.61, 
O NN
O
N O
O
N
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155.66, 136.16, 131.93, 130.03, 127.37, 114.04, 96.47, 53.85, 46.12, 42.22, 37.76, 36.45, 31.36, 
27.90, 25.60, 21.39, 18.61, 17.31, 12.60. 
 
4.9 General Protocol for Probe Assembly. 
First Phase. 
 
1. Prepare the peptide on the synthesizer or manually (ensure removal of the the last Fmoc). 
2. Prepare an appropriately sized solid-phase extraction (SPE) column with a stopcock (the 
white end piece that fits on those plastic SPE columns nicely). If you are only using a portion 
of your peptide (which I recommend but it is not necessary you can use all that you’ve made) 
use one of the smaller SPE columns, however I prefer the ones that can hold >15 mL. 
3. Add a stir bar. 
4. Transfer the amount of peptide (still on resin) you wish to carry forward through the 
synthesis (example: if you have 1 mol of peptide on resin and it’s in 1 mL of a mixture (mix 
thoroughly), if you transfer 0.5 mL you will have transferred 0.5 moles). 
5. Wash with DMF 5 times for 3 minutes each (use volumes appropriate to your SPE column, I 
use ~ 5mL usually, with the stir bar on) to ensure no residual deprotection agent.  
6. To the SPE column add 5 mL of DMF. 
7. To the mixture add 10 equivalents of triethylamine. 
8. To the mixture add 5 equivalents of your tag (in this case biotin-NHS). 
9. Allow to react for 5 hours (you can let it go overnight but at your own peril as it is generally 
completed after 5 hours and the resin is sensitive). 
10. Wash with DMF 5 times for 3 minutes each. 
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11. Wash with DCM 5 times for 3 minutes each (this removes all the DMF). 
 
This completes the first phase of your probe synthesis. Next will be the soft cleavage from the 
resin. 
 
Second Phase. 
 
1. Still in your SPE column. Treat your resin with 2% TFA in DCM for 2 minutes (2.5 mL, 
there should be a visible reaction). Collect the flow through. Repeat one additional time 
to ensure cleavage.  
2. The resin should have turned black (or very dark in any case). If it is not, repeat step 1 
from phase 2.  
3. Remove deprotection cocktail under vaccum. 
4. Weigh your sample (determine how many moles you have as well). 
 
 
You have now produced a tagged portion of your peptide with a free C-terminal acid. Next you 
will couple your electrophile. 
 
Third Phase. 
 
1. Take your peptide starting material up in DCM (5 mL). 
2. To the solution add 20 equivalents of diispropylethylamine.  
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3. To the solution add 3 equivalents of EDCI. 
4. To the solution add 2 equivalents of HOBt. 
5. Allow to solution to react for 15 minutes at RT. 
6. To the solution add 4 equivalents of your electrophile (in this case it’s the HCl salt of Ile-
chloromethyl ketone). 
7. Allow to react for at least 4 hours.  
8. Monitor reaction by TLC in DCM:MeOH 90:10 until no change is observed. 
9. Remove solvent under vacuum. 
10. Run on combiflash. The default time for the column you select should be fine, the 
columns have approximate weight ranges for your reference. Use DCM:MeOH gradient 
0-30% MeOH over the course of the gradient. Do not exceed 30% MeOH if you can 
avoid it. 
11. You will have to check your fractions by MALDI to find your peptide (the MALDI 
matrix solution is slightly acidic and may deprotect some of your peptide, watch for 
deprotection peaks as well).  
12. Collect appropriate fractions and remove solvent under vacuum. 
 
You now have produced TAG-Peptide(protected)-Electrophile. Next is global deprotection and 
purification.  
 
Fourth Phase. 
 
1. Weigh your sample. 
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2. Prepare the deprotection cocktail: 95:2.5:2.5 TFA:TIS:H2O (10 mL is plenty for any size 
application 0.2 mmol or less) 
3. To your sample add the deprotection cocktail. 
4. Stir for 4 hours. 
5. Triturate with ether (abundant precipitate should form). 
6. Spin down for 10 minutes on the Genevac (no vacuum!). 
7. Decant off solution (save it until you confirm you have your product). 
8. Dry the solid precipitate under vacuum. 
9. Confirm by MALDI that you have successfully synthesized the probe before attempting 
to purify it. 
10. Take up your sample in as little DMSO as possible. Use the best DMSO you can find as 
water and other contaminates will react with your electrophile. I keep a bottle in the 
biolab, with the gel reagents, for such purposes you can use this but do not contaminate it 
lest you plan to order more and wait. 
11. The methods I have prepared on the HPLC will work for your biotinylated peptide (look 
for “Prep Scale” Methods, “after deprotection” “isohold” in the methods section of the 
HPLC software).  
12. When considering how much to inject, it helps if you work out the math at how much you 
could possibly recover per injection volume and the resolution you are obtaining (if your 
product is more pure upfront this is easy). In short though, more is generally better and 
you will just have to feel it out as it is a new compound.  
13. Determine/confirm where the compound elutes by MALDI.  
14. Collect the appropriate fraction(s). 
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15. Remove sample under vacuum (Genevac allows for the most hands free approach, set to 
HPLC and confirm that it is still running every so often). 
16. Weigh your sample (and calculate the moles, it is a salt). 
17. If you have enough; produce a 10 mM stock solution of your peptide and freeze it as soon 
as possible.  
 
 
4.9.1 
 
 
PKI(14-22)-2-Cl-trityl Resin Synthesis.  2-Chlorotrityl Chloride (2-CTC) resin preloaded with 
Ile was purchased from ChemImpex (200-400 mesh, Catalog #03472). Peptide couplings were 
carried out manually via standard Fmoc amino acid protection chemistry. Amino acids were 
Cl
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2-Chlorotrityl 
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activated and added to resin with (Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) and diisopropylethylamin (DIEA). The resin was swelled with 
DCM (5 min) then DMF (5 min).  All amino acids were added by the general procedure that 
follows (with the exception of Arg, which underwent double couplings): Fmoc deprotection 
(20% piperidine in DMF, 3 x 5 min), wash with DMF 3x, amino acid coupling (PyBOP,DIEA 
0.1 M in DMF, 1 hr, X2 for Arg), wash with DMF 3x. After the final deprotection (Arg 22) with 
20% piperidine in DMF, the resin-bound product was taken directly to the next step. 
 
 
4.9.2 
 
 
 
Rhodamine-PKI(18-22)-2-Cl-trityl Resin Synthesis.  To the peptide on resin was added 35 (6 
eq) and TEA (10 eq) in DMF (0.05 M of 35). The reaction was stirred for 3 h, washed with DMF 
5x, then DCM 5x. The resin-bound product was taken directly to the next step. The Rhodamine-
peptide bound to resin was cleaved under soft conditions with 2% TFA in DCM. Solvent 
removed in vacuo. MS (MALDI) C103H132N15O16S2 calculated 1898.9418, found 1898.6289. 
O NEt2
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4.9.3 
 
 
 
38. Rhodamine-PKI(18-22)-OH (0.05 mmol, 37) was taken up in DCM (5 mL). PyBOP (0.065 
mmol), DIEA (0.2 mmol), and chloromethyl ketone 32 (0.065 mmol) were added to the solution. 
The reaction was stirred for 16 h. Solvent was removed and the purified on a silica gel gravity 
column, washed with DCM, and eluted with 20% MeOH/DCM. The solid was then globally 
debrotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr. Then triturated with ether to afford 
the crude product. Product purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). MS 
(MALDI) C61H92ClN16O10 calculated 1243.6871, found 1244.1763. 
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4.9.4 
 
 
 
PKI(14-22)-2-Cl-trityl Resin Synthesis (39).  2-Chlorotrityl Chloride (2-CTC) resin preloaded 
with Ile was purchased from ChemImpex (200-400 mesh, Catalog #03472). Peptide couplings 
were carried out manually via standard Fmoc amino acid protection chemistry. Amino acids 
were activated and added to resin with (Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) and diisopropylethylamin (DIEA). The resin was swelled with 
DCM (5 min) then DMF (5 min).  All amino acids were added by the general procedure that 
follows (with the exception of Arg, which underwent double couplings): Fmoc deprotection 
(20% piperidine in DMF, 3 x 5 min), wash with DMF 3x, amino acid coupling (PyBOP,DIEA 
0.1 M in DMF, 1 hr, X2 for Arg), wash with DMF 3x, acetyl cap (pyridine:acetic anhydride 
20:20, 0.15 M in DMF, 30 min). After the final deprotection (Gly 14) with 20% piperidine in 
DMF, the resin-bound product was taken directly to the next step. 
 
 
 
 
 
 
 
H2N Gly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-O
39
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4.9.5 
 
 
 
 
40. To the peptide on resin (39) was added 35 (6 eq) and TEA (10 eq) in DMF (0.05 M of 35). 
The reaction was stirred for 3 h, washed with DMF 5x, then DCM 5x. The resin-bound product 
was taken directly to the next step. The Rhodamine-peptide bound to resin was cleaved under 
soft conditions with 2% TFA in DCM. Solvent removed in vacuo. MS (MALDI) 
C134H181N22O24S3 calculcated 2578.2781, found 2578.9558. 
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4.9.6 
 
 
 
41. Rhodamine-PKI(14-22)-OH (0.05 mmol, 40) was taken up in DCM (5 mL). PyBOP (0.065 
mmol), DIEA (0.2 mmol), and chloromethyl ketone 32 (0.065 mmol) were added to the solution. 
The reaction was stirred for 16 h. Solvent was removed and the purified on a silica gel gravity 
column, washed with DCM, and eluted with 20% MeOH/DCM. The solid was then globally 
deprotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr. Then triturated with ether to afford 
the crude product. Product purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). MS 
(MALDI) C75H118ClN23O15 calculated 1615.8850 , [C75H118ClN23O15 + Na] calculated 1638.8748 
found 1638.7704. 
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4.10 Synthesis of Fluoromethyl Ketone 
4.10.1 
 
 
 
2-(3-fluoro-2-hydroxypropyl)isoindoline-1,3-dione (42). Procedure adapted from ChemBioChem 
2012, 13, 80-84.135 (1.34465g, 60%). To a round bottom flask add 10 mL DMF and 1.7596g of 
potassium phthalamide. To the mixture add 1-chloro-3-fluoro-2-propanol (0.87 mL). Reflux for 
16 hr. Triturate with ether, collect precipitate. The crude product was purified over silica gel 
chromatography to obtain the desired product. 1H NMR (400MHz, CDCl3) δ 7.8 (m, 2H), 7.7 (m, 
2H), 4.5 (m, 1H), 4.4 (m, 1H) 4.1 (m, 1H), 3.8 (m, 1.5H), 3.1 (s, 0.5H), 2.9 (s, 1H), 2.8 (s, 1H), 
2.0 (s, 0.5H), 1.2 (m, 1H). HRMS (ESI) [C11H10FNO3 +H] calculated 224.0645, found 224.0716. 
 
4.10.2 
 
 
 
1-amino-3-fluoropropan-2-ol (43). Procedure adapted from ChemBioChem 2012, 13, 80-84.135 
N F
OH
O
O
H2N F
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To a solution of 42 (1.12g, 5 mmol) in MeOH (100 mL) was added hydrazine hydrate (0.23mL, 
0.95 equiv to 42) and the reaction mixture was stirred at ambient temperature for 20h, during 
which time a precipitate formed. Conc. aq. HCl (1mL of a 37% soln, 2 equiv to 42) was added 
and the mass was stirred 3 hours. The precipitate was then filtered out. The MeOH was removed 
in vacuo. Then 30 mL of water was added and then cooled to 0°C. Crude solution taken forward 
to next step. 
 
4.10.3 
 
 
(9H-fluoren-9-yl)methyl (3-fluoro-2-hydroxypropyl)carbamate (44). Procedure adapted from 
ChemBioChem 2012, 13, 80-84.135 To the solution of 43 generated previously was added 10% 
Na2CO3 (30 mL). To the solution was added 1.102g fmoc-chloride dissolved in 50 mL dioxane. 
Solution allowed to reach 16 hr. Dioxane was removed under vacuum and crude product was 
extracted with EtOAc. The organic layer was washed with saturated NaCl solution and solvent 
removed in vacuo. The crude product was purified over silica gel chromatography to obtain the 
desired product. 1H NMR (400MHz, CDCl3) δ 7.8 (d, 2H J=7.52), 7.6 (m, 2H), 7.4 (m, 2H), 7.3 
(m, 2H), 4.4 (m, 2H), 4.1 (m, 1H), 2.9 (s, 4H), 1.3 (s, 2H). HRMS (ESI) [C18H18FNO3 +Na] 
calculated 315.1271, 338.1161 (Na adduct) found 338.1172. 
 
H
N F
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O
O
	   182	  
4.10.4 
 
 
(9H-fluoren-9-yl)methyl (3-fluoro-2-oxopropyl)carbamate (45). Procedure adapted from 
ChemBioChem 2012, 13, 80-84.135 44 (81.33 mg, 0.26 mmol) was taken up in DCM (5 mL). To 
the solution was added DMP (275.69 mg, 0.65 mmol). Reaction monitored by TLC to 
completion. Solvent removed in vacuo. The crude product was purified over silica gel 
chromatography to obtain the desired product. 1H NMR (400MHz, CDCl3) δ 7.8 (d, 2H J=7.52), 
7.6 (m, 2H), 7.4 (m, 2H), 7.3 (m, 2H), 5.4 (s, 1H), 5.0 (s, 1H), 4.9 (s, 1H), 4.4 (m, 2H), 4.3 (s, 
2H), 4.2 (m, 1H), 1.2 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 202.2, 156.3, 143.9, 141.4, 127.9, 
127.2, 125.0, 120.1, 84.1, 67.2, 48.2, 47.3. HRMS (ESI) [C18H16FNO3 +Na] calculated 313.1114, 
336.1012 (Na adduct) found 336.1017. 
 
4.10.5 
 
2,2,5,5,8,8-hexamethyl-3,7-dioxa-2,8-disilanonane. To a round bottom flask was added 32 mL 
diethylether. To the diethylether was added 2,2-dimethylpropane-1,3-diol (1g, 9.6 mmol). To the 
solution was added 3.35 mL TEA (24 mmol). To the solution was added TMSCl over 5 minutes 
and allowed to react for 16 hr at ambient temperature. White precipitate filtered off. Ether layer 
H
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O
O
O
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washed with water. Solvent removed in vacuo to afford pure product as a clear liquid. 1H NMR 
(400MHz, CDCl3) δ 3.2 (s, 4H), 0.7 (s, 6H), 0.0 (s, 18H). 
13C NMR (125 MHz, CDCl3): δ 68.5, 
37.7, 22.0, 0.2.  
 
4.10.6 
 
 
(9H-fluoren-9-yl)methyl ((2-(fluoromethyl)-5,5-dimethyl-1,3-dioxan-2-yl)methyl)carbamate 
(46). Procedure adapted from ChemBioChem 2012, 13, 80-84.135 45 (61.24 mg, 0.20 mmol) was 
taken up in DCM (7 mL). To the solution was added THS protected diol from previous step 
(69.58 mg, 0.28 mmol). Solution cooled to 0°C. To the reaction was added TMSOTf (catalytic, 
0.02 mmol). Reaction allowed to reach ambient temperature and equilibrate for 16 hr. Solvent 
removed in vacuo. The crude product was purified over silica gel chromatography to obtain the 
desired product. 1H NMR (400MHz, CDCl3)  matched previously reported data.
135 δ 7.8 (d, 2H 
J=7.52), 7.6 (m, 2H), 7.4 (m, 2H), 7.3 (m, 2H), 5.4 (s, 1H), 5.0 (s, 1H), 4.9 (s, 1H), 4.4 (m, 2H), 
4.3 (s, 2H), 4.2 (m, 1H), 1.2 (s, 1H). 13C NMR (125 MHz, CDCl3): δ 202.2, 156.3, 143.9, 141.4, 
127.9, 127.2, 125.0, 120.1, 84.1, 67.2, 48.2, 47.3. HRMS (ESI) [C23H26FNO3 +Na] calculated 
399.1846, 422.1744 (Na adduct) found 422.1751. 
 
 
 
H
N F
O
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4.10.7 
 
 
 
(2-(fluoromethyl)-5,5-dimethyl-1,3-dioxan-2-yl)methanamine (47). 46 (52 mg) was taken up in 3 
mL ACN. To the solution was added 0.23 mL diethyl amine and reaction monitored by TLC. 
Solvent removed under vacuum. Crude reaction mixture used as is in the following steps. 
4.11 Synthesis of Remaining Peptide Probes. 
4.11.1 
 
 
Rhodamine-PKI(14-22)-OH (0.05 mmol, 40) was taken up in DCM (5 mL). PyBOP (0.065 
mmol), DIEA (0.2 mmol), and fluoromethyl ketone 47 (0.065 mmol) were added to the solution. 
The reaction was stirred for 16 h. Solvent was removed and the purified on a silica gel gravity 
column, washed with DCM, and eluted with 20% MeOH/DCM. The solid was then globally 
deprotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr. Then triturated with ether to afford 
O NEt2
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the crude product. Product purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). MS 
(MALDI) C142H195FN23O25S3 calculated 2737.3841, found 2737.3524. 
 
 
4.11.2 
 
2,5-dioxopyrrolidin-1-yl 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoate (49). 
Procedure adapted from JACS 2007, 129, 13987.138 To a round bottom flask add 17.2 mL DMF, 
590 mg D-biotin (2.41 mmol), and 277 mg N-hydroxysuccinimide (2.41 mmol). To the mixture 
add N,N′-Dicyclohexylcarbodiimide (DCC, 645 mg, 3.13 mmol). Heat until dissolved, stir then 
allow to reach ambient T. Allow to react for 16 hr. Triturate with ether and collect precipitate. 
Spectral data matched previously reported.138 
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4.11.3 
 
 
50. To the peptide on resin was added 49 (6 eq) and TEA (10 eq) in DMF (0.05 M of 35). The 
reaction was stirred for 3 h, washed with DMF 5x, then DCM 5x. The resin-bound product was 
taken directly to the next step. The Biotin-peptide bound to resin was cleaved under soft 
conditions with 2% TFA in DCM. Solvent removed in vacuo. MS (MALDI) C111H157N21O23S4 
calculated 2280.0644 [C111H157N21O23S4 + Na] calculated 2303.0542 found 2301.0534. 
 
4.11.4 
 
 
Biotin-PKI(14-22)-OH (0.05 mmol, 50) was taken up in DCM (5 mL). PyBOP (0.065 mmol), 
DIEA (0.2 mmol), and fluoromethyl ketone 47 (0.065 mmol) were added to the solution. The 
reaction was stirred for 16 h. Solvent was removed and the purified on a silica gel gravity 
column, washed with DCM, and eluted with 20% MeOH/DCM. The solid was then globally 
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deprotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr. Then triturated with ether to afford 
the crude product. Product purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). MS 
(MALDI) C52H94FN22O14S calculated 1301.7008, found 1302.1126. 
 
 
4.11.5 
 
 
 
Aoc-PKI(14-22)-2-Cl-trityl Resin Synthesis (52).  2-Chlorotrityl Chloride (2-CTC) resin 
preloaded with Ile was purchased from ChemImpex (200-400 mesh, Catalog #03472). Peptide 
couplings were carried out automatically via standard Fmoc amino acid protection chemistry. 
After the final deprotection (Aoc) with 20% piperidine in DMF, the resin-bound product was 
taken directly to the next step. 
 
 
 
 
 
 
AocGly-Arg(Pbf)-Thr(t-Bu)-Gly-Arg(Pbf)-Arg(Pbf)-Asn(Trt)-Ala-Ile-O
52
H2N
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4.11.6 
 
 
53. To the peptide on resin was added 49 (6 eq) and TEA (10 eq) in DMF (0.05 M of 35). The 
reaction was stirred for 3 h, washed with DMF 5x, then DCM 5x. The resin-bound product was 
taken directly to the next step. The Biotin-peptide bound to resin was cleaved under soft 
conditions with 2% TFA in DCM. Solvent removed in vacuo. MS (MALDI) C119H172N22O24S4 
calculated 2421.1798 found 2422.4553. 
 
4.11.7 
 
 
54. Biotin-Aoc-PKI(14-22)-OH (0.05 mmol, 53) was taken up in DCM (5 mL). PyBOP (0.065 
mmol), DIEA (0.2 mmol), and fluoromethyl ketone 47 (0.065 mmol) were added to the solution. 
The reaction was stirred for 16 h. Solvent was removed and the purified on a silica gel gravity 
column, washed with DCM, and eluted with 20% MeOH/DCM. The solid was then globally 
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deprotected with 95:2.5:2.5 TFA:TIS:H2O (5 mL) for 1 hr. Then triturated with ether to afford 
the crude product. Product purified on HPLC (95:5 to 75:25 H2O:ACN over 20 minutes). MS 
(MALDI) C60H109FN23O15S3+ calculated 1442.8162, found 1442.8860. 
4.12 Biology Experimentals: 
Overlap of Figure 43. 
To overlap the gels, they were saved as .tiff files and inserted into a Microsoft Word 
document. Once in the word document the transperancy of the images were adjusted so that both 
could be observed when overlapped. By positioning the images such that the reference points in 
the C199A mutant lanes were in line (lanes 7 and 8) immediately the predominant species was 
identified as the bottom band. This is a curious find in that the upper band always had a more 
robust signal intensity, but it is actually present in significantly less quantities than the lower 
band. This leads into the hypothesis of the probe having significant isoform selectivity; however, 
the differences between the two band at this point were unknown and further characterization 
was required.  
 
Overlap of Figure 46. 
To overlap the gels, the fluorescence and Coomassie images were saved as .tiff files and 
inserted into a Microsoft Word document. Then the transparency of the overlapping images was 
adjusted such that both could be observed simultaneously. By positioning the images such that 
the reference points in the BSA and PKACα were aligned the predominant species was again 
identified as the bottom band. This spurred a return to the literature were this issue had 
previously been reported. The two bands differ by phosphorylation at Thr197, the top band is the 
phosphorylated form (pThr197) and the bottom is the non phosphorylated species.87,130,131 To 
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confirm the new hypothesis that the double banding issue is the same reported in the literature, 
recombinant PKACα was exposed to physiologically relevant phosphorylating conditions 
detailed below.  
 
Figure 47: 
To examine the effect of phosphorylation of Thr197 on labeling with Rh-PKI(14-22)-G-(CMK) 
recombinant PKACα was phosphorylated in vitro. To promote phosphorylation at Thr197, the 
enzyme that performs this catalytic action in vivo (3-phosphoinositide-dependent protein kinase 
1, PDK1) was purchased from Invitrogen. Recombinant PKACα was diluted to 0.1mg/mL in 
MOPS buffer (50 mM MOPS, pH 7.4, 100 mM NaCl, 10 mM BME, 10 mM MgCl2, and 1 mM 
ATP). To the solution of PKACα was added 6 μL of a 0.33 mg/mL solution of PDK1. The 
resulting solution was allowed to react for 90 minutes at ambient temperature. After the reaction 
was complete the solution was buffer exchanged back in to phosphate buffer solution (25 mM 
PO4 pH 7.2, for labeling reactions). In Figure 47, the labeling characteristics of the probe were 
examined against the wild-type recombinant PKACα and with recombinant PKACα that was 
treated with PDK1. Both protein solution concentrations were determined by absorbance at 280 
nM and diluted to 1 mg/mL in phosphate buffer (25 mM PO4 pH 7.2). Appropriate amounts of 
protein were added to reaction vessels (epindorf tubes). The probe was made as a 10 mM stock 
solution in DMSO and diluted accordingly for appropriate final concentrations in the gel 
experiments. The gel was cast as 1.5 mm thick and the wells were a total volume of 20 μL. The 
the samples were incubated with probe for 1 hr. The samples were quenched with a denaturing 
sample buffer (made in house and detailed in the biological experimental section) and incubated 
at 100°C for 5 minutes. The denaturing sample buffer contained a disulfide reducing agent 
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(betamercaptoethanol, BME). Coomassie staining was performed with blue G250 in a 
H2O/MeOH/AcOH solution, and destained with a H2O/MeOH/AcOH solution. Images of the 
Coomassie stained gel were taken with a galaxy S4 smart phone camera (13 megapixels, 
autofocus and default settings). 
 
 
 
Bradford assay 
Standard solutions of bovine serum albumin (BSA, provided in kit) were prepared at 0.5, 0.25, 
0.125, 0.1, 0.05 mg/mL in 25 mM NaPO4 buffer pH 7.2. The BioRad Bradford assay reagent is 
5X and must be diluted to 1X in H2O. A 96 well clear bottom plate from Greiner was used. To a 
well was added 10 μL of analyte solution and 200 μL Bradford detection solution. The resulting 
solution was allowed to incubate for 5 minutes. The absorbance was read on a FlexStation 3 at 
595 nM. Absorbance values were graphed in excel and used to determine the concentration of 
unknown (linear range of assay is from 0.05 to 0.5 mg/mL). 
Preparation of Lysates 
MCF7 Lysates. The MCF7 cell line was grown up in T75 flasks in RPMI buffer with 10% FBS 
(no antibiotic present). Every second or third day (whichever time the cell line was 75% 
confluent) they were passaged at 1:10. Once three consecutive T75 flasks were growing the 
MCF7 cell line, they were grown to complete confluence and harvested and gently centrifuged 
(1000 rpm for 4 minutes) into a pellet. The pellet was resuspended in 5 mL phosphate buffer (25 
mM NaPO4, pH 7.2). The suspension was homogenized with a Dounce homogenizer and the 
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debris removed by centrifugation (31,200 rpm for 45 minutes). Supernatant was decanted and 
aliquoted. Protein concentration determined by Bradford assay.  
Bradford Assay for MCf7 Cell Lysates: 
 
Figure 70. Bradford assay graph for MCF7 lysates. 
 
 
 
Table 13. Results of Bradford assay for MCF7 cell lysates. 
  Absorbance 
Concentration 
(mg/mL) 
MCF7 0.9692 0.077 
 
Preparation of MDA-MB-231 Cell Lysates 
MDA-MB-231 Lysates. The MDA-MB-231 cell line was grown up in T75 flasks in RPMI buffer 
with 10% FBS, and 1% ampicillin. Every second or third day (whichever time the cell line was 
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75% confluent) they were passaged at 1:5. Once four consecutive T75 flasks were growing the 
MDA-MB-231 cell line, they were grown to complete confluence and harvested and gently 
centrifuged (1000 rpm for 4 minutes) into a pellet, cell count was 2,820,000 (89.36% viable). 
The pellet was resuspended in 3 mL phosphate buffer (25 mM NaPO4, pH 7.2) with 1X Rouche 
Protease Inhibitor Cocktail and 1 mM EDTA. The suspension was homogenized with a Dounce 
homogenizer and the debris removed by centrifugation (31,200 rpm for 45 minutes). Supernatant 
was decanted and aliquoted. Protein concentration determined by Bradford assay.  
Bradford Assay for MDA-MB-231 Cell Lysates: 
 
 
Figure 71. Bradford assay graph for MDA-MB-231 cell lysates. 
 
 
Table 14. Results of Bradford assay for MDA-MB-231 cell lysates. 
  Absorbance Concentration (mg/mL) 
MDA-MB-
231 1.2321 0.25 
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Preparation of bovine heart lysates. 
Bovine heart was obtained from a local butcher shop and immediately cut into equal 10 g 
portions and the portions not being used were frozen. One 10g portion was submerged in 
phosphate buffer (25 mM NaPO4, pH 7.2) with 1X Rouche Protease inhibitor cocktail with 1 
mM EDTA. The tissue was homogenized with a tissue homogenizer and the debris removed by 
sequential centrifugation (8,000 rpm for 30 minutes then 31,200 rpm for 45 minutes). The 
soluble fraction was collected and aliquoted out. The concentration was determined by Bradford 
Assay.  
Figure 72. Bradford assay graph for bovine heart lysates. 
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Table 15. Results from Bradford assay of bovine heart lysates. 
 
 
 
Preparation of mouse heart lysates. 
Mouse hearts harvested from HEB6 mice were a generous gift from Dr. Jolene Windle. Intact 
hearts were submerged in PBS buffer with Roche Protease Inhibitor at 1X concentration (at 0 oC) 
immediately after harvesting. The tissue was homogenized with a tissue homogenizer on ice and 
cellular debris removed by sequential centrifugation (8,000 rpm for 30 min, then 31,200 rpm for 
45 min).  The soluble fraction was collected and concentration determined by Bradford assay.  
 
Figure 73. Bradford assay graph for mouse heart lysates.  
  Absorbance (0.1x) Concentration (mg/mL) Actual (mg/mL) 
Bovine heart lysates 0.7516 0.25 2.5 
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Table 16. Results from Bradford assay for mouse heart lysates.  
  Absorbance (.01x) 
Concentration 
(mg/mL) 
Actual 
(mg/mL) 
Mouse Heart 
Lysates 0.83945 0.26 26 
 
 
 
4.1 Gel Electrophoresis 
Gel recipes: 
 
Resolving gel (10%) 1 gel 2 gels 
      
Water 3.20 ml 6.40 ml 
Lower buffer 2.00 ml 4.00 ml 
Glycerol 0.80 ml (1.01 g) 1.60 ml (2.02 g) 
40% acrylamide 2.00 ml 4.00 ml 
10% APS (freshly prep.) 40 μl 80 μl 
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TEMED 10 μl 20 μl 
 
 
Stacking gel 1 gel 2 gels 
      
Water 1.95 ml 3.90 ml 
Upper buffer 750 μl   1.5 ml 
40% acrylamide 300 μl   600 μl   
10% APS (freshly prep.) 30 μl   60 μl   
TEMED 7.5 μl   15 μl   
 
 
 
Lower buffer - 100 ml (pH 8.8) 
   
     Final conc. Component M.W. Amount (g) Volume (ml) 
1.5 M Tris 121.14 18.171 – 
0.40% SDS – 0.4 – 
  Water – – q.s. 
Adjust to pH 8.8 with HCl 
   
     Upper buffer - 100 ml (pH 6.8) 
   
     Final conc. Component M.W. Amount (g) Volume (ml) 
0.5 M Tris 121.14 6.057 – 
0.40% SDS – 0.4 – 
  Water – – q.s. 
Adjust to pH 6.8 with HCl 
    
 
General Sample preparation procedure for gel electrophoresis 
In vitro labeling of wild type and C199A PKACα. 2.0 mg of protein was diluted into 40 mL 
PBS (25 mM NaPO4 pH 7.2), final concentration ~1.2 mM. The proteins were incubated with the 
relevant concentration of probe for 1 hr. 10 mL of a 5x SDS-Page Sample buffer was added and 
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separated on a 10% SDS-PAGE gel.  Fluorescent imaging was performed on an Amersham 
Imager 600 (AI600) instrument. The gel was then stained with Coomassie and imaged on the 
AI600.  
 
In vitro oxidation and labeling of wild type PKACα. 2.0 mg of protein was diluted into 40 mL 
PBS (25 mM NaPO4 pH 7.2), final concentration ~1.2 mM. Wild type PKACα was incubated 
with 2 mM Ellman’s reagent for 1 and 4 hours. The oxidized and non-treated proteins were then 
incubated with 300 nM probe for 1 hr. 10 mL of a 5x SDS-Page Sample buffer was added and 
separated on a 10% SDS-PAGE gel.  Fluorescent and Coomassie imaging was performed on an 
AI600 instrument.  
 
In vitro saturation of labeling of wild type PKACα. 2.0 mg of protein was diluted into 40 mL 
PBS (25 mM NaPO4 pH 7.2), final concentration ~1.2 mM. Wild type PKACα was incubated 
with increasing concentrations of PKI(14-22)Amide for 1 hr. The treated and non-treated 
proteins were then incubated with relevant concentrations of probe for 1 hr. 10 mL of a 5x SDS-
Page Sample buffer was added and separated on a 10% SDS-PAGE gel.  Fluorescent and 
Coomassie imaging was performed on an AI600 instrument.  
 
In vitro labeling of mouse heart lysates. Lysates were diluted in 1X protease inhibitor cocktail 
to a concentration of 2.5 mg/mL, with or without cAMP at 100 mM and with or without Probe at 
300 nM for 1hr. The resulting proteome solution was concentrated to 25 mg/mL with a 10 kDa 
molecular weight cut off spin filter. 10 mL of a 5x SDS-Page Sample buffer was added and 
separated on a 10% SDS-PAGE gel.  Fluorescent imaging was performed on an Amersham 
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Imager 600 instrument. The gel was then transferred to a PVDF membrane and bands detected 
by colorimetric HRP reaction with a T197 specific rabbit antibody, image taken on AI600 
instrument.  
 
In vitro labeling of bovine heart lysates. Lysates were diluted in 1X protease inhibitor cocktail 
to a concentration of 2.5 mg/mL, with or without cAMP at 100 mM and with or without Probe at 
300 nM for 1hr. The resulting proteome solution was concentrated to 25 mg/mL with a 10 kDa 
molecular weight cut off spin filter. 10 μL of a 5x SDS-Page Sample buffer was added and 
separated on a 10% SDS-PAGE gel.  Fluorescent imaging was performed on an Amersham 
Imager 600 instrument. The gel was then transferred to a PVDF membrane and bands detected 
by colorimetric HRP reaction with a T197 specific rabbit antibody, image taken on AI600 
instrument.  
 
In vitro labeling of MCF7 lysates. Lysates were used at the concentration harvested, with or 
without cAMP at 100 mM and with or without Probe at 300 nM for 1hr. The resulting proteome 
solution denatured with 10 μL of a 5x SDS-Page Sample buffer and separated on a 10% SDS-
PAGE gel.  Fluorescent imaging was performed on an Amersham Imager 600 instrument. The 
gel was then transferred to a PVDF membrane and bands detected by colorimetric HRP reaction 
with a T197 specific rabbit antibody, image taken on AI600 instrument.  
 
In vitro labeling of MDA-MB-231 lysates. Lysates were used at the concentration harvested, 
with or without cAMP at 100 mM and with or without Probe at 300 nM for 1hr. The resulting 
proteome solution denatured with 10 μL of a 5x SDS-Page Sample buffer and separated on a 
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10% SDS-PAGE gel.  Fluorescent imaging was performed on an Amersham Imager 600 
instrument. The gel was then transferred to a PVDF membrane and bands detected by 
colorimetric HRP reaction with a T197 specific rabbit antibody, image taken on AI600 
instrument.  
 
 
 
Gel Electrophoresis 
1) Cast the gel (add reagents in order listed in recipe, TEMED starts the solidifying 
reaction) 
2) Prepare the electrophoresis setup 
3) Prepare the samples 
4) Prepare the sample buffer, add 0.1x volume of BME to the amount of sample buffer 
required (10uL per well, calculate for a few extra ie. 7 wells you should make 100uL of 
buffer) 
5) Denature the Samples with 5x Sample Buffer (10uL to 40uL for a total of 50uL) 
a. 5minutes at 100oC 
6) Spin the samples in microcentrifuge for 30 seconds to collect all volume at bottom 
7) Load 40uL of the denatured sample into respective lanes on the gel (50 is max but it does 
not all fit properly) 
8) Load 2uL undiluted Ladder to lane(s) 
9) Place top of gel electrophoresis chamber on 
10) Turn on the instrument 
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11) Set to constant voltage of 170, for 60 minutes 
 
Western Blot: 
Transfer to membrane 
1) Collect the gel and wash with tap water 5x, leave in Petri dish submerged in water until 
needed 
2) Submerge membrane in MeOH for 3 minutes 
3) Prepare 1L of transfer buffer (see buffer bottle for dilution instructions) 
4) Submerge filter paper and fiber pads in transfer buffer 
5) Decant MeOH off the membrane and then immediately submerge in transfer buffer (do 
not let dry, if it does and you see white spots, repeat step 2) 
6) Follow the setup depicted for the Western blot (ie black side of cartridge down, then in 
this order: Fiber pad, filter paper, gel, membrane, filter paper, fiberpad) 
7) Place second cartridge into the electrophoresis chamber and fill chamber up with 
remaining buffer  
8) Place cold pack into electrophoresis chamber 
9) Top off chamber to Western blot line with buffer (or water if only a small amount is 
required) 
10) Set to constant 100 mAmps and run for 60 minutes 
Protein Detection (for colorimetric only, for ECL see manufacturer instructions) 
1) Collect the membrane and submerge in blocking buffer (5% BSA) for 1hr. 
2) Decant blocking buffer off 
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3) Incubate with primary antibody for 2hrs (dilute antibody 1:1000 in blocking buffer, 
10mL total) 
4) Wash with TBS 5x 
5) Incubate with secondary antibody for 1hr (dilute antibody 1:1000 in blocking buffer, 
10mL total) 
6) Wash 5x with TBS 
7) Leave submerged in TBS until ready for staining 
8) Prepare colorimetric staining solution according to BioRad specifications (ie 9 mL of 
H20, 1 mL of 10x buffer, 60 uL of reagent B; then right before adding to membrane 2  
mL reagent A) 
9) Allow to develop until color change stops 
10) Quench with tap water and let dry 
11) Image on gel imager 
General Procedure for the trypsin digest mass spectrometry 
Unmodified PKACα or PKACα incubated with probe was buffer exchanged into a lysis buffer 
(25 mM Tris pH 7.6, 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 10 mM 
DTT). The protein solution was mixed with trypsin at a ratio of 20:1 protein to protease. The 
resulting solution was incubated at 37oC for 24 hr. The sample was analyzed by MALDI mass 
spectrometry with CHCA matrix (Sigma) on a Voyager DE-ProTM MALDI TOF Mass 
Spectrometer.  
Procedure for Biotin Pull-Down Experiment. 
Streptavidin column and buffers were purchased from BioRad as a complete kit. The column 
was washed with biotin solution to block all irreversible binding sites prior to usage. Subsequent 
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reactivation of the streptavidin column (stripping of reversible binding sites) with acidic buffer 
was then performed according to manufacturers instructions, followed by neutralization with 
supplied PBS. Then, 1 mL of mouse heart lysates was incubated with the streptavidin resin for 
45 minutes. The lysate solution was eluted with PBS and the appropriate fractions were collected 
(determined by absorbance at 280 nm on spectrophotometer). The collected fractions were 
pooled and diluted to a final volume of 10 mL with 25 mM PO4 buffer with 1X Rouche Protease 
inhibitor cocktail and 1 mM EDTA. To the resulting solution was added biotinylated probe and 
allowed to react for 1 hr. The solution was then incubated with the streptavidin column for an 
additional 45 minutes. The column was washed with PBS until no absorbance was detected on 
the spectrophotometer. Then biotinylated compounds were eluted with a 2 mM biotin solution 
provided in the kit. The appropriate fractions were collected (as determined by absorbance at 280 
nM) and pooled. Gel electrophoresis experiments and Western blots were conducted to confirm. 
Procedure for generation of plasmids 
Initial cultures for plasmid isolation were grown up in 10 mL LB buffer at 37 °C for 16 hr with 
gentle shaking. The plasmids were collected with a QIA prep Spin miniprep kit w/ centrifuge 
according to manufacturers instructions as follows: 
1) cell centrifuged to a pellet and solution decanted (1600xG 5 min) 
2) cells taken up in 250μL Buffer P1 and transferred to an epindorf tube 
3) to the solution was added 250 μL buffer P2 and inverted 5 times (solution turns blue) 
4) to the solution was added 350 μL of Buffer N3, inverted 5 times (precipitate forms) 
5) centrifuge for 10 minutes at 17,900xG for 3 minutes 
6) decant solution into QIA prep spin column 
7) centrifuge for 1 minute and discard flowthrough 
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8) Add 500 μL of Buffer PB and centrifuge for 1 minute, discard flowthrough 
9) Add750 μL of Buffer PE centrifugre for 1 minute, discard flowthrough 
10) Centrifuge an additional time for 1 minute and discard flowthrough 
11) Place QIAPrep column in new (clean) epindorf tube 
12) Add 50 μL Buffer EB and let equilibrate for 1 minute 
13) Centrifuge for 1 minute 
14) Collect flowthrough and freeze 
 
Procedure for prep scale production of proteins (by day) 
Day 1: Initial culture.  
To a sterile test tube add 5 mL of LB media (solution of tryptone, yeast extract, and NaCl) with 
amp or kan (for dual expression use both antibiotics) selection. Cells directly from the -80 °C 
were added, without freezing and as small amount as could be reliably harvested (a pipette tip 
was used to scratch the surface of the frozen cells and the end submerged in the test tube media). 
Incubated at 37 °C with gentle shaking for 16 hrs. 
Day 2: Scale up from initial culture. 
Prepared 1 L vessels for growing by adding auto induction media to each (1 L amount) and 
autoclaving. To the auto induction media add 20 mL of 50x glyceral, glucose, lactose solution, 1 
mL of 1 M MgCl2 salt, and 1 mL of amp solution (50 mg/mL) (and kan solution for dual 
expression). From the initial culture on the previous day, extract 1 mL and add to the auto 
induction media that has been treated to promote growth. Incubate at 37 °C for 16 hr with gentle 
shaking. 
Day 3: Isolation and Purification. 
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Collect media and spin down at 6000 rpm for 10 minutes. Collect cells in minimal amount of 
solvent you wish to lyse into (PBS is fine, but solvent for the Ni column is preferred). Lyse cells. 
Spin lysates for 30 minutes at 20,000 RPM to remove debris. Decant onto activated nickel 
column. Wash with 1 mM imidazole solution until no absorbance detected. Elute with 100 mM 
imidazole. Collect appropriate fractions.  
 
Procedure for moving PDK1 into pRSF Duet vector. 
PDK1 initially in pMCSG10 vector and the plasmid was isolated as described above. The pRSF 
duet vector (kan resistance) plasmid was simultaneously isolated in the same manner. To a micro 
centrifuge tube was added: 10 μL of PDK1 Plasmid, 2 μL Green buffer, 1 μL BglII, 1 μL NdeI, 
and 6 μL H2O. To a separate micro centrifuge tube was added: 10 μL of pRSF Plasmid, 2 μL 
Green buffer, 1 μL BamHI, 1 μL NdeI, and 6 μL H2O. Digested at 37 °C for 30 minutes. The 
resulting solutions were run on agarose gel that was made in house (50 mL stock Tris Acetate 
EDTA (TAE) in H2O, 0.5 g agarose, bring to boil then add 5 μL ethidium bromide and pour onto 
plate after solution has slightly cooled). Gel was run at 100 V for ~45 minutes with obersvation 
until adequate separation for isolation had occurred. Bands excised with scalpel. The appropriate 
excised gel fragments were placed in an epindorf tube with a solution of 1:3 isopropanol:buffer 
QG (100 mg gel = 100 μL volume). Incubate at 50 °C for 10 minutes (or until dissolved). 
Transfer to QIAquick spin column and spin for 1 minute, discard flowthrough. Add 0.5 mL 
buffer QG, spin 1 minute, discard flowthrough. Add 0.75 mL buffer PE incubate for 5 minutes, 
spin 1 min, discard flowthrough. Spin down an additional 1 minute and discard flowthrough. 
Move QIAquick column to a 1.5 mL centrifuge tube and add 30 μL of elution buffer allow to 
equilibrate for 1 minute. Spin for 1 minute and collect flowthrough. To a fresh microcentrifuge 
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tube add 17 μL DNA mixture, 2 μL of ligation buffer, 1 μL ligase and incubate at room temp for 
30 minutes. Competent scarab cells were transformed with the resultant mixture as follows:  
200 μL of competent scarab cells were thawed from the -80 °C freezer. To the cells was added 
10 μL ligation mixture. Cells made to sit in ice for 30 minutes. Heat shock at 42 °C in water bath 
for 1 minute. Plate onto antibiotic plate. Incubate at 37 °C overnight.  
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